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Shu-Yu Chung 
THE MULTIDIMENSIONAL KIDNEY TRANSPLANT SELF-MANAGEMENT 
SCALE: DEVELOPMENT AND PSYCHOMETRIC TESTING 
Poor long-term kidney transplant outcomes are a significant problem in the U.S. 
Interventions must focus on preserving allograft function by managing modifiable risk 
factors. An instrument capable of identifying problems with post-kidney transplant  
self-management behaviors may enable the design and testing of self-management 
interventions. This study’s purpose was to test the psychometric properties of the new 
Kidney Transplant Self-Management Scale (KT–SM). The Zimmerman framework 
adapted for kidney transplant self-management guided the cross-sectional study. A total 
of 153 kidney recipients recruited from Facebook® completed the Self-Efficacy for 
Managing Chronic Disease (SEMCD), Patient Activation Measure (PAM), Kidney 
Transplant Questionnaire (KTQ), and KT–SM Scale instruments via a REDCap® survey. 
Most participants were female (65%), White (81.7%), and middle-aged (M = 46.7; SD = 
12.4 years) with a history of dialysis (73%) and received a kidney transplant an average 
of 6.58 years previous (SD = 6.7). Exploratory factor analysis results supported the  
16-item KT–SM Scale as a multidimensional scale with five domains with loadings 
ranging between .39 and .89: medication adherence, protecting kidney, cardiovascular 
risk reduction, ownership, and skin cancer prevention. Internal consistency reliability for 
the total scale (Cronbach’s α = .84) and five domains ranged from .71 to .83. The total 
and domains were positively correlated, ranging from r = .51 to .76, p = .01.  
Criterion-related validity was evidenced by significant correlations of KT–SM and 
domains with SEMCD (r =.22 to .53, p = .01), PAM (r = .31 to .52, p = .01), and the 
viii 
overall KTQ (r = .20 to .32, p = .01) except for one KT–SM domain: protecting kidney. 
Construct validity was evaluated using multivariate regression analysis. The linear 
combination of age, patient activation, and self-efficacy explained 45% of the variance in 
KT–SM behaviors; 47% of the variance in KTQ (measuring quality of life) was predicted 
by age, comorbidity, and self-efficacy. These findings provide beginning evidence of 
reliability and validity for the newly developed KT–SM scale. Instruments like this may 
provide a means to capture the self-management behaviors of the kidney transplant 
population, which is critical for future work on interventions. 
 Eileen Hacker, PhD, RN, APN, AOCN, FAAN, Chair 
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CHAPTER ONE 
THE NATURE OF THE STUDY 
Short-term kidney transplant (KT) outcomes have improved because of advances 
in surgical techniques and the introduction of more potent immunosuppressive (IS) 
medications. Improved outcomes include abatement in acute transplanted kidney 
rejection episodes and increased first-year allograft survival rates of 92%–95% 
(Legendre, Canaud, & Martinez, 2014; Sherston, Carroll, Harden, & Wood, 2014; 
Wekerle, Segev, Lechler, & Oberbauer, 2017). In contrast, long-term post-KT outcomes 
remain a significant problem (Levy et al., 2014; Napoli et al., 2014; Sherston et al., 2014; 
Stegall, Gaston, Cosio, & Matas, 2015; Wekerle et al., 2017). In a retrospective study of 
data from the United Network for Organ Sharing (UNOS) and the University of 
California Los Angeles KT registries from 1969 to 2005, the reported 10-year graft 
survival rates show miniscule improvement from 1985 to 2005 despite the introduction of 
new IS agents (Kaneku & Terasaki, 2006). Similarly, Gondos, Döhler, Brenner, and 
Opelz (2013) examined first-, fifth-, and tenth-year graft survival between the United 
States and Europe, employing data for the years 2005 to 2008 from the UNOS/Organ 
Procurement and Transplantation and from European transplant centers. Gondos et al. 
found that the overall first-year graft survival rates were almost equal between the United 
States and Europe. However, the overall 5- and 10-year graft survival rates in U.S. were 
67% and 43% compared to Europeans’ 77% and 56%, respectively. Legendre et al. 
(2014) arrived at a similar conclusion that allograft function loss and mortality increase 
significantly five years’ post-transplant. Factors contributing to poor long-term transplant 
2 
outcomes are categorized as donor factors, recipient factors, and immunological factors 
(Cangro, 2014; Legendre et al., 2014; Wekerle et al., 2017).  
Donor factors refer to the quality of the kidney. There are two types of kidney 
donor transplants: living and deceased. Both types of kidney recipients have better  
long-term outcomes when compared to people receiving long-term dialysis, though 
living-donor KT patients have longer graft survival and lower mortality than  
deceased-donor KT recipients (Englum et al., 2015; Hart et al., 2017). Another  
donor-related factor is the increasing use of extended-criteria donor (ECD) kidneys 
worldwide. A donor is considered ECD if he or she is more than 60 years of age or 
between 50 and 60 years but with two or more of the following risk factors: hypertension, 
diabetes mellitus, creatinine greater than 1.5 mg/dL, or death due to stroke (Barba et al., 
2013; Zens et al., 2018). The use of ECD for KT permits more end-stage renal failure 
patients (including older patients) to have a KT, but this practice is not without risk. The 
recipients of ECD have higher mortality rates, more cardiovascular (CV) episodes, and 
poorer allograft function compared to standard criteria donor kidney recipients (Barba  
et al., 2013; Legendre et al., 2014; Palkoci, Vojtko, Fialová, Osinová, & Lajčiaková, 
2018).  
Recipient factors including age, race, pre-transplant dialysis duration, 
obesity/weight gain, and CV disease prior to the transplant have been linked to early graft 
loss and high mortality rates (Hellegering et al., 2013; Hoogeveen et al., 2011). Although 
older recipients have lower long-term graft survival rates as compared to younger 
recipients, they still have longer life expectancy, lower mortality, and better quality of life 
than dialysis patients (Englum et al., 2015; Knoll, 2013; Matas, et al., 2015). African 
3 
Americans have higher acute kidney rejection rates and chronic allograft failure than 
other ethnic groups due to immunological factors such as a strong immune response or 
non-adherence to prescribed treatments and non-immunological factors including higher 
CV risk factors and low socioeconomic status (Cole, Johnson, Egede, Baliga, & Taber, 
2018; Gralla, Le, Cooper, & Wiseman, 2014; Narayanan et al., 2014). Another important 
recipient factor is duration of dialysis prior to KT. Longer duration of pre-transplant 
dialysis is associated with worse allograft survival and patient survival  
(McAdams-DeMarco et al., 2017; Ramesh Prasad, Ruzicka, Burns, Tobe, & Lebel, 2009; 
Remport et al., 2011; Smail et al., 2013); the longer patients remain on dialysis, the 
higher these risks become. Late graft loss and premature death with a functioning graft is 
linked to CV disease; experts estimate that CV disease cause 30%–55% of deaths of KT 
recipients (Carpenter et al., 2012; Helanterä, Räihä, Finne, & Lempinen, 2018).  
Pre-transplant obesity also is associated with poor kidney function as well as being a risk 
factor for CV disease. Furthermore, first-year post-KT weight gain is a stronger predictor 
of graft loss and mortality than pre-transplant obesity (Hoogeveen et al., 2011; Viscido  
et al., 2018). Lack of exercise, increased appetite, side effects from IS medication, and no 
longer being on food restrictions are common reasons for excessive weight gain (Aksoy, 
2016; Ryan et al., 2014). Cashion and colleagues estimated that KT recipients gain 11 to 
22 pounds after transplant; weight gain of 10%–35% in the first year following transplant 
also was reported (Cashion et al., 2014). First-year post-KT weight gain is positively 
correlated with post-KT hypertension, new-onset diabetes after transplant, and 
dyslipidemia; each of these conditions is also a CV risk factor (Viscido et al., 2018).  
4 
Immunological factors also have an effect. Research findings associate long-term 
use of IS medications with side effects and risks such as increased cancer risk, CV 
disease, infections, nephrotoxicity, new-onset diabetes after transplantation, obesity, and 
osteoporosis even though IS medications effectively decrease kidney rejection (Alshayeb, 
Josephson, & Sprague, 2013; Heldal et al., 2018; Sarno, Muscogiuri, & De Rosa, 2012). 
All these side effects and risks link to graft loss and mortality (Pasha, Alijanpour, Khafri, 
Basim, & Afshang, 2017). Another important immunological factor is IS medication  
non-adherence (Maw, 2014; Nankivell & Kuypers, 2011), which accounts for 32%–36% 
of graft loss (Butler, Roderick, Mullee, Mason, & Peveler, 2004; Maw, 2014). Reports 
estimate that 22%–35% of KT recipients are non-adherent to IS medications (Russell  
et al., 2010; Scheel et al., 2018). Transplant rejection rates in patients with poor 
adherence are seven times higher than for those who are adherent (Burkhalter et al., 2014; 
Scheel et al., 2018).  
These three factors (donor factors, recipient factors, and immunological factors) 
contribute to poor long-term transplant outcomes. However, not all these factors are 
modifiable. Risk factors such as extended criteria donor kidney use, older age, gender, 
ethnicity, and IS treatment regimens are not amenable to intervention. To improve  
long-term KT outcomes, interventions need to focus on preserving the transplanted 
allograft function as long as possible by managing modifiable factors including CV risk 
reduction, infection prophylaxis, skin cancer prevention, and IS medication adherence 
(Chadban, 2008; Maw, 2014; Jamieson et al., 2016).  
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Problem Statement 
After transplant, each KT recipient experiences a complex situation. Recipients 
are responsible for lifelong, day-to-day self-management (SM) tasks including adherence 
to IS treatment regimens; surveillance of allograft function; infection prophylaxis; skin 
cancer precautions; healthy lifestyle maintenance including exercise, proper diet, and 
weight management; and sound decision-making on seeking care (Jamieson et al., 2016; 
Kasiske et al., 2009; Ndemera & Bhengu, 2017; Urstad, Andersen, Øyen, Moum, & 
Wahl, 2011; Weng et al., 2013). However, few studies examined the effectiveness of 
discharge education used to improve post-transplant SM (Urstad et al., 2011). 
Additionally, current post-KT discharge education may not enable patients to manage 
complex post-transplant SM tasks (Haspeslagh et al., 2013; Hwang, & Yi, 2015; Urstad, 
Wahl, Andersen, Øyen, & Fagermoen, 2012). Researchers indicate that KT recipients 
may not be trained sufficiently to develop SM skills. Most intervention programs focus 
mainly on improving medication adherence; knowledge regarding kidney allograft 
monitoring and maintaining a healthy lifestyle have not been addressed (Urstad et al., 
2012). 
There are three instruments related to KT SM (Kosaka et al., 2013;  
Schmid-Mohler, Schäfer-Keller, Frei, Frei, & Spirig, 2014; Weng, Dai, Huang, & 
Chiang, 2010). One limitation of these instruments is that their reliability or construct 
validity analyses are low or not reported, indicating they may not be reliable or valid. 
Lack of theoretical foundation and inadequate definitions of concepts related to  
SM are concerns as well. Theory plays a vital role in instrument development because it 
helps researchers to think clearly about what to include in the measure and how to 
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interpret the results (DeVellis, 2012). Moreover, carefully defining constructs of interest 
conceptually and operationally is the initial step of instrument development because 
many constructs are not directly observable and might be composed of multiple domains 
(Johnson & Morgan, 2016). An instrument that has no guiding theory and fails to define 
the constructs of interest is highly likely to have poor construct validity (Pett, Lackey, & 
Sullivan, 2003). Wording of the questionnaire is another concern. Many of the items on 
existing surveys are double- or triple-barreled questions—that is, questions may have two 
or three different answers, but the respondent is forced to provide one only. Lastly, lack 
of generalizability due to lifestyle, food preference, and cultural differences between 
Western and Asian countries make these instruments difficult to apply to U.S. KT 
recipients. For example, some questions include, “I eat small dried fish to help boost 
bone health,” “I wear a mask all the time if I am in a crowded, public place,” and “I eat a 
non-greasy bland diet and avoid spicy food.” These questions may not be relevant or 
even understood by people who are not used to the referenced practices. Therefore, an 
instrument capable of identifying problems with post-transplant SM behaviors 
specifically designed for U.S. KT recipients will set the stage for the design and testing of 
SM interventions.  
Purpose 
This study’s purpose was to test the reliability and validity of a newly developed 
KT-SM scale among adult KT recipients aged 18 years and older. The conceptual 
framework used to guide the study was adapted from Zimmerman and Young’s  
SM framework (see Figure A-1 for permission). The adapted framework incorporates 
Bandura’s concept of self-efficacy (1998) and the patient activation model developed by 
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Hibbard and colleagues (Hibbard, Mahoney, Stockard, & Tusler, 2005; Hibbard, 
Stockard, Mahoney, & Tusler, 2004). Correlations among variables including  
self-efficacy, patient activation, post-transplant SM, and the outcome health-related 
quality of life (HRQoL) was used to evaluate the psychometric properties of the newly 
developed KT-SM scale. 
Specific Aims and Hypotheses 
Aim 1: Examine the content validity of the Kidney Transplant Self-Management 
(KT-SM) scale. 
H1: The KT-SM scale will demonstrate evidence of a content validity index (CVI) 
of 0.9 or greater for individual items and for the overall scale based on a review by four 
content experts of construct definition, item relevance, wording clarity, and item 
appropriateness. 
Aim 2: Estimate the reliability of a new instrument, the KT-SM scale, among 
adult KT recipients.  
H2: The KT-SM scale will have adequate internal consistency coefficient as 
evidenced by corrected item-to-total correlations, mean inter-item correlations of greater 
than or equal to .30, and Cronbach’s alpha greater than or equal to .70 among KT 
recipients aged 18 or greater. 
Aim 3: Estimate dimensionality of the KT-SM scale through exploratory factor 
analysis (EFA). 
H3: The EFA results will support that the KT-SM scale is a multidimensional 
scale with more than one factor extracted, and items within each factor will have factor 
loading values greater or equal to .40. 
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Aim 4: Estimate construct validity of the KT-SM scale guided by the conceptual 
model by exploring relationships between the KT-SM scale and the Self-Efficacy for 
Managing Chronic Disease (SEMCD) scale, the Patient Activation Measure (PAM), and 
the Kidney Transplant Questionnaire (KTQ-25).  
H4: Controlling for demographic and clinical variables, a significant amount of 
variance in the KT-SM scale will be explained by self-efficacy and patient activation.  
H5: Controlling for demographic and clinical variables, a significant amount of 
variance in HRQoL will be explained by self-efficacy, patient activation, and KT-SM 
behavior. 
H6: Criterion-related validity will be supported as the 16-item KT-SM total scale 
and five domain scales are statistically significantly correlated with the PAM-13, 
SEMCD, and KTQ-25 and 5 subscales. 
Framework 
The conceptual framework that guided this study was adapted from Dr. Lani 
Zimmerman’s unpublished work (2012). The theoretical foundation of the framework 
consisted of Bandura’s social cognitive theory, the concept of self-efficacy, and patient 
activation theory (Hibbard et al., 2005). The adapted KT-SM framework depicts 
hypothesized relationships among antecedents/risk factors; mediating variables including 
patient activation level, self-efficacy, and SM behavior; and the outcome of HRQoL, as 
shown in Figure 1.  
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Figure 1. KT-SM Framework. Adapted from Zimmerman & Young Model. Used with 
permission (see Appendix A). 
The antecedents/risk factors are hypothesized to be associated with patient 
activation level, self-efficacy, SM behavior, and HRQoL. In this study, the 
antecedents/risk factors were used to describe characteristics of the study population. 
Antecedents (Risk Factors) 
There are few studies of post-KT SM itself, but based on a broad review of  
KT-related studies, the antecedents and risk factors associated with is regimen  
non-adherence and adverse clinical outcomes can be put into two categories:  
1. Demographic characteristics such as age, race, gender, marital status, 
employment, and education level (Chisholm-Burns, Erickson, 2012; Cole  
et al., 2018; Ruppar & Russell, 2009; Schaeffner, Mehta, & Winkelmayer, 
2008; Woodward et al., 2008).  
2. Clinical variables including comorbidities, long-term dialysis prior to 
transplant, time since transplant, and type of transplant (Aksoy, 2016; Lam 
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et al., 2017; Legendre et al., 2014; Lim, Johnson, Hawley, Pascoe, & 
Wong, 2018; Szeifert et al., 2010).  
Mediators: Post-KT SM, Patient Activation, & Self-Efficacy 
Post-KT SM. SM has been studied widely in chronic diseases such as asthma, 
diabetes, heart disease, mental health, lung disease, and arthritis. Efficacious SM is 
associated with improved long-term outcomes, including better HRQoL, engagement in 
self-care behaviors, fewer emergency room visits, and lower medical costs (Ditewig, 
Blok, Havers, & van Veenendaal, 2010; Haines, Coppa, Harris, Wisniveski, & Lin, 2018; 
Redman, 2007, 2009). Previous studies have shown that SM behaviors can be promoted 
by increasing a patient’s perceived self-efficacy (Harrington, Carter-Templeton, & Appel, 
2017; King et al., 2010; Kuwaiti, Ghadami, & Yousefi, 2017; Wang et al., 2017; Weng  
et al., 2010) and giving tailored education based on an individual’s activation levels 
(Hibbard & Greene, 2013; Hibbard, Greene, Sacks, Overton, & Parrotta, 2017; Mosen  
et al., 2007).  
Patient activation. Judith Hibbard and colleagues (2005) developed the concept 
of patient activation. Knowledge, skills, and confidence are the essential components that 
enable people to self-manage a chronic condition successfully. Hibbard and colleagues 
(2004) posited that activation level is developmental and can be increased with tailored 
educational interventions based on individuals’ confidence, skill, and knowledge levels. 
In past studies, patients with a high level of activation were found to be more likely to 
perform health-related behaviors including self-managing behaviors, maintaining a 
healthy lifestyle, and seeking health information regarding their own care (Bilello et al., 
2018; Hibbard et al., 2017; Nijman, Hendriks, Brabers, de Jong, & Rademakers, 2014; 
11 
Remmers et al., 2009; Ryvicker et al., 2013; Shively et al., 2013). Moreover, researchers 
have found that highly activated individuals are more likely to have better health 
outcomes such as success in controlling diabetic HgbA1C, fewer hospitalizations, and 
better health resource utilization (Bilello et al., 2018; Greene & Hibbard, 2012; Hibbard 
et al., 2004; Mitchell et al., 2014). From a psychological aspect, Magnezi, Glasser, 
Shalev, Sheiber, and Reuveni (2014) found that highly activated patients reported better 
HRQoL and fewer depressive symptom.  
Self-efficacy. In social cognitive theory, self-efficacy is defined as confidence in 
one’s own competence and ability to successfully perform a given task and reach the 
desired goal (Bandura, 1997; Bodenheimer, Lorig, Holman, Grumbach, 2002). Perceived 
self-efficacy affects various aspects of human functioning including behavior change, 
effort and engagement, thought process, and emotional response (Bandura, 1994). In 
addition, the strength of perceived self-efficacy contributes to skill building and 
development; the development of essential skills is hindered and impeded when people 
have low self-efficacy but continues to grow in people with high self-efficacy (Bandura, 
1994; Pajares, 2002). 
In the adapted KT-SM framework, self-efficacy is a mediator. Previous studies 
have confirmed positive correlations among self-efficacy, SM behavior, and HRQoL 
(Harrington et al., 2017; Jones & Riazi, 2011; McAuley et al., 2006; Motl, McAuley, 
Snook, & Gliottoni, 2009; Sarkar, Fisher, & Schillinger, 2006; Weng et al., 2010). 
Although there is insufficient evidence for a direct association/effect between  
self-efficacy and patient activation, these two variables have positive correlations with 
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SM and HRQoL. Therefore, in the KT-SM framework, self-efficacy is hypothesized to be 
associated with post-KT SM behavior, patient activation, and HRQoL.  
Outcome: HRQoL 
Several studies have recognized HRQoL as an important post-transplant outcome 
measure (Fujisawa et al., 2000; Kumnig et al., 2014; Prihodova et al., 2014; Weber et al., 
2014; Zhang et al., 2017). Clinical and psychological risk factors associated with 
mortality and graft loss have been found to be associated with HRQoL in KT recipients 
and include depression, age, unemployment, immunosuppressant side effects, limited 
physical function, diabetes, CV disease, serum level of creatinine, and glomerular 
filtration rate (Fujisawa et al., 2000; Griva, Davenport & Newman, 2013; Molnar-Varga 
et al., 2011; Ortiz et al., 2014; Prihodova et al., 2014). Researchers have also found that 
KT recipients’ perceived HRQoL can be used to predict long-term mortality and graft 
loss risk factors (Griva et al., 2013). 
Conceptual and Operational Definitions 
Independent Variables 
Demographic factors. Demographics are the characteristics of the study 
population, including age, race, gender, marital status, and education (Kane & 
Radosevich, 2010). The primary investigator (PI) collected demographic data using 
patient survey form (see Appendix B) to describe the sample and to examine if poor SM 
behaviors, low self-efficacy, low patient activation levels, and poor HRQoL are 
associated with certain demographic characteristics. This self-administered, categorical, 
nominal, and open-ended questionnaire collected: gender (dichotomous response), age 
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(open-ended question), and other information such as race, marital status, employment 
status, and education (categorical response).  
Clinical factors. The investigator collected biological and physiological clinical 
factors such as time since transplant, pre-transplant dialysis, and type of transplant using 
a self-reported medical history review developed for this study (see Appendix C). Time 
since transplant and years of pre-transplant dialysis were collected using open-ended 
questions. Categorical response options were offered for type of transplant. 
Comorbidities. Comorbidities refer to one or more chronic diseases that coexist 
with the index disease. The comorbidities could be post-KT-related or pre-existing 
chronic disease (Hollisaaz et al., 2007; Valderas, Starfield, Sibbald, Salisbury, & Roland, 
2009). The investigator collected comorbidity information was using the Charlson 
Comorbidity Index (CCI; Charlson, Pompei, Ales, & MacKenzie, 1987). The CCI has 
been validated in several populations including dialysis patients (Beddhu, Bruns, Saul, 
Seddon, & Zeidel, 2000; Cho et al., 2017; Hall, Luciano, Pieper, & Colón-Emeric, 2018) 
and KT recipients (Hollisaaz et al., 2007; Jassal, Schaubel, & Fenton, 2005; Levine, 
Schuler, & Gourishankar, 2017; Machnicki et al., 2011) for predicting long-term 
outcomes including graft survival, mortality, healthcare resource use, and HRQoL 
(Hollisaaz et al., 2007; Jassal et al., 2005; Wu et al., 2005). Traditionally, CCI is 
calculated based on patient medical record and administration data collected by trained 
researchers or professionals. This study collected data was using a web-based  
survey—the investigator used a questionnaire version of the CCI developed by Katz and 
colleagues (1996) and validated in multiple studies (Habbous et al., 2013; Horton, 
Rudick, Hara-Cleaver, & Marrie, 2010; Ng, Low, & Thumboo, 2015; Sridharan, 
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Berdeprado, Vilar, Roberts, & Farrington, 2014) for the study. The survey (Appendix D) 
asked participants to indicate which of 16 diseases they had and provided explanations or 
examples for medical terminology that might cause confusion to participants (e.g., 
connective tissue disease, cerebrovascular, peptic ulcer disease, etc.). 
Mediating Variables 
Post-KT SM. Post-KT SM includes the range of behaviors patients perform in 
managing their own care, such as ways they follow prescribed post-transplant treatment 
regimens, promote their own health, prevent health deterioration, and preserve graft 
function (Berger, 2014; Gordon, Gallant, Sehgal, Conti, & Siminoff, 2009; Haspeslagh  
et al., 2013; Kasiske et al., 2010). To be more specific, KT SM includes IS medication 
management, adherence to post-transplant treatment regimen, healthy lifestyle 
maintenance including regular exercise, proper diet and weight management, allograft 
function self-monitoring, infection prophylaxis, skin cancer precautions, and  
decision-making about seeking care (Haspeslagh et al., 2013; Hedayati, Shahgholian, & 
Ghadami, 2017; Kasiske et al., 2010; Ndemera & Bhengu, 2017; Schäfer‐Keller, 
Steiger, Bock, Denhaerynck, & De Geest, 2008). 
The study measured SM behaviors using the new PI-developed 29-item KT-SM 
scale. Think-aloud interviews conducted by the investigator with six adult KT recipients 
(three females and three males) recruited from the KT program at Indiana University 
Health demonstrated face validity (Table E-1). Content validity was established with a 
CVI of 0.931 (Table F-1). The items are scored on a 5-point Likert-type scale ranging 
from 1 (strongly disagree) to 5 (strongly agree). Scores were totaled for a total score and 
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for single domain scores. Higher scores indicated that the KT recipients engaged in the 
desired post-transplant SM behaviors.  
Patient activation. Patient activation conceptually is defined as the level of a 
patient’s active engagement in his or her own care and the knowledge, skill, and 
confidence the patient has about his or her ability to improve and maintain health, 
collaborate with healthcare providers, make decisions, and seek appropriate care 
(Hibbard et al., 2004; Shively et al., 2013; Smith, Curtis, Wardle, von Wagner, & Wolf, 
2013). 
The study measured patient activation with the 13-item PAM (Hibbard et al., 
2005; see Figure A-2 for permission). The PAM is an interval level, Guttman-like scale 
with scores ranging from 0–100. Test scores were categorized into four levels, with Level 
1 (the lowest patient activation level) and Level 4 (the highest patient activation level). 
Self-efficacy. Self-efficacy is an individual’s confidence in his or her own 
capability to successfully perform given tasks and achieve a preset goal (Bandura, 1997; 
Bodenheimer et al., 2002). Patients with high self-efficacy engage more in SM behaviors 
and have better physical function and quality of life (De Pasquale et al., 2014; Mersal & 
Aly, 2014; Weng et al., 2010). 
The study measured participants’ self-efficacy with the SEMCD 6-item scale 
(Lorig, Sobel, Ritter, Laurent, & Hobbs, 2001). The investigator asked (see Table G-1) 
participants about their confidence levels of managing emotional distress, physical 
discomfort, illness condition, and low energy related to their chronic disease with 
questions such as: “How confident are you that you can keep from getting discouraged 
when nothing you do seems to make any difference?” Responses ranged from 1 (Not at 
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all confident) to 10 (Totally confident). Possible total scores range from 6 to 60. A lower 
score indicates that the patient has less efficacy in self-managing post-transplant care. 
Outcome Variable 
The conceptual definition of HRQoL is an individual’s subjective experiences of 
satisfaction with his or her physical, emotional, social functioning, and well-being 
(Maglakelidze, Pantsulaia, Tchokhonelidze, Managadze, & Chkhotua, 2011;  
Molnar-Varga et al., 2011; Shumaker, Ellis, & Naughton, 1997). Data was measured with 
the 25-item KTQ-25 (Laupacis et al., 1993; Appendix H). Questions on the KTQ-25 are 
measured with a 7-point Likert-type scale and incorporate five disease-specific 
dimensions including physical symptoms, fatigue, appearance, uncertainty/fear, and 
emotion (Appendix H). Scores are summed for a total score and for five single domain 
scores. A higher score indicates good quality of life (Laupacis et al., 1993; Neipp et al., 
2006).  
Summary 
Despite the tremendous improvement in first-year graft survival and reduction in 
episodes of acute kidney rejection, the 5- and 10-year graft survival rates after KT have 
seen little improvement over the past decades. Moreover, the top three leading causes of 
death among the KT population are CV disease, infection, and cancer; as a result, many 
transplant recipients die prematurely with a functioning allograft. Whether effective  
post-KT SM can improve long-term post-transplant outcomes including HRQoL still is 
unclear. Likewise, little is known about how KT recipients manage their post-transplant 
condition by maintaining a healthy lifestyle, engaging in cancer precautions and infection 
prophylaxis, self-monitoring graft function, and taking medications as prescribed. An 
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instrument capable of identifying and measuring post-transplant SM behavior may help 
healthcare providers and researchers provide tailored interventions based on individual 
need. Existing instruments to measure these behaviors have limitations. Therefore, the 
investigator in this study developed a new KT-SM scale and tested its psychometric 
properties. This study also examined associations among self-efficacy, patient activation, 
and post-KT SM behavior as well as whether SM is associated with post-transplant 
HRQoL. 
Chapter Two presents a literature review of the current state of science regarding 
risk factors and potential variables of post-KT SM behavior and long-term outcomes. The 
chapter discusses research findings regarding SM behaviors and reviews existing post-KT 
SM scales. 
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CHAPTER TWO 
REVIEW OF THE LITERATURE 
Chapter Two provides a literature review of the current state of science regarding 
contributing risk factors and potential mediating/moderating variables pertaining to  
post-KT SM behavior and long-term outcomes. This chapter consists of four sections that 
cover risk factors/antecedents that contribute to non-adherence to post-transplant SM 
behavior, self-efficacy and patient activation and their relationships to post-transplant SM 
behaviors, post-KT HRQoL and its relationship to SM, and a review of existing post-KT 
SM scales. 
Antecedents/Risk Factors 
Demographic Factors 
The risk factors contributing to poor post-KT outcomes and non-adherence 
behavior such as graft loss, IS medication non-adherence, and low HRQoL are well 
established and include older age, low income, unemployment, non-White race, male 
gender, single status, and low education level (Gordon, Ladner, Caicedo, & Franklin, 
2010; Malek, Keys, Kumar, Milford, & Tullius, 2011; Scheel et al., 2018). Likewise, 
these demographic factors are accepted widely as risk factors in chronic condition  
SM behaviors, but little is known about how they affect specific post-transplant SM 
behaviors. The following sections examine the relationships among demographic factors, 
post-transplant SM, and HRQoL. 
Age. As wait times for KTs increase, the number of candidates on wait lists who 
are aged 50 years and older has increased over the past 10 years (Hart et al., 2017; Matas 
et al., 2015). Moreover, the number of elderly KT recipients is growing rapidly because 
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of the aging of the U.S. population (Englum et al., 2015; Gill et al., 2013; Gill et al., 
2011; Hart et al., 2017; Knoll, 2013; McAdams-DeMarco, James, Salter, Walston, & 
Segev, 2014). Since 2005, approximately 2,200 to 3,100 recipients over age 65 have 
received KT surgeries each year, and the number is expected to increase (Matas et al., 
2015). There also is increasing concern regarding elderly recipients’ post-KT outcomes. 
Elderly KT recipients have more comorbidities prior to transplant (Legendre et al., 2014) 
and frequently undergo transplant surgeries with allografts from older deceased donors 
because of new Organ Procurement and Transplant Network (OPTN) deceased-donor 
kidney-allocation policies (Gill et al., 2013; Pinter et al., 2017). According to these 
policies, each kidney candidate is assigned an Expected Post-Transplant Survival (EPTS) 
score and the donor kidney quality is measured by the Kidney Donor Profile Index 
(KDPI). The EPTS score is calculated based on candidate’s age, time on dialysis, and 
history of previous transplant. Kidney candidates with the top 20% of EPTS scores are 
offered the best-quality donor kidneys first. Candidates with older age are less likely to 
be offered a high-quality donor kidney (OPTN, 2014). 
Older age in kidney candidates also presents a potential barrier to IS medication 
adherence and SM of chronic conditions. Kidney recipients aged 65 years or older tend to 
be less adherent to treatment regimens, perhaps because of vision or memory problems, 
complexity of the therapeutic regimen, limited physical function, or difficulty in 
swallowing (Chisholm, Melroy, Johnson, Malloy, & Spivey, 2008; Griva, Davenport, 
Harrison, & Newman, 2012; Russell et al., 2010; Shetty, Wertheim, & Butt, 2017). 
Moreover, researchers estimate that more than 65% of people aged 65 or older have more 
than two comorbid conditions, and an increased number of comorbidities and poor 
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physical function have been reported as barriers to SM in this population (Bayliss, Ellis, 
& Steiner, 2007). 
Race. Being African American is positively associated with poor transplant 
outcomes and non-adherence to medical treatment (Butler, Peveler et al., 2004; Contreras 
et al., 2012; Gonzalez-Suarez & Contreras, 2017; Gordon et al., 2010; Keith & Patrie, 
2011; Patzer & Pastan, 2013). Other studies indicate risk factors contributing to shorter 
graft survival among African Americans include strong cell-mediated immune response, 
different pharmacokinetic mechanisms than Whites, medication non-adherence, high 
prevalence of diabetes mellitus and hypertension, and unequal access to KT because of 
late referral to transplant physicians (Gonzalez-Suarez & Contreras, 2017; Gordon et al., 
2010; Legendre et al., 2014; Malek et al., 2011; McGee et al., 2011). In a cohort study 
conducted by the Department of Veterans Affairs that enrolled 79,361 KT recipients, 
African American KT recipients had a 30% higher risk of allograft failure compared to 
non-African American KT recipients (relative risk 1.31; 95% CI 1.26 to 1.36; Chakkera 
et al., 2005). Results of another retrospective study confirmed that African Americans 
had the highest graft failure rate among all ethnic groups, experienced more CV events, 
and had higher prevalence of hypertension and diabetes mellitus (Palanisamy et al., 2015; 
Taber, Egede, & Baliga, 2017).  
Gender. Women have a lower probability of being placed on the KT list than 
men and thus have limited access to transplants (Lipford et al., 2018; Monson et al., 
2015). A multi-center study of 4,118 KT recipients indicated that women had a 28% 
lower transplant rate than men (Jindal, Ryan, Sajjad, Murthy, & Baines, 2005). Despite 
gender disparities in access to KT, women have better survival rates as compared to men 
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(Vahed, Samadi, Mostafidi, Ardalan, & Omidi, 2016). This fact may be because women 
possess better health-related knowledge, utilize healthcare more effectively, are more 
compliant with IS medication regimens, actively seek care, and demonstrate more 
concern about protecting kidney function (Jindal et al., 2005; Puoti et al., 2016). 
However, the results are inconsistent in the literature. Johnson, Wicks, Milstead, Hartwig, 
and Hathaway (1998) conducted a survey to examine if gender had any effect on post-KT 
HRQoL, an important indicator of post-transplant patients’ recovery. Each participant 
completed an HRQoL questionnaire at baseline, 6-, and 12-months’ post-transplant. 
Although HRQoL improved after transplant in both genders, the HRQoL scores were 
consistently lower in women (p ≤ .005).  
Whether gender affects post-transplant SM behavior has not yet been well 
examined. Studies regarding patient SM behaviors in diabetes and heart failure have 
shown that women experience more psychosocial distress than men, report more 
depressive symptoms, lack social support, and experience poor physical function and 
comorbidities. Each of these factors contribute to not engaging in SM activities (Boerner, 
Eccleston, Chambers, & Keogh, 2017; Chesla, Kwan, Chun, & Stryker, 2014; Heo, 
Moser, Lennie, Riegle, & Chung, 2008; McCollum, Hansen, Lu, & Sullivan, 2005).  
Marital status and education level. People who are unmarried, live alone, or 
have little social support have been shown to have poor health outcomes and to be  
non-adherent to medical regimens (Gerull et al., 2017; Griva et al., 2012; Hucker et al., 
2017; Taber et al., 2016). Studies have shown that education level is positively associated 
with health literacy, medication adherence behaviors, and graft survival (Demian, 
Shapiro, & Thornton, 2016; Hod & Goldfarb-Rumyantzev, 2014; Morony et al., 2018; 
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Taber et al., 2016). In addition, patients with fewer than 12 years of education were less 
likely to be placed on the transplant wait list compared to college graduates. Possible 
explanations may be that patients with more education demonstrate better health literacy, 
possess the ability to seek health information, have access to healthcare resources, and 
communicate more effectively with healthcare providers. Patients with higher education 
also have been found to have lower mortality and less graft loss (Hod &  
Goldfarb-Rumyantzev, 2014). However, the results are mixed; the KT literature also 
reported a tendency of KT recipients with higher education to be non-adherent (Dobbels 
et al., 2010; Gelb, Shapiro & Thornton, 2010; Griva et al., 2012; Prendergast & Gaston, 
2010). 
Employment. Unemployed KT recipients have much higher rates of post-KT 
graft loss, mortality rates, and low HRQoL compared to those who are employed (Begaj, 
Khosla, Ray, & Sharif, 2013; Danuser, Simcox, Studer, Koller, & Wild, 2017; Nour, 
Heck, & Ross, 2014; Prihodova et al., 2015; Tzvetanov et al., 2014). The majority of KT 
recipients are between the ages of 18 and 64 years during which period adults are 
commonly employed; therefore, it is expected that KT recipients will return to productive 
roles after successful transplants (Tzvetanov et al., 2014). Full-time employment is a 
source of income and health insurance, as well as a significant indicator of an 
individual’s health recovery (Danuser et al., 2017; Ferrario, Verga, Piolatto, & Pira, 
2014; Nour et al., 2014; Tzvetanov et al., 2014). However, the post-KT employment rate 
is lower than that of the general population. The employment rate post-transplant is 
between 28%–58% (Danuser et al., 2017). Nour et al. (2014) surveyed 60 KT recipients 
in Canada (average age 49.4 years) and reported that pre-transplant employment rates 
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decreased (p = .00) from 68.3% prior to the transplant to 38.3% post-transplant, while the 
retirement rate increased 10% post-transplant. Nour et al. (2014) and Tzvetanov et al. 
(2014) also found that unemployed KT recipients were more likely to be elderly, live 
alone, have a low education level, live on a limited income, and perceive low emotional 
and physical health status (p < .01). Other researchers have found that people who were 
non-diabetic, employed before transplant, and aged 25–54 years had higher rates of 
returning to full-time employment post-transplant (Danuser et al., 2017; Helanterä, 
Haapio, Koskinen, Grönhagen-Riska, & Finne, 2012) 
Clinical Variables 
Comorbidities. Achieving optimal clinical outcomes in patients with chronic 
conditions mainly depends on the patient’s SM. However, SM behaviors can be complex 
for individuals with multiple comorbidities (Bayliss et al., 2007; Schulman-Green et al., 
2012). Kerr and colleagues (2007) conducted a survey with 1,901 diabetes patients and 
found that an increased number of comorbidities is negatively correlated to SM ability 
and disease prioritization (p < .001). The presence of comorbidities is one of the 
predictors of post-KT outcomes, and the increased number of comorbid conditions is 
positively associated with higher patient mortality and graft loss (Cossart, Staatz, 
Campbell, Isbel, & Cottrell, in press; Vranian et al., 2018; Wu et al., 2005).  
Jassal and colleagues (2005) analyzed 6,324 Canadian KT recipients and found 
that 21% had at least one comorbid condition. Machnicki et al. (2011) examined United 
States Renal Data System data for 24,963 deceased KT recipients between 1995–2002 
and found that 25% of KT recipients had more than three comorbidities per the CCI, and 
20% had more than six comorbidities per the Elixhauser Comorbidity Index. In the 
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Machnicki et al. analyses, the most reported comorbidities were hypertension (74.73%) 
and diabetes (30.47%). Furthermore, investigators (Chakkera et al., 2005) estimate that 
15%–30% KT recipients will develop new onset diabetes after transplantation (NODAT) 
within one-year post-transplant. Those KT recipients with NODAT also have been found 
to have up to 60% increased incidence of graft loss and 90% increased mortality risk 
(Chakkera et al., 2005). In addition, CV disease is the leading cause of death in KT 
recipients, and diabetes, hypertension, dyslipidemia, obesity, and use of 
immunosuppressant corticosteroids and tacrolimus are well established CV risk factors 
(Carpenter et al., 2012; Laging et al., 2016; Vanrenterghem et al., 2011; Young, Kupzyk, 
& Barnason, 2017).  
Duration on pre-transplant dialysis. Evidence suggests that longer duration on  
pre-transplant dialysis links to increased risk factors for CV events and cancer, which are 
the major causes of death among KT recipients (Haller, Kainz, Baer, & Oberbauer, 2017; 
Helanterä et al., 2014; Remport et al., 2011; Wong et al., 2013). Chronic dialysis patients 
have an increased cancer risk compared to age-matched general population, and KT 
recipients are at even higher cancer risk because of side effects from IS medication. 
Studies suggest that chronic pre-transplant dialysis is an independent risk factor 
contributing to increased patient mortality and graft loss rates; KT recipients with fewer 
than one year or one to three years of pre-transplant dialysis demonstrate better transplant 
outcomes than KT recipients with more than three years of dialysis (Helanterä et al., 
2014; Remport et al., 2011; Wong et al., 2013).  
Type of KT. Those KT recipients who receive a kidney from a living donor have 
approximately 50% less graft loss after one year and 80% less graft loss after two years 
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than patients who receive a kidney from a deceased donor (Chisholm-Burns, Erickson, 
Spivey, & Kaplan, 2012; Denhaerynck et al., 2007; Gremigni et al., 2007; Hansen, 
Seifeldin, & Noe, 2007; Hart et al., 2017; Prendergast & Gaston, 2010). In addition, 
kidneys may come from a related or unrelated living donor; both types of living KT share 
similar long-term outcomes (Davis & Delmonico, 2005).  
Post-Transplant SM, Patient Activation Level, and Self-Efficacy 
Post-Transplant SM 
In chronic conditions, SM is defined as the actions taken to manage the impact of 
the chronic condition in all aspects of daily life; this process involves attitudes, behaviors, 
and skill sets (Lawn & Battersby, 2009). In KT, SM is the range of behaviors patients 
perform in managing their own care, including ways they follow prescribed  
post-transplant treatment regimens, promote their own health, prevent health 
deterioration, and preserve graft function (Berger, 2014; Gordon et al., 2009; Haspeslagh 
et al., 2013; Hedayati et al., 2017; Kasiske et al., 2009). To be more specific, KT SM 
includes IS medication management, adherence to post-transplant treatment regimen and 
diet recommendations, self-monitoring of allograft function, infection prophylaxis, 
decision-making about seeking care, and physical function maintenance, lifestyle 
modification (e.g., weight management), and skin cancer precautions (Haspeslagh et al., 
2013; Hedayati et al., 2017; Kasiske et al., 2009; Schäfer-Keller et al., 2008).  
SM and medication adherence. The definition of medication adherence includes 
no missed medication episodes, timely prescription refills, seeking help from a health 
professional to adjust medication or dose if any acute side effects present, and taking 
medication as prescribed including time, frequency, and correct dosage (Butler, Roderick 
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et al., 2004; Nevins, Nickerson, & Dew, 2017). Unfortunately, KT recipients have the 
highest medication non-adherence rate among all types of organ transplant patients at 
35.6% per year (Russell et al., 2010). Poor post-KT outcomes may be attributed to poor 
IS medication adherence (Nevins et al., 2017). Adherence to IS medication regimens is 
the major predictor of the long-term outcome of the transplanted kidney, with 
consequences of poor IS medication adherence including graft failure, return to dialysis, 
second transplant, or death (Low, Williams, Manias, & Crawford, 2014; Reese et al., 
2017; Russell et al., 2010).  
Kidney shortage is a major problem facing patients with end-stage renal disease 
(ESRD) or kidney failure. The demand for KT increases each year. As of January 30, 
2018, a total of 95,296 candidates were on the wait list, according to the UNOS (n.d.). 
Maximizing the survival of transplanted kidneys by promoting KT recipients’ medication 
adherence is crucial considering the demand for kidneys, the negative impact of IS 
medication non-adherence on transplant outcomes, and the economic burden of  
non-adherence (Marsicano et al., 2015; Reese et al., 2017).  
Factors associated with poor adherence to IS regimens include forgetfulness and 
complexity of post-transplant regimens (Dobbels et al., 2010; Gheith, El-Saadany,  
Abuo Donia, & Salem, 2008; Nevins et al., 2017; Russell et al., 2007; Simons & Blount, 
2007). Greenstein and Siegal (1998) reported that 47% of non-adherence was the result of 
accidental forgetting. This type of non-adherence may be improved by assisting KT 
recipients to form habits, create organization, and simplify medication dosing (Cossart  
et al., in press). Kuyper et al. (2013) conducted a randomized multi-center controlled trial 
to assess the impact of once-daily IS regimens (QD) compared to twice-daily regimens 
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(BID) on KT recipients’ medication adherence (N = 219). Each participant had been 
taking a twice-daily regimen for 3 months, and 145 participants were assigned randomly 
to the QD group. The QD group showed higher adherence rates than the BID group 
during the 6 months after the intervention (p = .0009).  
After-transplant IS medication non-adherence is a complex behavioral issue. 
Transplant recipients who perceived the benefits of the transplant and associated 
treatment in their lives were motivated to be adherent to their treatment regimens 
(Dobbels et al., 2017; Mellon et al., 2017). However, motivation is not a stable and strong 
predictor for KT recipients following treatment regimen. The medication-adherent 
behavior of KT recipients declines over time post-transplant. For example, Massey and 
colleagues (2015) showed that KT recipients’ medication adherence decreased to 69% at 
18 months post-transplant. The perceived necessity of medication and the perceived 
impact of the transplant on HRQoL also decreased. Understanding KT recipients’ 
exceptions of allograft outcomes, perceived barriers to following a treatment regimen, 
and motivations to maintain medication adherence behaviors and integrating these with 
SM goals may help promote treatment adherence in this population (Massey et al., 2015; 
Nevins et al., 2017). 
Researchers have suggested that interventions to promote medication adherence 
should combine education with behavioral and social support (Denhaerynck et al., 2005; 
Nevins et al., 2017; Scheel et al., 2018). Chisholm-Burns et al. (2013) conducted a 
pharmacist-led intervention study to evaluate whether a one-year behavioral intervention 
program impacted kidney recipients’ medication adherence behaviors, healthcare 
utilization, and cost. Patients in the intervention group (n = 76) were highly adherent to 
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medication compared to the control group (p < .0001) and had lower hospitalization rates 
of 23.9% during the 12 months of the study compared to the control group’s 57.3%. 
Fewer hospitalizations resulting in cost savings also were noted.  
SM and clinical outcomes. The results of numerous studies have shown that 
efficacious SM helps patients with chronic illness to reduce distress and leads to less  
re-hospitalization, fewer emergency room visits, and reduced healthcare costs by 
preventing or alleviating disease progress. Furthermore, those individuals who effectively 
self-manage their illness ultimately have better quality of life (Lorig & Holman, 2003; 
Novak, Costantini, Schneider, & Beanlands, 2013; Redman, 2007, 2009; Zimbudzi, Lo, 
Ranasinha, Kerr, Usherwood et al., 2017). Among the Type 2 diabetes population, 
Norris, Lau, Smith, Schmid, and Engelgau (2002) systematically reviewed 31 
randomized controlled trials to examine the effects of a diabetes SM education 
intervention on type 2 diabetes glycemic control at baseline and at follow-up intervals. 
The results showed that the interventions decreased HgbA1C by 0.76% (95% CI,  
0.34–1.18) more than the control group. SM skills, behavior, and habits may take time to 
learn and form (Steinsbekk, Rygg, Lisulo, Rise, & Fretheim, 2012). Steinsbekk et al. 
(2012) reviewed 21 randomized controlled trials and found that clinical outcomes 
including HgbA1c (p = .006), lifestyle, SM skills (p = .001), and diabetes knowledge 
were significantly improved at 6 months (p = .00001).  
Hypertension, diabetes, and chronic kidney disease are well established as risk 
factors for CV events. McManus et al. (2014) conducted a randomized controlled trial 
that included 552 adult hypertensive patients with coronary heart disease, diabetes, or 
chronic kidney disease to examine the effect of SM on blood pressure control. At 12 
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months, participants in the intervention group had reduced their mean systolic blood 
pressure by 9.2mmHg (95% CI, 5.7–12.7) and diastolic blood pressure by 3.4mmHg 
(95% CI, 1.8–5.0) compared to the usual care group.  
SM and physical function. Transplant recipients’ physical function is tied to 
post-transplant mortality and outcomes (Lorenz et al., 2017). Death and CV events with 
functioning graft are linked strongly to low physical activity (Afsar et al., 2018). Regular 
exercise has been found to improve physical function and quality of life in the transplant 
population (Mathur et al., 2014; O’Connor et al., 2017). Cramm and Nieboer (2012) 
conducted a study in the Netherlands to examine correlations between SM abilities, 
physical function, and depressive symptoms in patients with CV disease, chronic 
obstructive pulmonary disease, and diabetes (N = 2,899). They found that SM abilities 
can be used to predict physical function and depressive symptoms in all groups (p < 
.0001), and as SM abilities increased, the decline of physical function slowed and there 
were also fewer depressive symptoms.  
SM and lifestyle modification. Long-term use of IS medications is associated 
with high risk of developing NODAT, CV disease, dyslipidemia, obesity, and 
hypertension, all of which are linked to graft loss and mortality (Ahmadi et al., 2014; 
Cooper et al., 2017; Glicklich, Lamba, & Pawar, 2017; Sarno et al., 2012). Researchers 
estimate that more than 50% of kidney recipients will have weight gain at 12 months 
post-transplant (Cashion et al., 2014; Chan et al., 2014; Kugler et al., 2015). Adhering to 
lifestyle recommendations including healthy diet, exercise, and weight loss has been 
found to reduce CV risk (Chow et al., 2014; Klaassen et al., 2017; Lidin, Ekblom-Bak, 
Rydell Karlsson, & Hellénius, 2017). In chronic disease populations, de Alba Garcia and 
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colleagues (2007) interviewed 62 Mexican diabetes patients in their investigation of 
lifestyle modification and SM behavior attributed to good HbA1C control (< 7.0%). The 
study results demonstrated that patients with well controlled HbA1C exercised regularly, 
ate a healthy diet, and knew their target blood glucose level. Pettman et al. (2008) 
conducted a lifestyle intervention study in Australia with 153 overweight/obese (mean 
BMI was 36.6 ± 0.7) adults with metabolic syndrome. Investigators randomly assigned 
participants to control group and intervention group. Both groups were provided 
education booklets about healthy eating and physical activity, but the intervention group 
additionally was provided with exercise sections and lifestyle SM information classes 2 
hours per week for 4 months. Results indicated that reduction in body fat mass, blood 
pressure (DBP r = -0.31, p < 0.001; SBP r = -0.28, p = 0.01), cholesterol (r = -0.35, p < 
0.001), and glucose (r = -0.35, p < 0.001) were positively correlated with attendance at 
exercise and information sessions.  
SM and skin cancer screening. Cancer is one of the leading causes of death in 
the KT population (Kato et al., 2016; Wong, Chapman, & Craig, 2014). Skin cancer 
mortality in U.S. KT population was reported at 35.25 per 100,000 person-year (Garrett, 
Lowenstein, Singer, He, & Arron, 2016). Transplant recipients are at 10- to 250-fold 
greater risk of developing nonmelanoma skin cancer because of the combined effects of 
long-term use of IS medication and ultraviolet radiation exposure or certain types of viral 
infection. In addition, the risk of developing nonmelanoma skin cancer increases with 
time under IS medication treatment (Bannon et al., 2014; Burke et al., 2015; Engels et al., 
2011; Kang, Sampaio, Huang, & Bunnapradist, 2017; Wheless, Jacks, Potter, Leach, & 
Cook, 2014). Monthly skin and lip self-examinations, annual clinical skin examinations, 
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and sun protective precautions are recommended for transplant recipients to detect and 
prevent skin cancers (Acuna et al., 2017; Feuerstein & Geller, 2008; Kasiske et al., 2010).  
Interventions related to skin cancer prevention have been found to effectively 
promote participants’ engaging in self-skin examination and sun protection behaviors 
(Tsai, Frank, & Bordeaux, 2017). A randomized controlled trial assessed effectiveness of 
skin cancer education on sun protective behavior, self-skin examination, and knowledge 
regarding skin cancer among African Americans. Tsai et al. (2017) reported a statistically 
significant score difference between pre-intervention and post-intervention for sun 
protective behavior (p < .02), confidence in conducting self-skin examination (p < .001), 
and knowledge regarding skin cancer risk (p = .001).  
Oliveria et al. (2004) conducted a case control study of the effect of a nurse-led 
education intervention on patients’ adherence to self-skin examination (n = 100). At  
4-month follow-up, 61.2% of the patients in the intervention group reported performing 
self-skin examination more than three times during the past 4 months (p = 0.039) 
compared to 37% of the control group (p = 0.001). Males aged 50 years or greater have a 
higher incidence rate and death rate of skin cancer than females. Janda and colleagues 
(2014) conducted a randomized clinical trial with 870 men aged 50 years or older. 
Participants were randomly assigned into a brochure-only group and a video-based 
intervention group. Both groups reported receiving a physician-conducted skin 
examination in the previous 6 months (56.4% for intervention group and 52.8% in control 
group, p = .28), but 35.3% of the intervention group performed a whole-body self-skin 
examination compared to 27.2% of the control group (p = .01). Robinson et al. (2014) 
aimed to enhance sun protection behaviors in the KT population. Robinson and 
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colleagues found that knowledge and perception regarding the risk of developing skin 
cancer, attitude toward sun protection, and willingness to engage in behavior change were 
significantly higher in the intervention group (p < 0.01); engaging in sun protection 
behaviors was significantly higher in the intervention group (p < 0.013).  
SM summary. Post-KT SM is a complex and multi-dimensional task; kidney 
recipients are expected to self-manage their own care actively. However, it must be kept 
in mind that post-transplant SM is a lifelong, day-to-day task for kidney recipients, and 
SM skills and behaviors do not develop spontaneously and persist without support from 
healthcare professionals (Dwarswaard, Bakker, Staa, & Boeije, 2015; Hedayati et al., 
2017). Novak and colleagues (2013) reported that education is a crucial part of SM 
support. Furthermore, the patient’s readiness to learn about his or her care needs should 
be identified before intervening.  
In addition to focusing on self-managing general clinical conditions, this literature 
review addressed SM interventions that can enhance and promote a healthy lifestyle and 
reduce cancer and CV disease risk. The relationships among patient activation, SM 
behaviors, HRQoL, and demographic variables/antecedents also were depicted in this 
literature review. Previous studies of SM in other chronic disease populations have 
indicated that perceived self-efficacy has direct effects on SM behaviors, and there is a 
positive correlation between patient activation and SM behaviors. Thus, this study 
examined the relationships among self-efficacy, patient activation, and disease-specific 
SM behaviors and their association with post-transplant SM and HRQOL in the KT 
population.  
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Patient Activation 
The individual plays an active role in managing his or her own care and has the 
knowledge, skill, and confidence to improve and maintain health, collaborate with 
healthcare providers, and seek appropriate care and information (Bilello et al., 2018; 
Hibbard et al., 2004; Shively et al., 2013; Smith et al., 2013). Highly activated patients 
are more likely to perform health-related behaviors including self-managing behaviors, 
adapting to healthy lifestyle, and seeking health information (Bilello et al., 2018; 
Hibbard, 2017; Nijman et al., 2014; Ryvicker et al., 2013; Shively et al., 2013). 
Individuals with a high patient activation level have been shown to be more successful in 
controlling HgbA1C by self-monitoring blood glucose, following diet and treatment 
recommendations, and modifying their lifestyles (Sacks, Greene, Hibbard, Overton, & 
Parrotta, 2017; Salgado et al., 2017). Patient activation levels also are negatively 
correlated with 30-day post-discharge readmission and emergency room visits (Greene & 
Hibbard, 2012; Hibbard et al., 2004; Mitchell et al., 2014).  
Magnezi et al. (2014) studied the relationships among patient activation levels, 
quality of life, and depressive symptoms for 278 subjects recruited from two primary care 
clinics in Israel. They found that PAM scores were negatively correlated with scores on 
the Patient Health Questionnaire-9 (r = -0.35, p < .0001) and positively correlated with 
scores on the 12-Item Short Form Health Survey (SF-12; r = 0.39, p < .0001). 
Evangelista et al. (2015) investigated the effect of an intervention program on patient 
activation, self-care, and quality of life among heart failure patients. The Evangelista  
et al. study revealed positive associations among patient activation (r = 0.658, p < .0001), 
self-care maintenance (r = 0.335, p = 0.033), and overall quality of life (r = 0.329,  
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p = 0.35). Demographic characteristics associated with PAM scores were reported in 
other studies; men, individuals with 12 or more years of education, higher income 
earners, and younger people scored higher on the PAM (Hendriks & Rademakers, 2014; 
Nijman et al., 2014).  
Self-Efficacy 
Self-efficacy is one’s belief or confidence in being able to successfully master a 
given task (in this case, SM behavior) and reach the desired goal (Bandura, 1997; 
Denhaerynck et al., 2007). In chronic disease SM studies, interventions intended to 
improve self-efficacy have shown positive effects on individuals’ health promotion 
practices and on patient outcomes (Andela et al., 2017; Chirico et al., 2017; Farrell, 
Wicks, & Martin, 2004; Lorig & Holman, 2003). Moreover, perceived self-efficacy has 
been shown to be positively associated with health behavior change and maintenance 
including medication adherence, following exercise or diet recommendations, and stress 
management (Chirico et al., 2017; Kauric-Klein, Peters, & Yarandi, 2017; Tokdemir & 
Kav, 2017; Weng et al., 2010). Sarkar et al. (2006) examined the relationships between 
diabetes SM behavior and self-efficacy and found that self-efficacy for diabetes SM was 
positively associated with four of five SM domains (p < .01), including following diet 
recommendation, exercising regularly, self-monitoring blood glucose, and foot care. 
Jones and Riazi (2011) systematically reviewed 22 articles on post-stroke self-efficacy 
and SM and concluded that self-efficacy is positively associated with various post-stroke 
outcomes including quality of life, perceived health status, less depressive syndrome, and 
higher physical functioning.  
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In KT studies, the correlations between self-efficacy and medication adherence 
behavior have been well examined (Weng, Yang, Huang, Chiang, & Tsai, 2017).  
De Pasquale et al. (2014) conducted a study with 120 Italian KT recipients and found 
positive correlations between self-efficacy, disease management, and quality of life.  
De Pasquale et al. also found that high self-efficacy was correlated with mental health; 
for example, as self-efficacy increased, patients’ perceived mental health improved. 
Similarly, KT recipients with higher self-efficacy also scored higher on problem-solving, 
patient–provider partnership, medication adherence, and self-care/self-managing behavior 
(Weng et al., 2010; Weng et al., 2017). 
In summary, self-efficacy has been used to predict a broad range of both physical 
and psychological health behaviors and health outcomes. It is positively correlated with 
treatment adherence, quality of life, SM behaviors, physical function, and mental health.  
HRQoL 
Factors that Influence HRQoL 
Tharavanij and colleagues (2008) reported that KT recipients have higher HRQoL 
compared to dialysis patients and ESRD patients. Nevertheless, KT may not fully restore 
KT recipients’ level of HRQoL to that of the general population. In addition, decreased 
HRQoL can result in patients’ treatment non-adherence behavior (Tharavanij et al., 
2008). Researchers report that patients’ perceived HRQoL reflects their current health 
status (Joekes, Van Elderen, & Schreurs, 2007). As a result, HRQoL has been recognized 
as an imperative post-transplant outcome (Fujisawa et al., 2000; Kugler et al., 2013; 
Prihodova et al., 2014). Clinical and psychological risk factors that negatively impact 
post-transplant outcomes also have negative effects on HRQoL among the KT 
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population, including depression, age, unemployment, immunosuppressant side effects, 
limited physical function, diabetes, CV disease, serum level of creatinine, and glomerular 
filtration rate (Fujisawa et al., 2000; Griva et al., 2013; Molnar-Varga et al., 2011; Ortiz 
et al., 2014; Prihodova et al., 2014).  
HRQoL and Clinical Outcomes 
Can a patient’s perceived HRQoL be used to predict KT long-term mortality and 
graft loss risk factors? In a 12-year longitudinal study conducted in the United Kingdom 
(Griva et al., 2013), 347 KT recipients were asked to complete the Medical Outcomes 
Study Short Form-36 (SF-36) at baseline. Eighty-six (24.8%) KT recipients died during 
the 12-year follow-up period; of these, 64 died with a functioning graft. In addition, 38 
KT recipients had returned to dialysis. Lower physical HRQoL increased risk of 
mortality and graft failure significantly during the study period. The physical component 
score of the SF-36 was associated with long-term mortality and graft failure after 
adjusting for risk factors such as CV disease; long-term mortality and graft survival could 
also be predicted by HRQoL.  
Another longitudinal study conducted in the Slovak Republic had similar results 
(Prihodova et al., 2014). A total of 151 KT recipients were asked to complete the ESRD 
check list, a socioeconomic and medical data questionnaire, and SF-36 at baseline. The 
results showed that KT recipients who perceived less severe medication side effects and 
demonstrated high self-efficacy for emotional coping were associated with higher 
HRQoL at baseline. Moreover, those who reported better graft function, high physical 
component and mental health component scores on the SF-36, and older age at baseline 
also reported better 10-year graft survival rate and lower patient mortality rates. 
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Prihodova et al. (2014) suggested that close monitoring of early HRQoL along with graft 
function at baseline could lead to improved odds of 10-year graft and patient survival 
rates. 
HRQoL and SM 
Better disease SM and lifestyle modifications have been shown to result in 
improved HRQoL (Kidd et al., 2017; Tharavanij et al., 2008). Gaston-Johansson et al. 
(2013) reported that a SM intervention effectively improved quality of life in patients 
with stage 2, 3, and 4 breast cancer (N = 73) who were undergoing chemotherapy. 
Gaston-Johansson et al. provided participants in the intervention group with education 
materials and taught relaxation and coping skills two weeks before the patients were 
admitted to the hospital, during chemotherapy treatment, and three months after 
discharge. All survey data from the Quality of Life Index-Cancer Version (correlation 
coefficient, 0.95) were collected at baseline and at one-year follow-up. There were 
statistically significant improvements in the intervention group in overall quality of life  
(p < 0.01), health and functioning (p < 0.05), and psychological/spiritual well-being (p < 
0.01). E Vries and colleagues (2007) conducted a randomized controlled trial to 
determine if a general practitioner-led SM (SM) program resulted in improved Asthma 
Quality of Life (correlation coefficient, 0.95), limited activity days, and respiratory 
functions in asthma patients (N = 214). Asthma control, limited activity days, overall 
asthma quality of life (p = 0.055) and emotion domain (p = 0.055) were significantly 
improved in the SM group compared to the usual care group. McGillion et al. (2014) 
conducted a meta-analysis with nine trials included (N = 1,282) examining an SM 
intervention effect on stable angina symptoms, HRQoL, and psychological  
38 
well-being. Patients’ HRQoL was measured with the Seattle Angina Questionnaire 
(SAQ), which consisted of four subscales: angina frequency, physical limitation, disease 
perception, and treatment satisfaction. The analytic results suggest that angina frequency 
(standard mean difference: 0.30 (95% CI 0.14, 0.47, p = 0.0003) and SAQ physical 
limitation (95% CI 0.20, 0.55, p < 0.0001) were significantly improved by the SM 
intervention.  
However, the results reported in the literature are inconsistent. Walters et al. 
(2013) conducted a randomized controlled trial to evaluate the effectiveness of a 
telephone-delivered health-mentoring intervention for chronic obstructive pulmonary 
disease patients. The HRQoL of these patients was measured using the SF-36 and  
St. George’s Respiratory Questionnaire, with data collected at baseline, 6 months, and 12 
months. Findings showed no difference in the quality of life scores in both groups, 
although SM capacity (95% CI 0.03 to 0.29) and knowledge (95% CI 0.00 to 0.50) 
increased in the SM group. Weng et al. (2010) reported similar results; they found a 
positive correlation between self-efficacy and SM in KT recipients, but no direct effect 
on the physical component of the SF-36.  
HRQoL Summary 
In past studies, HRQoL has been recognized as an important post-transplant 
outcome measure because it is an indicator of treatment effectiveness in KT. Risk factors 
associated with graft loss and patient mortality have been found to be associated with 
HRQoL as well. Recently, researchers have examined whether early post-transplant 
HRQoL can be used as a predictor in predicting long-term KT outcome. In the adapted 
KT-SM framework, HRQoL was used as a post-KT outcome because one of the study 
39 
hypotheses was that improvement in patient activation level would enhance transplant 
recipients’ SM behaviors and further improve HRQoL in KT recipients. 
Existing Post-KT SM Scales 
There are three existing KT SM-related instruments (Kosaka et al., 2013;  
Schmid-Mohler et al., 2014; Weng et al., 2010). Table I-1 (Appendix I) presents a review 
of the KT SM scales. The following list categorizes the limitations of the three different 
SM scales:  
1. Weak theoretical foundation: In developing a questionnaire that has 
validity and clinical usefulness (utility), a clear conceptual framework (or 
theory) is essential (DeVellis, 2012). The content of a measuring tool may 
not reflect the phenomenon of study without theoretical grounding (Jordan 
et al., 2013). Experts suggest that clear construct definition is the first and 
foremost step in scale development, and theory is an aid to clarifying the 
construct to be measured in study (DeVellis, 2012; Netemeyer, Bearden, 
& Sharma, 2003). Of the three KT SM scales, only the one by  
Schmid-Mohler et al. (2014) was developed according to Lorig and 
Holman’s (2003) conceptualization of SM tasks and demonstrated logical 
consistency. Weng et al. (2010) claimed to use Bandura’s concept of  
self-efficacy, but the authors failed to conceptually define self-efficacy 
and post KT self-care. Kosaka and colleagues (2013) did not report what 
framework/theory they used to guide the study.  
2. Lack of construct definition: Items of each subscale do not reflect the 
researchers’ SM definitions. For instance, Weng et al. (2010) indicated 
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that medication-taking behavior, better dietary control, and  
health-promoting behavior are associated with better quality of life  
post-KT but did not include items about any of these subjects in their 
scale. Kosaka et al. (2013) did not conceptually define post-transplant SM 
in their article. 
3. Item writing and wording clarity: A good item should be straightforward 
to read, contain short sentences, consider the reading level of the target 
population, and avoid double-barreled items (DeVellis, 2012; Netemeyer 
et al., 2003). Schmid-Mohler and colleagues (2014) did not provide a 
sample of their written items and based on their description of their paper, 
they were at the beginning phase of item development. Many items in the 
existing scales were lengthy and can be considered double- or  
triple-barreled questions, such as “When decrease of urine or edema 
occurs, I would spontaneously control the absorption of water and take 
lesser salt” (Weng et al., 2010) and “I perform gargling and hand 
washing” (Kosaka et al., 2013) or were too general to answer, such as “I 
keep my house clean” (Kosaka et al., 2013).  
4. Reliability or validity issues: Schmid-Mohler and colleagues (2014) did 
not report reliability and construct validity data. Neither Kosaka et al. 
(2013) nor Weng et al. (2010) reported construct validity statistics. 
5. Translation quality and cross-cultural adaption issues: Translation quality 
is a major concern. These three scales were developed and tested in 
Taiwan, Japan, and Switzerland. The investigator in this study is a native 
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Chinese speaker, a U.S.-trained doctoral candidate, and can read Chinese 
and Japanese; the investigator requested English and source language 
(Japanese and Mandarin Chinese) versions of the scales by Kosaka et al. 
(2013) and Weng et al. (2010). Upon review, the English translations of 
some items did not match the original-language versions. The investigator 
used the backward translation procedure suggested by Sousa and 
Rojjanasrirat (2011) to translate Weng’s English version back to Chinese 
and compared two versions. There were many discrepancies in meaning 
and word choice. Cross-cultural adaptation is another concern. Some items 
such as, “I would avoid going to public spaces where there are too many 
people or the air quality is bad,” or “I would not eat strong flavored food” 
could have been developed based on geographic reasons and food 
preferences in Eastern culture. However, similar items are difficult to 
apply to the U.S. population. Therefore, it became clear to the investigator 
that a new, comprehensive, and specific scale is necessary for the U.S. KT 
population. 
Summary 
The chapter presented research findings regarding SM behaviors and reviews 
existing post-KT SM scales. It discussed risk factors/antecedents that contribute to  
non-adherence, self-efficacy and patient activation, and post-KT HRQOl. The chapter 
concluded by presenting the three existing KT SM scales. Chapter Three presents the 
methodology used in this study including participant eligibility, the study design, 
recruitment strategies and the data analysis methods used.  
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CHAPTER THREE 
METHODOLOGY 
This chapter describes the methods used to conduct the present study including 
participant eligibility criteria, study design development, discussion of the sample size for 
psychometric testing of the new KT-SM scale, methods and procedures used for 
recruiting the sample from Facebook, strategies to prevent survey non-response, 
protection of human subjects, and online data collection. A description of the data 
analysis methods also is included. The final section presents the results of the cognitive 
review and content validity scores of the new KT-SM scale. 
Eligibility Criteria 
The inclusion criteria for this study required KT recipients to: 1) be more than 18 
years of age, 2) have received a KT that is still functioning, 3) be willing to complete a 
study survey, and 4) have been treated and received follow-up care in the U.S. Exclusion 
criteria included transplantation of any organ other than the kidney.  
Study Design 
The study used a cross-sectional, descriptive, correlational design. Data were 
collected using a self-administered, online survey developed and delivered through 
REDCap® (Research Electronic Data Capture).  
Sample 
To conduct factor analysis for psychometric testing of the KT-SM scale, the 
investigator selected a rule of five subjects per item for sample size estimation. The  
KT-SM scale contains 29 items; therefore, a sample size of 153 adult KT recipients was 
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sufficient for this study (DeVellis, 2012; Fall, Gauchet, Izaute, Horne, & Chakroun, 
2014; Williams, Onsman, & Brown, 2012).  
Considering that KT recipients constitute a relatively small population, to obtain a 
large enough study sample for psychometric testing a social network-based recruitment 
strategy using Facebook® was utilized. This strategy included a Facebook study page, 
Facebook support groups, and paid Facebook advertising. Facebook is the most popular 
social networking site in the U.S. and is used by an estimated 68% of American adults 
(Pew Internet & American Life Project, 2015). Facebook has been found in recent years 
to be an effective recruiting tool in health-related research including clinical trials and 
intervention studies (Kayrouz, Dear, Karin, & Titov, 2016; Pedersen et al., 2015; 
Pedersen & Kurz, 2016; Weiner, Puniello, Siracusa, & Crowley, 2017). Advantages of 
using social media recruitment include timely data collection, low cost, efficient use of 
recruitment efforts, wider coverage of the study population, and broader geographic 
range (Dillman, Smyth, & Christian, 2014; McPeake, Bateson, & O’Neill, 2014; Sikkens, 
van San, Sieckelinck, Boeije, & de Winter, 2017).  
Studies using online surveys and Facebook as a recruitment tool have 
demonstrated that surveys with 10%–20% unanswered items may be accepted and 
included in the final data analysis (Akard, Wray, & Gilmer, 2015; Pedersen et al., 2015). 
In this study, surveys with 10% or more unanswered items were excluded from data 
analysis to ensure data quality. Two hundred and thirty-two adult KT recipients were 
needed based on an estimate of 60% nonresponse plus drop-out rates. Initially, 183 
surveys were obtained. Of these, 30 surveys were eliminated because of 
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misrepresentation issues—that is, survey takers may not have been kidney recipients but 
were pretending they were. This left 153 usable surveys for the data analyses.   
Procedures 
Facebook Recruitment Methods 
Using Facebook as a recruitment tool along with online surveys is cost- and  
time-efficient and makes it possible to approach hard-to-reach populations including 
young people, low-income populations, and small-in-number populations of interest 
(Batterham, 2014; Kayrouz et al., 2016; Sikkens et al., 2017; Weiner et al., 2017). The 
investigator found the following strategies effective in recruiting research participants 
using Facebook (Alshaikh, Ramzan, Rawaf, & Majeed, 2014; Amon, Campbell, Hawke, 
& Steinbeck, 2014; Ramo, Rodriguez, Chavez, Sommer, & Prochaska, 2014) for this 
study: creating and paying to promote a Facebook study page, recruiting from Facebook 
support groups, and paying for standard Facebook Ads.  
Promoting the Facebook study page. The PI designed a Facebook study page 
(Figure J-1) to use as a recruiting tool and to address questions or concerns from potential 
participants. The investigator paid Facebook to promote the page, which increases 
visibility with a targeted audience (Facebook Business, About business page promotions, 
n.d.). To increase effectiveness of the Facebook study page itself as a recruiting source, 
the content of the page included descriptions of the study information and posts intended 
to recruit participants. The posts also included the study purpose, time required to 
complete the online survey, contact information of the PI, and a link to the REDCap 
study information and screening page. The investigator posted recruiting posts and 
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pinned (i.e., locked in a specific location) them on the timeline of the Facebook study 
page, so people who visited the page would see them.  
A study page may be seen by more people when Facebook’s page-promoting 
function is used, and Facebook users invite others to like (i.e., to indicate that a person 
supports the group associated with the page or the topic being discussed) and share (i.e., 
to post the information to their personal) the page. The cost of promoting the study page 
was determined by the desired number of people who see and click on the page per day. 
The minimum and maximum daily budget ranged from $5 for 3–14 likes per day to $20 
for 17–69 likes per day. The investigator managed the money spent on page promotion 
using the daily budget and promotion duration through the Ads Manager function on the 
Facebook site. The PI adjusted the budget and advertising duration based on the number 
of survey respondents obtained in the first and subsequent weeks. The second method the 
investigator employed to increase Facebook study page visibility to a wider audience was 
to invite participants who had completed the survey and their friends to share or like the 
study page on their Facebook news feed or to leave comments on the study page. When 
people share, like, or comment on the study page, their Facebook contacts also may see 
the activities on their own Facebook newsfeed. Using these two methods reached some 
additional people who were not in any KT support groups. 
Recruiting from Facebook support groups. The investigator conducted a search 
of Facebook to identify KT support groups. Key words used to conduct the search 
included transplant, kidney transplant, transplant support group, and transplant survivors. 
The search identified and targeted six KT-related support groups, which have a total of 
more than 30,000 members. The PI contacted the administrators of each group, and 
46 
administrators from three of the groups agreed to help in the recruiting process 
(Appendix K). 
• Kidney Transplant Survivors and Donors has a total of 642 members 
(https://www.facebook.com/groups/390173347706273/members/); 
• Kidney Transplant and Weight Loss has a total of 551 members 
(https://www.facebook.com/groups/637119173042669/); and 
• Kidney Transplants has 888 members (https://www.facebook.com/groups/ 
26240800215/). 
In total, these three groups have a total of more than 2,081 members. Each support group 
administrator agreed to post and pin an initial public recruitment message on their 
Facebook support group page, and to post a second recruitment message one week later. 
They posted a thank you message two weeks after the second recruitment message 
(Appendix L).  
Using standard Facebook ads. The investigator also used paid advertising in this 
study because the three KT support groups discussed in the previous section only 
consisted of approximately 2,000 members. The PI expected the number of accessible, 
eligible participants from the support groups to be even fewer because people can join 
Facebook KT support groups even if they are not recipients, not all members in the three 
targeted transplant support groups are living in the U.S., and memberships in the support 
groups were likely to overlap.  
Paid Facebook advertisements have been found to be a time- and cost-effective 
method for recruiting participants, and the cost ranges from $1.35 to $8.88 per person 
(Akard et al., 2015; Pedersen et al., 2015; Thornton, Harris, Baker, Johnson, &  
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Kay‐Lambkin, 2016). Facebook advertisements can be targeted (this study’s targets 
enclosed in parentheses) to age (aged 18 years and above), geographic location (U.S.), 
language (English), and Facebook users’ interests within their profile (KT). Chan (2011) 
examined the impact of Facebook advertising on a university library’s Facebook page. 
The Facebook ads in the Chan study were targeted specifically and displayed only to 
current students who had not yet liked the university library’s Facebook page. After two 
months of Facebook ads, more than 50% of the new connections to the library’s 
Facebook page were added through Facebook advertising.  
There are two main types of Facebook advertising: impression-based and  
click-based (Facebook Business, Impressions, n.d.; Facebook Business, Updating how 
cost per click is measured on Facebook, n.d.). Impression ads display to a user viewing a 
Facebook page regardless if the user clicks on the ad or not. The cost of impression-based 
ads is determined by cost-per-thousand impression; for instance, the PI would pay $5 per 
day to have 1,000 people see the ad (impression). Click-based advertising is the  
cost-per-click; advertisers pay only when a viewer clicks their ads. To use Facebook 
standard ads more cost-efficiently, the investigator chose the cost-per-click method for 
the Facebook ad campaign in this study. The PI set the daily spending limit to $10 for the 
first week, with an overall limit set to $200. 
Recruitment Messages 
The Facebook recruitment strategy included the following messages: (1) a public 
recruitment message posted on each of the three transplant support group pages,  
(2) textual public recruitment message to provide information to those people who might 
not be in a transplant support group, and (3) paid Facebook advertisement messages that 
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appeared publicly in a space determined by Facebook. All messages and textual content 
were written using a seventh to eighth grade reading level (Gordon et al., 2012). The 
readability levels of the text messages were evaluated using the Simple Measure of 
Gobbledygook (SMOG; Online-Utility.org, n.d.) and the Flesch Kincaid Grade Level 
tools built into Microsoft Word 2013 (Kandula & Zeng-Treitler, 2008; McGee, 2010; 
Mcinnes, & Haglund, 2011; Walsh & Volsko, 2008). The average Flesch Kincaid Grade 
Level and SMOG index scores for the messages were eighth grade and seventh grade, 
7.3), respectively.  
The PI wrote the recruitment messages and textual content on the Facebook study 
page (Appendix J) based on the concept of social exchange (Andrews, Nonnecke, & 
Preece, 2007; Dillman et al., 2014; McPeake et al., 2014), which is that people feel 
motivated and needed when they are asked for help and advice only they can provide. To 
motivate potential participants to respond to surveys, experts suggest asking interesting 
questions, asking for participants’ advice, telling potential participants how the survey 
results will be useful, informing potential participants that only a limited number of 
people may participate in the study, providing incentives, and sharing a summary of the 
study results with survey respondents (Andrews et al., 2007; Dillman et al., 2014). 
Knowing their help can contribute may be another motivating factor (Dillman et al., 
2014; Laguilles, Williams, & Saunders, 2011). Confidentiality and privacy concerns 
regarding a Web-based survey may be a reason for people not to take a survey (Andrews 
et al., 2007). Therefore, each recruitment message included text such as “no personally 
identifiable information will be asked or collected.”  
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Strategies to Prevent Survey Non-response and Drop-out 
A lengthy survey could be burdensome to respondents and result in high  
non-response and drop-out rates (Dillman et al., 2014; Galesic & Bosnjak, 2009). The 
investigator employed strategies in this survey that have been found to be effective in 
increasing response rates and preventing respondents from quitting the survey 
prematurely: ordering of survey questions, visual presentation of questions and survey 
design, offering an incentive, and sending survey reminders (Dillman et al., 2014; 
Galesic, 2006; McPeake et al., 2014; Van Mol, 2017).  
Ordering of survey questions. This study’s survey incorporated eight sections 
that include six scales with a total of 125 questions; therefore, survey fatigue could be an 
issue. Survey fatigue occurs when respondents perceive that excessive time and effort are 
involved in completing a survey (Porter, Whitcomb, & Weitzer, 2004). They may rush 
through the survey, quit the survey, or avoid survey sub-questions by proving untruthful 
responses to reduce fatigue (Rolstad, Adler, & Rydén, 2011). The investigator thus 
arranged the order of scales according to their level of importance to the study. The 
sequence of the scales/survey questions was the KT-SM scale, the PAM, the  
SEMCD 6-item scale, the 25-item KT questionnaire, a patient survey form, a medical 
history review form, and the self-administered comorbidity questionnaire (SCQ). 
Visual presentation of questions and survey design. All text was set in black 
Arial font (Chaparro, Bernard, Mills, Peterson, & Storrer, 2001; Dillman et al., 2014). An 
existing font size adjustment button located at the top right of the first survey page 
allowed respondents to change the font size if they desired. There are two common types 
of survey designs used in online surveys: scrolling design, in which questions are 
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presented on one page, and paging design, in which questions are presented as separate 
pages without scrolling. The PI selected a scrolling design after considering the survey 
length and the different response formats of each scale. For this study, each page 
represented one survey questionnaire, so the scrolling design only created six survey 
pages. The page number displayed on the screen so that respondents were able to see 
their progress in the survey along with the total number of pages (e.g., 5/6; Crawford, 
McCabe, & Pope, 2005; Dillman et al., 2014; Peytchev, Couper, McCabe, & Crawford, 
2006). The PI realized that item non-response rate could be potentially higher in the 
scrolling design; therefore, only surveys with less than 10% non-response items were 
included in the study. To avoid survey fatigue, all participants could save survey progress 
and return to finish using a code generated by the REDCap system (Akard et al., 2015). 
Offering an incentive. Previous studies have shown that both lottery-based 
incentives and guaranteed incentives such as a gift card have a positive effect on online 
survey response rates and response quality. To be more specific, any monetary incentive, 
for example, a high-probability lottery with a small prize or a low-probability lottery with 
a large prize, increases the web survey response rate compared to no incentive. However, 
a guaranteed incentive has the best impact on response rate (Berk, 2012; Funkhouser  
et al., 2017; Halpern et al., 2011; McCluskey & Topping, 2011; Ziegenfuss, 
Niederhauser, Kallmes, & Beebe, 2013). Therefore, the investigator emailed respondents 
who submitted completed surveys a $5 electronic Amazon gift card.  
Sending survey reminders. Email reminders boost online survey response rates 
from 42% to 62% after two email reminders and increase 1% each time for third and 
fourth reminders (McPeake et al., 2014; Toledo et al., 2015). Dillman et al. (2014) 
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suggest sending multiple email reminders in case the original email is sent to the spam 
(i.e., non-requested, junk electronic mail) mail folder. It is necessary to vary the content 
of each email because sending the same email content repeatedly is unlikely to convince 
people to respond, and there is a high possibility that repeated similar emails will be sent 
to the spam mail folder. Janke (2014) found that mentioning the incentive in the email 
subject line may increase the response rate. Therefore, the investigator wrote four survey 
email reminders with different subject lines based on Dillman et al.’s (2014) examples of 
email contacts and Janke’s suggestions (Appendix M). A link to the survey was 
embedded in the email for convenient access to the survey (McPeake et al., 2014). 
Eligible participants who did not complete the full survey within seven days received the 
link, and a second email reminder was sent at 7 a.m. on the following Monday through 
the REDCap system (McPeake et al., 2014; Toledo et al., 2015). However, only two 
reminders were sent to non-respondents because REDCap had a relative complex 
procedure to resume an incomplete survey, and data collection was shorter than 
anticipated. 
Enrollment 
Regardless of the location from where participants were recruited, they each 
followed the embedded link to be directed to the study information page and an eligibility 
screening page located within the REDCap system. Each participant was asked to read 
the study information sheet attached to the REDCap page. By clicking the “yes” button, 
participants agreed that they had read the study information sheet. They were then 
automatically directed to the screening page.  
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There is a major concern when using an online survey that respondents may 
misrepresent themselves, meaning that participants are not eligible but present 
themselves as being eligible. This issue is linked to low survey quality (Al Baghal & 
Lynn, 2015; Dillman et al., 2014; Pedersen et al., 2015; Shropshire, Hawdon, & Witte, 
2009). Therefore, the PI asked each potential participant to answer four screening 
questions (Appendix N) as suggested by Kramer and colleagues (2014) to ensure that 
they have insider knowledge. In addition, the investigator asked each potential participant 
where he or she learned about the study, such as through standard Facebook ads, 
Facebook study page, Facebook support group, a friend, or other. This also helped the PI 
to assess the effectiveness of each recruiting campaign (Kramer et al., 2014; Ramo et al., 
2014). The participants who passed the screening questions linked immediately to the 
first page of the full survey. Ineligible participants received an automatic electronic 
message indicating they were not eligible for the study, thanking them for their time, and 
directing them to close their browser.  
Protection of Human Subjects 
The study received approval from the Indiana University–Purdue University 
Institutional Review Board (IUPUI IRB; Appendix O) prior to the investigator publishing 
the Facebook study page, purchasing standard Facebook Ads, paying to promote the 
study page, and collecting data. Subjects’ privacy and health information were protected 
per Health Insurance Portability and Accountability Act (HIPAA) rules.  
The investigator conducted Facebook recruitment by: (1) paying to promote the 
Facebook study page, (2) posting public recruitment messages on three KT support 
groups (total 2,081 members), and (3) using Facebook’s paid advertising feature. The 
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IRB previewed the recruitment messages for these three recruiting sites. The messages 
included the study title with an image and the directions for how to take the survey, 
required time to complete the survey, information about the incentive, and a link to the 
study information sheet page and screening page. Study information included the purpose 
of the study and the participants’ right to not answer survey questions and to terminate 
participation at any time without consequences. Participants had to read the information 
sheet and click the agree button to start the eligibility screening section.  
The risks to participating subjects were minimal; however, answering questions 
regarding post-KT care may evoke some uncomfortable feelings, especially if 
participants do not maintain a healthy lifestyle or do not always comply with their 
transplant doctor’s recommendations. The messages included the PI’s contact 
information so that participants could reach the researcher via Facebook message, email, 
and/or phone calls Monday through Friday during business hours if they had any 
concerns or questions regarding the study.  
Data Collection 
A REDCap survey was used to collect data electronically as well as store  
project-specific data. REDCap is a secure application that can export survey data to 
common statistical packages, eliminating the need for manual data entry (Akard et al., 
2015; Harris et al., 2009; Patridge & Bardyn, 2018; Wong, Captur et al., 2014). A data 
management professional conducted a pilot test with 10 artificial data sets prior to official 
data collection to ensure that the survey tool functioned without flaws. The survey 
questionnaire consisted of eight sections: (1) study information page (Appendix J) and 
eligibility screening questions (Appendix N); (2) the post KT-SM scale (Appendix P);  
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(3) the 13-item PAM (Hibbard et al., 2005; Appendix Q); (4) the SEMCD 6-item scale 
(Lorig et al., 2001; Appendix G); (5) the 25-item KTQ-25 (Laupacis et al., 1993; 
Appendix H); (6) demographic information collected using a patient survey form 
(Appendix B); and (7) clinical data collected using a medical history review form 
(Appendix C); the SCQ (Sangha, Stucki, Liang, Fossel, & Katz, 2003; Appendix D);  
(8) thank-you messages (Appendix L). Data were collected at a single point in time 
through a self-administered REDCap online survey. A total of 153 completed and useable 
surveys were obtained.  
Measures 
The main purpose of this study was to test the reliability and validity of a newly 
developed 29-item post-KT-SM scale. Self-efficacy, patient activation, HRQoL, 
comorbidities, and demographic data were measured in this study to describe the sample 
and test for the validity of post-KT SM. The sections that follow provide detailed 
descriptions of the instruments used in this study. Permission to use the PAM (Figure  
A-2), KTQ-25 (Figure A-3), and SCQ (Figure A-4) were obtained prior to data 
collection. The SEMCD 6-item scale is free to use without obtaining permission. 
Mediators: Post-KT SM, Self-Efficacy, & Patient Activation 
Post-KT SM is defined conceptually as the range of behaviors patients perform in 
managing their own care, including ways they follow prescribed post-transplant treatment 
regimens, promote their own health, prevent health deterioration, and preserve graft 
function (Berger, 2014; Gordon et al., 2009; Haspeslagh et al., 2013; Kasiske et al., 
2009). To be more specific, KT SM includes adherence to the post-transplant IS 
medication treatment regimen; maintaining a healthy lifestyle including regular exercise, 
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proper diet, and weight management; protecting the new kidney by self-monitoring 
allograft function and infection prophylaxis; and skin cancer precautions (Gordon, 
Prohaska, Siminoff, Minich, & Sehgal, 2005; Haspeslagh et al., 2013; Kasiske et al., 
2009; Schäfer-Keller et al., 2008). 
Development of the Post-KT SM Scale 
Initial item generation. The development of the KT-SM was guided by 
DeVellis’ (2012) eight-step scale development method. The investigator generated the 
initial items based on the conceptual definition (SM), the principal investigator’s (PI) 
clinical experience, careful review of the literature, KT practice guidelines  
(evidenced-based medicine), and patient education information (Kasiske et al., 2009; 
Takahashi, Hu, & Bostom, 2018). The first item pool comprised 40 items focused on 
medication management, diet management, lifestyle modification, and kidney function 
and infection surveillance. Each was rated using a 5-point Likert-type scale (see 
Appendix P): 1 (strongly disagree), 2 (disagree), 3 (neutral) 4 (agree), and 5 (strongly 
agree).  
Face validity. To pre-test the items and evaluate face validity, the investigator 
recruited six participants from a KT clinic at a university hospital in the U.S. Midwest 
between March and May of 2014. Cognitive interviews were conducted with three female 
and three male adult KT recipients to ensure clarity of survey questions and to obtain 
feedback and comments. The PI developed probing questions based on the questionnaires 
and using the check list created by Willis (2004) as guidance, such as, “What does the 
phrase ‘change the number of pills’ mean in this question?” and “What does it mean to 
you to change the antirejection pill dose?” Overall, participants agreed that the items 
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were easy to understand and answer, but there were some feedback and comments on 
wording, items that might not apply to their condition, or additional items suggested by 
participants. 
In the KT-SM item pool, interviewees found the terms side-effect, NSAIDS, and 
low-cholesterol food confusing and suggested avoiding abbreviations and providing 
examples that would help respondents to answer the questions. In addition, none of the 
participants knew the difference between low-cholesterol food and a low-fat diet; 
therefore, the item “I eat a low cholesterol diet” was removed. In the graft function 
monitoring section, “I take my blood pressure every day” and “I take my temperature 
everyday” were only relevant depending on an individual’s post-transplant condition, so 
adding “as needed” or “as the doctor instructed” was appropriate. The items on the  
KT-SM were modified and revised based on participants’ feedback and suggestions as 
presented in Appendix E. A total of 38 items were generated in the second draft.  
Content validity. To develop a high-quality instrument and to enhance the 
construct validity, evaluating the content validity of a scale is an essential step in 
ensuring that a scale has an adequate sample of items representing the construct of 
interest (Polit & Beck, 2006; Polit, Beck, & Owen, 2007; Wynd, Schmidt, & Schaefer, 
2003). Lynn (1986) suggested that when an instrument is being developed in a highly 
specialized field, a minimum of three content experts should review it. The final expert 
panel in this study consisted of four experts: three were doctoral-level experts, two of 
whom are nurse scientists whose research focuses on KT behavioral change and the other 
a public health researcher whose research focuses on KT self-care and instrument 
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development. The fourth expert was a coordinator who has worked in a university KT 
program for more than 10 years. 
The four specialists who agreed to serve as content experts for the CVI validation 
process were sent a cover letter, a conceptual definition of post-KT-SM, the KT-SM 
scale, and instructions for evaluating the instruments as suggested by McKenzie, Wood, 
Kotecki, Clark, and Brey (1999). The experts were asked to evaluate each item of the 
KT-SM for representativeness on a 4-point scale as follows: 1 (not relevant), 2 (slightly 
relevant, the item needs major revision), 3 (moderately relevant, item needs minor 
revision), and 4 (highly relevant). According to Lynn (1986), for an expert panel of fewer 
than six reviewers, the single item CVI must be one. After removing 11 items with low 
CVI, the CVI for the final version of the 29-item KT-SM was 0.931 (Appendix F). 
Operational definition of KT-SM. The 29-item KT-SM was used to measure KT 
recipients’ post-transplant SM behavior in five domains: medication management (seven 
items), CV risk reduction (six items), graft monitoring (six items), infection prophylaxis 
(six items), and skin cancer prevention (four items). Items were scored on a 5-point 
Likert-type scale ranging from 1 (strongly disagree) to 5 (strongly agree). Scores were 
summed for a total score and for single domain scores. Higher scores indicated that the 
KT recipients engaged in the desired post-transplant SM behaviors.  
Patient activation. Patient activation is defined conceptually as the level of a 
patient’s active engagement in his or her own care and the knowledge, skill, and 
confidence the patient has about his or her ability to improve and maintain health, 
collaborate with healthcare providers, make decisions, and seek appropriate care 
(Hibbard et al., 2004; Shively et al., 2013; Smith et al., 2013). The PAM-13 is used to 
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assess participants’ knowledge, skills, and confidence that are necessary to self-manage a 
chronic condition (Hibbard, Mahoney, Stock, & Tusler, 2007). The PAM-13 is a 4-point 
scale of 1 (disagree strongly), 2 (disagree), 3 (agree), 4 (agree strongly), or 5 (not 
applicable). The final score ranges from 0–100 and can be categorized into four levels. 
Level 1 contains scores ≤ 47.0 and indicates low knowledge and confidence levels and 
poor adherence. Level 2 (47.1–55.1) indicates that individuals have some knowledge but 
are struggling to act. People at level 3 (55.2–67.0) are acting and have started building 
SM skills. Level 4 (≥ 67.1) individuals have adapted to new health behaviors (Greene & 
Hibbard, 2012).  
Psychometric testing of the PAM-13 has been conducted in various study 
populations including an employer-based health program (N = 625), adults with multiple 
sclerosis (N = 199), elderly heart failure patients (N = 21), and older adults with multiple 
chronic conditions (N = 855). The internal consistency for the PAM-13 has been 
satisfactory in these studies, with Cronbach’s alphas ranging from 0.87–0.9 (Evangelista 
et al., 2015; Fowles et al., 2009; Prey et al., 2016; Skolasky et al., 2011; Stepleman et al., 
2010). Construct validity has been supported by positive associations among patient 
activation and other theoretically important constructs. For example, Evangelista et al. 
(2015) found positive associations among increased patient activation (r = 0.658, p < 
.0001), self-care maintenance (r = 0.335, p = 0.033) and overall quality of life (r = 0.329, 
p = 0.35).  
The average score for PAM-13 in this study’s sample (N = 153) was 77.89 ± 
15.71, with a median of 77 and a range between 9 and 100. Overall, more than 94% of 
kidney recipients were at level 3 (26.1%) or 4 (68%), which means they were acting in 
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self-managing their post-transplant care or have adapted to post-transplant SM behavior 
and are trying to maintain it (see Table 1).  
Table 1 
Mean, Standard Deviation, Range, and Mode of PAM-13 
Scale n (%) M(SD) Range Median Mode (%) 
PAM-13 score 153(100) 77.89(15.71) 9–100 77.7 4 (68%) 
PAM level      
    Level 1 3(2%)     
    Level 2 3(2%)     
    Level 3 40(26.7%)     
    Level 4 104(69.3%)     
 
As shown in Table 2, the reliability coefficient alpha for the PAM-13 was .90, and 
corrected item-to-total correlations ranged between .50 and .73. The mean inter-item 
correlation was .45, indicating adequate internal consistency (DeVellis, 2012). This is the 
first study to test the PAM-13 in the KT population, so there are no empirical study 
results available for comparison; therefore, further study on item reliability with a larger 
sample size may be needed.  
Table 2 
Internal Consistency Reliability for the 13-Item PAM 
Scale Mean (SD) Cronbach’s 
Alpha 
Alpha if 
Item 
Deleted 
Mean  
Inter-Item 
Correlation  
Range of Item 
to Total 
Correlation 
PAM-13 77.89 
(15.71) 
.90 .90 .45 .50-.73 
Note. N = 153. 
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Self-efficacy. In this study, self-efficacy is conceptually defined as an individual’s 
confidence in his or her own capability to successfully perform given tasks and achieve a 
goal (Bandura, 1997; Bodenheimer et al., 2002). Patients with high self-efficacy engage 
more in SM behaviors and have better physical function and higher perceived HRQoL 
(De Pasquale et al., 2014; Mersal & Aly, 2014; Weng et al., 2010). Self-efficacy was 
measured with the 6-item SEMCD scale. The SEMCD incorporates the domains of 
symptom control, physical function, emotional function, and communication with 
physicians, which are common problems for people with chronic conditions (Lorig et al., 
2001). The SEMCD (Appendix H) includes questions such as: “How confident are you 
that you can keep from getting discouraged when nothing you do seems to make any 
difference?” Responses range from 1 (Not at all confident) to 10 (Totally confident). 
Possible scores range from 6 to 60. A lower score indicates that the patient is less 
confident in self-managing post-transplant care. 
Internal consistency reliability of the SEMCD has been supported in chronic 
kidney disease, arthritis, Parkinson’s disease, systemic sclerosis, and people with chronic 
disease, with Cronbach’s alphas of .81 to .95 (Johnson et al., 2016; Lorig et al., 2001; 
Riehm et al., 2016; Ritter & Lorig, 2014; Dal Bello-Haas, Klassen, Sheppard, & 
Metcalfe, (2011). Concurrent validity was demonstrated with a positive correlation 
between the French version of the SEMCD and the Health Education Impact 
Questionnaire (r = 0.49, 95% CI, p < 0.01; Hudon, 2014). Convergent construct validity 
between the German version SEMCD and the German General Self-Efficacy Scale was 
supported by Spearman rank correlation (r =. 578, p < .001). The result of principal 
component analysis also confirmed that the SEMCD is a uni-dimensional scale (Freund, 
61 
Gensichen, Goetz, Szecsenyi, & Mahler, 2013). Similarly, Riehm and colleagues (2016) 
conducted a psychometric test of the SEMCD with a systemic sclerosis population (n = 
553) in the U.S., Canada, and the U.K., and the confirmatory factor analysis results 
supported its unidimensionality. Convergent construct validity has been supported and 
showed significant positive correlations between the SEMCD and the psychological and 
physical functioning subscales of the Patient Reported Outcomes Measurement 
Information System (PROMIS; r = 0.48 to 0.67, p < 0.001) and negative correlations 
between the 8-item Patient Health Questionnaire (r = -.48 to -.64, p < 0.001) and the 
Health Assessment Questionnaire Disability Index (r = -.57, p < 0.001). 
The average score on the SEMCD in the present study was 7.44 ± 1.8 (SD) and 
the median was 7.67, with a range from 2 to 10. Internal consistency reliability of the 
SEMCD (Cronbach’s alpha) was .93, demonstrating that the scale has good internal 
consistency. The mean inter-item correlation was .68, with a range from .56 to .81. The 
corrected item-to-total correlation ranged between .74 and .8 (Table 3). This study’s 
results shows no differences from previously reported findings.  
Table 3. 
Internal Consistency Reliability for 6-Item SEMCD 
Scale Mean 
(SD) 
Cronbach’s 
Alpha 
Range of 
Alpha if 
Item 
Deleted 
Mean  
Inter-Item 
Correlation 
and Range 
Range of 
Item to 
Total 
Correlation 
SEMCD 7.44 
(1.80) 
.93 .90–.92 .68 (.56–.81) .74–.80 
Note. N = 153. 
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Outcome: HRQoL 
An individual’s subjective experiences of satisfaction with his or her physical, 
emotional, and social functioning and well-being is conceptually defined as HRQoL 
(Maglakelidze et al., 2011; Molnar-Varga et al., 2011; Shumaker et al., 1997). Compared 
to dialysis patients and ESRD patients, KT recipients experience higher HRQoL. 
Nevertheless, a KT may not fully restore KT recipients’ level of HRQoL to that of the 
general population. The requirement to take lifelong IS medications and side effects from 
long-term IS treatment are tied to decreased HRQoL (Gentile et al., 2013; Morales, Varo, 
& Lázaro, 2012). Therefore, a KT-specific HRQoL scale was needed for this study.  
This study used the 25-item KTQ-25 developed by Laupacis and colleagues 
(1993) to measure HRQoL. Questions on the KTQ-25 are measured with a 7-point 
Likert-type scale and incorporate five disease-specific dimensions: physical symptoms, 
fatigue, appearance, uncertainty/fear, and emotion (Appendix H). Scores are summed for 
a total score and for five single domain scores. Higher summed scores indicate better 
quality of life (Kosinski, Ware, Turner-Bowker, & Gandek, 2007). 
The reported mean scores on the KTQ-25 from previous literature were as 
follows: physical symptoms, 4.5–5.7; fatigue, 4.7–5.4; uncertainty/fear, 4.5–5.4; 
appearance, 5.7–6.8; and emotion, 4.8–5.4 (Chisholm-Burns, Erickson, Spivey, 
Gruessner, & Kaplan, 2011; Neipp et al., 2006; Tayebi et al., 2012). Internal consistency 
reliability for the total scale has been reported to be .80 to .95 in previous studies (Neipp 
et al., 2006; Rostami, Tavallaii, Jahani, & Einollahi, 2011; Tayebi et al., 2010; Tayebi  
et al., 2012). The reported Cronbach’s alpha for physical symptoms, fatigue, 
uncertainty/fear, appearance, and emotion subscales ranged from .82–.93, .81–.90,  
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.63–.81, .72–.62, and .82–.95 respectively (Chisholm-Burns et al., 2011; Neipp et al., 
2006; Rostami et al., 2011; Tayebi et al., 2010; Tayebi et al., 2012).  
Concurrent validity of the SF-12 Health Survey version 2 mental component 
summary and physical component summary) and the KTQ-25 has been confirmed in the 
adult U.S. KT population. Mental component summary (Chisholm-Burns et al., 2011) 
was positively correlated with KTQ-25 subscales (p < .01): physical symptoms (r = .43), 
fatigue (r = .48), uncertainty/fear (r = .33), emotion (r = .47), and appearance (r = .28). 
Physical component summary was positively correlated with subscales (p < .05) physical 
symptoms (r = .43), fatigue (r = .42), and uncertainty/fear (r = .2).  
As shown in Table 4, mean scores for the total and the five subscales (physical 
symptoms, fatigue, uncertainty/fear, appearance, and emotion) in this study were: 4.83, 
4.57, 4.62, 5.71, and 4.97, respectively. Internal consistency reliability scores for the five 
subscales of the KTQ-25 were .85, .95, .76, .72, and .89, respectively, with an alpha value 
of .79 for the total scale. This study’s findings are consistent with studies in the U.S. KT 
population that found that Cronbach’s alpha is lower in the uncertainty/fear and physical 
appearance subscales but still within acceptable range (Chisholm-Burns et al., 2011).  
Table 4 
Internal Consistency Reliability of KTQ-25 and 5 Subscales 
Scale/ 
Subscale 
M (SD) Cron-
bach’s 
Alpha 
Range of 
Alpha if 
Item 
Deleted 
Mean  
Inter-Item 
Correlation 
Range of Item 
to Total 
Correlation 
KTQ-total 4.94 (1.08) .94 .89–.91 .39  .28–.74 
Physical 4.83 (1.63) .92 .89–.91 .65 .69–.82 
Fatigue 4.57 (1.56) .95 .93–.95 .79  .78–.90 
Table continues 
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Uncertainty 4.62 (1.36) .76 .62–.86 .47  .29–.73 
Appearance 5.71 (1.15) .72 .49–.74 .38  .36–.74 
Emotion 4.97 (1.26) .89 .86–.89 .58  .62–.80 
Note. N =153. 26 respondents reported no physical symptoms.  
Antecedents: Comorbidities and Demographic Characteristics 
Comorbidities refer to one or more chronic diseases that coexist with the index 
disease. The comorbidities could be post-KT-related or pre-existing chronic disease 
(Hollisaaz et al., 2007; Valderas et al., 2009). The number of comorbid diseases was 
measured using the SCQ. The SCQ consists of yes/no questions about 12 common 
medical conditions and 3 additional open-ended options that allow individuals to provide 
diseases not on the SCQ list (Kyranou et al., 2013; Sangha et al., 2003; Sridharan et al., 
2014). An individual can obtain three points for each of 12 listed conditions and up to 3 
additional write-in conditions (one point each for presence of the disease, receiving 
treatment for that disease, and physical limitation due to disease; Kyranou et al., 2013; 
Sangha et al., 2003; Sridharan et al., 2014). The target population for this study was KT 
recipients with functional allograft; hence, the item kidney disease was removed 
(Sridharan et al., 2014). Therefore, the maximum scores ranged from 33–42 points.  
The reliability and validity of the SCQ have been confirmed in the literature. The 
test-retest reliability was moderate to high for most items, ranging from kappa = .40–.90, 
which demonstrates adequate internal consistency reliability (Sangha et al., 2003). 
Construct validity was assessed by Spearman correlation between the SCQ and the CCI 
and was Spearman r = .55 (Sangha et al., 2003). Predictive validity was assessed by 
computing the Spearman correlation between the SCQ and the SF-36; the physical 
component score was r = 0. 35, which was higher than the correlation between the CCI 
and SF-36 (r = 0. 23; Moltó & Dougados, 2014; Sangha et al., 2003; Sridharan et al., 
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2014). Mean score for the SCQ in this sample was 4.94 (SD = 4.52; median = 4), and the 
average number of comorbidities was 2.46 (SD = 1.86), ranging between 0 and 12.  
Table 5 shows the frequencies of comorbidities. The top three reported comorbidities 
were high blood pressure (60.8%), back pain (30.1%), and diabetes (25.7%). Frequently 
reported diseases not on the SCQ were systematic lupus erythematosus and 
hypothyroidism. The reported incidence rate of diabetes and hypertension has been 
reported in KT literature to range from 4%–30% and 60%–90%, respectively (Kislikova 
et al., 2015; Pourmand et al., 2015; Sarno et al., 2012; Seeman, 2009; Shah et al., 2006; 
Wu et al., 2005). This study’s results were consistent with previous findings except for 
back pain.  
Table 5 
Number of Comorbidities Reported 
Comorbidity n f (%) 
High Blood Pressure 153 93 (60.8) 
     Receive treatment  89 (95.7) 
     Limit activities  6 (6.5) 
Back pain 153 46 (30.1) 
     Receive treatment  11(23.9) 
     Limit activities  28 (60.9) 
Diabetes 152 39 (25.7) 
     Receive treatment  35 (92.1) 
     Limit activities  7 (18.4) 
   
Heart disease  152 18 (11.8) 
     Receive treatment  17 (94.4) 
     Limit activities    8 (44) 
Lung disease  152 9 (5.9) 
     Receive treatment  6 (66.7) 
     Limit activities  5 (55.6) 
Table continues 
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Ulcer or stomach disease 152 11 (7.2) 
     Receive treatment  10 (90.9) 
     Limit activities  3 (30) 
Liver disease 152 7 (4.6) 
    Receive treatment  2 (28.6) 
    Limit activities   3 (42.9) 
Anemia or other blood disease  152 24 (15.8) 
    Receive treatment  14 (58.3) 
    Limit activities  6 (25) 
Cancer 149 10 (6.6) 
    Receive treatment  6 (66.7) 
    Limit activities  5 (55.6) 
Depression 150 33 (22) 
    Receive treatment  20 (60.6) 
    Limit activities    17(51.5) 
Osteoarthritis or degenerative arthritis 151 25 (16.6) 
    Receive treatment  8 (32) 
    Limit activities    18 (72) 
Rheumatoid arthritis  151 4 (2.6) 
    Receive treatment  1 (25) 
    Limit activities    0 
   
Other medical problem 1 153 113 (73.9) 
    Receive treatment  23 (56.1) 
Other medical problem 2 152 10 (62.5) 
    Receive treatment  6 (37.5) 
    Limit activities    0 
Other medical problem 3  8 (5.3) 
    Receive treatment  6 (3.97) 
    Limit activities    2 (1.4) 
   
SLE  8 (5.3) 
Thyroid problem    6 (3.97) 
Gout  2 (1.4) 
Demographic Characteristics 
Demographics are the characteristics of the study population, including age, race, 
gender, marital status, and education (Kane & Radosevich, 2010). Demographic data 
were collected to describe the sample and used to examine whether poor SM behaviors, 
low self-efficacy, low patient activation levels, and poor HRQoL are associated with 
certain demographic characteristics. The demographic data for this study come from an 
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investigator-developed patient survey form (see Appendix B). It is a self-administered, 
categorical, nominal, and open-ended questionnaire. Gender was collected with 
dichotomous response. Age was collected using an open-ended question. Other 
information such as race, marital status, employment status, and education were collected 
using categorical responses. 
Data Management and Data Cleaning 
Data analysis for each hypothesis was conducted using IBM SPSS version 24.0 
statistical software. The level of significance for this study was set at p < 0.05. Data from 
REDCap were directly exported to .csv (comma separated variables) files; no hand entry 
of data was required. To ensure data quality, REDCap online survey and data entry forms 
were co-built and maintained by data management professionals from the biostatistics 
department at IUPUI. The data management professional conducted a pilot test of the 
REDCap survey system with 10 artificial data sets before the study started. Missing data 
were managed per recommendations from Tabachnick and Fidell (2012). In addition, 
surveys with more than 10% unanswered items were eliminated from the analysis. 
Descriptive statistics, scatterplots, and histograms were checked for distributions and 
outliers on all collected variables (Van den Broeck, Cunningham, Eeckels, & Herbst, 
2005).  
Descriptive statistics were performed to check missing values, means, standard 
deviations, and out-of-range values. Nominal variables were described as frequencies and 
percentages, while interval data were averaged as means and standard deviations. All data 
were analyzed for normality, linearity, and homoscedasticity. The analyses conducted to 
meet each study aim are described as follows.  
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Aim 1: Examine the content validity of the KT-SM scale. 
H1: The KT-SM scale will demonstrate evidence of a CVI of 0.9 or greater for 
individual items and for the overall scale based on a review by four content experts of 
construct definition, item relevance, wording clarity, and item appropriateness. 
There are two recommended methods to determine content validity: the content 
validity ratio (CVR) proposed by Lawshe (1975) and Lynn’s (1986) CVI. Lynn’s method 
was used to assess the content validity of the newly developed 40-item KT-SM scale. 
Content relevance is ranked as 1 (not relevant), 2 (slightly relevant with major revisions), 
3 (quite relevant with minor revisions), or 4 (highly relevant). Acceptable CVI score 
ranges of the items depend on the number of reviewers (DeVon et al., 2007). In this case, 
agreement about the relevance of each item must be at least 3 (quite relevant) or 4 (highly 
relevant) on average among the experts. The item CVI is a ratio that is calculated, based 
on the sum of the scores for each item divided by the number of experts. For example, if 
the expert panel ranked item 12 as 3, 4, 3, and 4, all four experts agree the item content is 
relevant but may require a minor wording revision so the CVI is 1 (number of  
agreement = 4/4 experts).  
Aim 2: Estimate the reliability of a new instrument, the Kidney Transplant  
SM scale (KT-SM), among adult KT recipients.  
H2. The KT-SM scale will have adequate internal consistency coefficient as 
evidenced by corrected item-to-total correlations, mean inter-item correlations of greater 
than or equal to .30, and Cronbach’s alpha greater than or equal to .70 among KT 
recipients aged 18 or greater. 
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Inter-item correlation, item-total correlation, and Cronbach’s alpha were 
estimated to check item homogeneity and internal consistency reliability of the final 
version of the KT-SM scale.  
Aim 3: Estimate construct validity of the KT-SM scale through EFA. 
H3: The EFA results will support that the KT-SM scale is a multidimensional 
scale with more than one factor extracted, and items within each factor will have factor 
loading values greater or equal to .40. 
To address H3, three assumptions must be met: (1) there must be no 
multicollinearity, (2) the data must be factorable, and (3) the sample size must be 
adequate. First, the investigator inspected correlation matrices to examine whether the 
values of the correlation coefficients were greater than .25 and less than .90 (Pett et al., 
2003; Polit, 2010). The second diagnostic test used to evaluate factorability in the present 
dataset was Bartlett’s Test of Sphericity, which tests the null hypothesis that variables in 
the matrices are orthogonal. Failure to reject the null hypothesis indicates that factor 
analysis is not amenable in this sample (Polit, 2010). Lastly, the Kaiser-Meyer-Olkin 
(KMO) test of sampling adequacy was computed to assess how suitable the sample size is 
for factor analysis; KMO scores greater than 0.5 are considered acceptable. 
To determine the underlying factor structure of the KT-SM scale, factor extraction 
was conducted by EFA using principal axis factoring (PAF) with varimax rotation (Pett 
et al., 2003; Netemeyer et al., 2003). The number of factors to be extracted was 
determined by the eigenvalues-greater-than-1 rule and the scree test (Tabachnick & 
Fidell, 2012). Items with factors loading less than .40 and communality less than .30 were 
removed. Item communality is “the total amount of variance in each item that is 
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explained by the extracted components” (Pett et al., 2003, p. 100). Communalities greater 
than .30 are preferable (Costello & Osborne, 2005).  
Aim 4: Estimate construct validity of the Kidney Transplant SM (KT-SM) scale 
guided by the conceptual model by exploring relationships between the KT-SM scale and 
the SEMCD scale, the PAM, and the KTQ-25.  
H4: Controlling for demographic and clinical variables, a significant amount of 
variance in the KT-SM scale will be explained by self-efficacy and patient activation.  
H5: Controlling for demographic and clinical variables, a significant amount of 
variance in HRQoL will be explained by self-efficacy, patient activation, and KT-SM 
behavior. 
H6: Criterion-related validity will be supported as the 16-item KT-SM total scale 
and five domain scales are statistically significantly correlated with the PAM-13, 
SEMCD, and KTQ-25 and 5 subscales. 
To determine the strength and direction of each proposed theoretical relationship 
in the framework, Pearson correlation coefficient/Spearman correlation coefficient was 
computed for the variables of self-efficacy, patient activation, KT SM behavior, and 
HRQoL. To address H4 and H5, the adapted KTSM framework shown in Figure 1 was 
used to assign order of entry of study variables; therefore, sequential multiple regression 
was employed to assess construct validity (Tabachnick & Fidell, 2012). In the first step, 
the investigator entered demographic and clinical variables into the regression equation to 
control their effect on the independent variables. According to Tabachnick and Fidell 
(2012), variables that are theoretically important could be entered in the early steps; 
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therefore, self-efficacy was added first to the regression equation and patient activation in 
the second step. To test H5, KT SM was entered in the last step. 
To test H5 the investigator entered variables into a regression equation in the 
following sequence: KT SM behavior, patient activation, and self-efficacy. HRQoL was 
added into the equation last. 
H6 is about criterion validity and will be supported with statistically significant 
intercorrelation among the scores of the KT-SM total scale and its five domain scales, 
PAM-13, SEMCD, and KTQ-25 and its five subscales. 
Summary 
Chapter Three presented the methodology used in this study including participant 
eligibility criteria, the study design, methods and procedures used for recruitment, and 
concluded with the presentation of the results of the cognitive review and content validity 
scores of the new investigator-developed KT-SM scale. The sequential regression 
analysis results showed that self-efficacy is a strong predictor of scores on the KTQ-25 
overall and its five subscales, but the KT-SM total score and four of the five domain 
scores and the PAM-13 did not reach statistical significance in predicting the KTQ-25 
score. Therefore, this discussion focused only on results pertaining to the KT-SM scale. 
The following chapter will present the study results beginning with a description 
of the data collection methods used and concluding with the results pertaining to each 
specific aim and hypothesis. 
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CHAPTER FOUR 
RESULTS 
This chapter consists of four sections. The first section begins with a description 
of the data collection methods. The second section describes the data cleaning procedure, 
including specific decision rules for keeping or deleting a completed online survey. A 
description of the sample is provided in the third section. A description of the study 
variables and the results pertaining to each specific aim and hypothesis are presented in 
the last section.  
Data Collection Methods 
A total of 538 respondents visited the KT study information page (Appendix J) 
from May 10, 2016, to June 9, 2016. Of these, 292 (54.28%) read the study information 
material and submitted valid email addresses. By clicking the acknowledge button, 
respondents agreed that they were fully informed about the study and agreed to 
participate. Twenty-seven respondents declined, as indicated by not clicking the 
acknowledge button, leaving 265 (90.75%) respondents who agreed to participate in the 
study and be screened for eligibility. Of these, 210 participants (79%) passed the 
screening question and took the full survey (Figure 2).  
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Figure 2. Recruitment process. 
Data Cleaning Procedures 
Data were collected using a self-administered REDCap online survey. All data 
were exported directly from the REDCap survey project platform into a Microsoft Excel 
file and analyzed in SPSS 24.0 software. To ensure online survey data quality, surveys 
were first screened for missing items, multiple submissions, and out-of-range survey 
taking time. Three decision rules were applied in determining whether to keep or delete a 
completed survey. First, if more than 10% of item responses were missing, the entire 
survey was deleted. After a careful investigation of the 210 submitted surveys for the 
number and patterns of missing items, 27 were deleted because more than 10% of the 
item responses were missing, leaving 183 surveys (Figure 2). To prevent multiple 
submissions, each respondent could use only one email address. Email addresses were 
searched for duplication using SPSS frequencies, and no duplicate email addresses were 
identified. Finally, the time spent taking the survey was examined for extreme values; 
rationales for examining online survey response time are discussed in detail in the 
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sections that follow (Brandon, Long, Loraas, Mueller-Phillips, & Vansant, 2013; Maniaci 
& Rogge, 2014; Meade & Craig, 2012; Revilla & Ochoa, 2015).  
Studies have shown that online survey response time has an impact on data 
quality (Brandon et al., 2013; Maniaci & Rogge, 2014; Meade & Craig, 2012; Revilla & 
Ochoa, 2015). A short survey response time may indicate that a respondent rushed 
through the whole survey by selecting random answers without reading the questions and 
instructions. In contrast, a longer response time shows that a respondent put more 
cognitive effort into completing the survey, but this could also be a result of being 
distracted (Meade & Craig, 2012). In addition, the speed of individual processing and 
comprehension is different, so a speed-reader could have short response times in 
completing a survey (Börger, 2016; Ramsey, Thompson, McKenzie, & Rosenbaum, 
2016; Revilla & Ochoa, 2015). Thus, examining surveys for the time spent in completion 
is a necessary step before performing statistical analyses (Maniaci & Rogge, 2014).  
There is no gold standard for determining the acceptable length of time for 
completing an online survey. Meade and Craig (2012) recommended that a cutoff point 
must be set to eliminate those who respond to survey questions too quickly. Therefore, 
decisions to keep or eliminate extreme cases in this study were determined by examining 
descriptive statistics. Identifying outliers in the original dataset was problematic because 
(1) several extreme values made the distribution positively skewed, (2) there was only 
one single bar shown on the histogram, and (3) the box plot displayed only one single 
line. Therefore, a base-10 logarithmic (log 10) transformation was performed (Feng et al., 
2014; Osborne, 2005; Tabachnick & Fidell, 2012), and Tukey’s (1977) 1.5 * interquartile 
(IQR) rule was followed to eliminate outliers that impacted score mean and distribution 
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(Acuna & Rodriguez, 2004; Hatcher, 2013, Hoaglin, 2003; Hubert & Van der Veeken, 
2008; Polit, 2010; Tabachnick & Fidell, 2012). An outlier is defined (Hatcher, 2013; 
Pallant, 2013) as a data value that exceeds 1.5 box-lengths from the lower quartile (Q1) 
or upper quartile (Q3). The values of IQR, Q1, and Q3 of the log 10-transformed data 
were 0.30, 0.954, and 1.255 respectively. The lower boundary and upper boundary were 
calculated based on the formulas Q1 - 1.5 * IQR and Q3 + 1.5 * IQR. The lower boundary 
was 0.504 (0.954 - 1.5 * 0.3), while the upper boundary was 1.705 (1.255 + 1.5 * 0.3). 
Data values below 0.504 or above 1.705 were identified as outliers. This means that 
people who took 3 minutes or fewer to complete the survey (n = 25) and those who took 
more than 65 minutes (n = 5) were eliminated; a total of 30 surveys were deleted, leaving 
153 completed surveys available for analyses (see Figure 2).  
As shown in Table 6, the shortest survey response time among the remaining 153 
respondents was 4 minutes (M = 15.07; SD = 6.12), consistent with Huang and 
colleagues’ (2012) recommended “2 seconds per item” rule for minimal survey response 
time. Applying this rule to the present study indicated a likely survey response time of 
4.1 minutes [(2 * 123 items)/60 seconds]. 
Table 6 
Descriptive Statistics for Average Survey Response Time 
 N Mean (SD) Mdn Range Skewness Kurtosis 
Original 183 89.21(955.65) 13 1 - 12928 13.47 181.94 
Outliers 
removed based 
on 1.5 * IQR 
rule 
153 15.07(6.12) 15 4 - 43 1.35 3.21 
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Examining Accuracy of the Dataset 
All collected data were exported directly into a Microsoft Excel file. Data entry 
errors should not be a concern, but means, standard deviations, and ranges were inspected 
for all continuous variables using univariate descriptive statistics (see Table 7).  
Table 7 
Mean, Standard Deviation, Range, Skewness, and Kurtosis of all Scales 
Variable N 
(%) 
M SD Mdn Range Skewness Kurtosis 
PAM-13 153 77.89 15.71 77.7     91 .66 1.41 
PAM-13 (if ID 44 
deleted) 
152 78.34 14.73 77.7     57 .22 .50 
SEMCD 153 7.44 1.8 7.67     8 -.57 -.32 
KTQ-physical 153* 4.83 1.63 4.83     5.50 -.21 -1.06 
KTQ-fatigue 153 4.57 1.56 4.80     6.00 -.33 -.77 
KTQ-fear 153 4.62 1.36 4.75     6.00 -.41 -.15 
KTQ-appearance 153 5.72 1.15 6.00     4.75 -.76 -.34 
KTQ-emotion 153 4.97 1.26 5.00     5.33 -.35 -.55 
KT-SM-Original 153 4.27 .47 4.34     2.17 -.60 -.34 
SCQ score 153 4.97 4.53 4.00     34 2.80 13.05 
Squared root-SCQ 153 .63 .30 .60     1.53 .17 - .06 
Note. *26 participants reported no physical symptoms. **13 reported no comorbidity.  
Missing Data 
A total of 153 surveys were examined for missing data. Missing data were 
analyzed using IBM SPSS MVA (missing values analysis) for continuous and categorical 
variables. The results indicated no missing values detected in the PAM-13, SEMCD 
scale, 29-item KT-SM scale, 25-item KTQ, and years since transplant. The amount of 
missing data for the rest of the continuous variables was less than 5% and was missing 
randomly at the item level. Missing values for the categorical variables of marital status, 
ethnicity, and pre-transplant dialysis were at 0.7%, 1.3%, and 0.7 %, respectively. Thus, 
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it was not necessary to replace missing data with means or to manage it using multiple 
imputation; instead, missing values were handled using SPSS’s pairwise deletion for 
descriptive statistics, while listwise deletion was the default for multiple regression 
analysis (Dong & Peng, 2013; Scheffer, 2002).  
Outlier and Data Normality 
Outliers and data distribution were checked by inspecting the boxplot, normal P-P 
plot, and detrended normal Q-Q plot and assessed with analysis of skewness and kurtosis 
for all variables. As displayed in Table 7, there are a wide range of values for the  
PAM-13 and the SCQ. The investigator identified record IDs 35 and 44 as outliers for the 
PAM-13 and record ID 88 as an outlier for the SCQ using the IBM SPSS EXPLORE 
program. The skewness and kurtosis statistics of all scales depict that most variables had 
values fairly close to zero except for the PAM-13 and the SCQ. The zero value indicates 
no skewness and kurtosis in the distributions. For severely skewed data, Tabachnick and 
Fidell (2012) recommend transformations because transformations may normalize the 
skewed data, improve the validity of analysis, and act as a remedy for outlying 
observations. 
Natural log and square root transformations were computed for the PAM-13, but 
there were no improvements in the distribution or kurtosis statistics. However, the 
skewness and kurtosis statistics of the PAM-13 decreased from -0.66 to -0.21, and from 
1.41 to -0.50, respectively, after excluding the outlier record ID 44. After cautiously 
examining all the survey data and response patterns of record ID 44, the investigator 
could not eliminate the possibility that this individual respondent may simply have lower 
confidence in managing long-term post-transplant life. In addition, Likert-type scales 
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have ceiling and floor effects such that a case with a lowest point or highest point is 
considered to reflect reality, therefore, record ID 44 was retained. Nevertheless, the slight 
violation of the normality assumption should not cause any major concerns. Skewness 
and kurtosis values of ± 2 are within acceptable ranges for psychometric testing (Molle & 
Froman, 2017) when the sample size is larger than 40. Parametric statistical tests were 
considered appropriate for the present study, which had a sample size of 153 subjects 
(Ghasemi & Zahediasl, 2012; Norman, 2010; Sullivan & Artino, 2013). In addition, 
Norris and Aroian (2004) compared the Cronbach’s alpha and the Pearson product 
moment correlation using original data and square root and log-transformed data; there 
was no difference between these data sets.  
Sample Description 
A sample of 153 adult KT recipients met the study criteria. Most of the 153 
subjects were recruited via Facebook Ads (51%; Appendix J), and three Facebook 
support groups (Kidney Transplant Survivors and Donors; Kidney Transplant and Weight 
Loss, & Kidney Transplants; 34%). As shown in Table 8, the average patient was  
middle-aged, White, non-Hispanic or Latino, female, married or living with a partner, 
and had a college degree or higher. More than half of the subjects were working full time.  
Table 8 
Characteristics of Participants 
 n (%) Mean (SD) Median Range 
Age 149 (97.4) 46.65(12.35) 47 19–78 
Gender 
Female 
Male 
152 (99.3) 
98 (64.5) 
54 (35.5) 
   
Table continues 
79 
Marital status 
Married 
Living with a partner 
Never married 
Separated/divorced 
Widowed 
152 (99.3) 
88 (57.9) 
16 (10.5) 
23(15.1) 
24 (15.8) 
1 (0.7) 
   
Race 
White 
Black/African-American 
Hispanic/Latin 
Asian 
American Indian/Alaska 
Native 
Native Hawaiian/Pacific 
Islander 
153 (100) 
125 (81.7) 
13 (8.5) 
8 (5.2) 
3 (2) 
1 (.70) 
3 (2.0) 
   
Education level 
Less than high school 
High School, diploma, or 
GED 
Some college 
College graduate 
Some graduate work 
Graduate degree 
Some doctoral work 
Doctoral degree 
153 
3 (2) 
18 (11.8) 
46 (30.1) 
46 (30.1) 
9 (5.9) 
25 (16.3) 
4 (2.6) 
2 (1.3) 
   
Employment  
Employed full-time  
Employed part-time  
Retired 
Unemployed 
Other 
Social security disability 
Student 
153 
71 (46.4) 
13 (8.5) 
23 (15) 
31 (20.3) 
 
14 (9.2) 
1 (.70) 
   
Recruiting setting 
Facebook ads 
Three Transplant Support 
Groups 
Facebook study page   
Google+   
Search engine 
A friend    
 
78 (51) 
52 (34) 
12 (7.8) 
2 (1.3) 
1 (.70) 
8 (5.2 
   
Clinical characteristics of the sample are shown in Table 9. The majority of the 
sample received living donor KTs. Nearly 73% of the sample reported being on dialysis 
80 
prior to transplant; of these, the average years of dialysis was 2.89. The mean years  
post-transplant was 7.01. The mean SCQ score was 4.94; on average, individual 
participants reported 2.46 comorbidities.  
Table 9 
Clinical Characteristics 
 n (%) Mean (SD) Median Range 
Donor type 
Non-living donor 
Living donor (Related) 
Living donor (Non-related) 
153 
69 (45.1) 
52 (34) 
32 (20.9) 
   
Pre-transplant dialysis 
Yes 
No 
 
111 (72.5) 
39 (27.5) 
 
 
  
Years receiving dialysis 153 2.89 (3.32) 2.00 0.08–16.42 
Years since transplant    145 (94.8) 6.94 (6.65) 4.50 0.83–27.83 
Squared root-SCQ Score 
Numbers of comorbidity reported  
152 
153 
1.97 (.93) 
2.46 (1.86) 
4.00 
2.00 
0–34 
0–12 
Note. n < 153 indicates missing data.  
Aims, Hypotheses, and Research Questions 
A brief description of the item reduction process follows. Psychometric testing of 
a newly developed instrument is an iterative process. Forty items were included in the 
original KT-SM scale. Based on content validity results, 11 items were removed (Aim 1) 
so that the initial EFA included 29 items (Aim 3). After further testing and removal of 
items, the final solution included 16 items. Internal consistency reliability testing (Aim 2) 
was conducted on the final 16-item KT-SM scale. Construct validity testing of the 
relationships among KT SM, patient activation, self-efficacy, and quality of life (Aim 4) 
used the final 16-item instrument. 
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Aim 1: Examine the content validity of the KT-SM scale. 
H1: The KT-SM scale will demonstrate evidence of a CVI of 0.9 or greater for 
individual items and for the overall scale based on a review by four content experts of 
construct definition, item relevance, wording clarity, and item appropriateness. 
H1 was supported. The CVI score for the reduced 29-item KT-SM scale was .93. 
Initially, the KT-SM scale with a total of 40 items was mailed electronically to four 
content experts, whose recommendations led to 11 items with CVI scores of .50 or below 
being removed from the scale. For the remaining 29 items, there were 21 items with  
CVI = 1 and 8 items with CVI value of .75. The CVI for the total scale was .93, which 
was calculated based on the following formula: ((21 items * 1) + (8 items * .75)) / 29 
items. A CVI value of .70 or greater is preferable (Tilden, Nelson, & May, 1990); 
therefore, the first hypothesis is determined to be supported. Detailed results are provided 
in Appendix F. Some items with CVI score of .75 were retained in the scale because they 
are conceptually important and are recommended by KT guidelines (Kasiske et al., 
2010). Wording changes on these items were made based on comments from reviewing 
experts.  
Aim 2: Estimate the reliability of a new instrument, the KT-SM scale, among 
adult KT recipients.  
H2: The KT-SM scale will have adequate internal consistency coefficient as 
evidenced by corrected item-to-total correlations, mean inter-item correlations of greater 
than or equal to .30, and Cronbach’s alpha greater than or equal to .70 among KT 
recipients aged 18 or greater. 
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H2 was supported. The item-to-total correlations for the overall final version of 
the 16-item KT-SM scale and 5 domains were greater than .38. The inter-item 
correlations for the 5 subscales ranged from .38 to .63. Cronbach’s alpha for the overall 
scale was .84 and had a range of .70 to .83 for the five domains. 
To examine the internal consistency reliability of the newly developed KT-SM 
scale, corrected item-to-total correlations, mean inter-item correlations, and Cronbach’s 
alpha coefficients were estimated for the reduced 16-item scale after the EFA. These 
analyses were done within each dimension as the scale is multidimensional (Netemeyer  
et al., 2003). 
Basic Item Analysis 
The KT-SM scale consists of five conceptually distinct components; therefore, 
item statistics and reliability statistics were reported for the five subscales (Clark & 
Watson, 1995; DeVellis, 2012; Georgiou & Kyza, 2017; Welch, 2002): medication 
adherence, CV risk reduction, protecting the new kidney, ownership of post-KT care, and 
skin cancer prevention. Items were examined for item statistics, corrected item-to-total 
correlation, and alpha coefficient. Table 10 displays the item means and standard 
deviations. Item means for these 16 items ranged from 3.27 to 4.70, and the standard 
deviation ranged from .67 to 1.23. DeVellis (2012) suggests that item means should be 
close to the center of the possible score range; for this study, an item mean value around 
3 was desirable. The results revealed that some level of ceiling effect did exist. 
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Table 10  
Item Statistics and Item-Total Statistics for the 16-item KT-SM Domains 
Domains /Item Cronbach’s 
alphaa 
Mean (SD) Mean 
IIC 
Corrected 
Item-Total 
Correlation 
SMC Alpha if 
Item 
Deleted 
Medication adherence (3 items) .83 4.60    .62    
I take my antirejection pills as instructed by my 
transplant doctor 
 4.73 (.80)  .65 .43 .80 
I call my transplant team if my antirejection pills make 
me sick 
 4.42 (.94)  .73 .54 .73 
I tell my transplant doctor about problems and concerns 
with my antirejection pills 
 4.66 (.74)  .70 .50  .60 
Cardiovascular risk reduction (4 items) .70  3.56    .38    
I avoid eating sweets, fried foods and other high calorie 
foods most of the time 
 3.27 (1.08)  .64 .41 .55 
I eat low fat foods like chicken, poultry, lean meats, or 
low-fat dairy products most of the time 
 3.71 (1.01)  .47 .26 .65 
I read food labels most of the time  3.84 (1.17)  .45 .23 .67 
I exercise at least 5 times per week  3.44 (1.23)  .42 .20 .69 
Table continues 
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Protecting kidney (4 items) .72 4.36    .40    
I limit alcoholic drinks to no more than one drink per day  4.68  .38 .21 .73 
I call my transplant team if I gain more than 3 pounds in 
one day 
 4.18  .53 .32 .66 
I call my transplant doctor if I urinate (pee) less than usual  4.22  .59 .37 .61 
I call my transplant doctor when I have signs of an 
infection like fever, flu-like symptoms, pain on urinating 
or a cough 
 4.39  .59 .38 .62 
Ownership (2 items) .77 4.69    .63    
I keep every appointment with my transplant doctor  4.67  .63 .40 - 
I keep my blood (lab) test appointments  4.71  .63 .40 - 
Skin cancer prevention (3 items) .72 ¤     .47    
I use sunscreen when outdoors  3.98 (1.02)  .44 0.20 0.75 
I examine (look at carefully) my skin and lips at 
least once a month 
 3.89 (1.12)  .62 0.43 0.54 
I call my doctor if there is a change or suspicious 
lesion on my lips or skin 
 4.25 (.86)  .60 0.41 0.58 
Note. N = 153. Item mean scores reflect the following response choices: 1 (strongly disagree), 2 (disagree), 3 (neutral), 4 (agree),  
5 (strongly agree). IIC = Inter-Item Correlation. SMC = Squared Multiple Correlation. 
aOverall Cronbach’s alpha for the 16-item scale was .84. 
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Corrected item-to-total correlation has been used as a criterion for assessing item 
performance in psychometric testing research, and a range from .30–.90 is recommended 
(DeVellis, 2012; Netemeyer et al., 2003). The corrected item-to-total correlations for the 
16-item KT-SM scale ranged from .38 to .73 (Table 10).  
Cronbach’s alpha is a diagnostic test to assess internal consistency reliability; a 
value greater than or equal to .70 is generally accepted (Nunnally & Bernstein, 1994). 
Cronbach’s alpha was .84 for the reduced 16-item scale and ranged from .70 to .83 for 
the five subscales (see Table 10).  
Mean inter-item correlation provides more useful information about internal 
consistency reliability than Cronbach’s alpha, especially when a scale is comprised of 
very few items (Netemeyer et al., 2003). The mean IIC for the five subscales ranged from 
3.8 to 6.3, achieving the investigator’s preset goal that mean IIC must be greater than .30 
(see Table 10).  
In summary, the item-to-total correlation values for each item in the subscales 
were greater than .38. The IIC for the five subscales ranged from .38 to .63. The 
Cronbach’s alpha values were at .84 overall and had a range of .70 to .83 for the five 
subscales. Based on these estimates, the investigator concludes that H2 is supported. 
Aim 3: Estimate construct validity of the KT-SM through EFA. 
H3: The EFA results will support that the KT-SM scale is a multidimensional 
scale with more than one factor extracted, and items within each factor will have factor 
loading values greater or equal to .40. 
The investigator conducted EFA on the 29-item KT-SM scale with a sample of 
153 KT recipients; EFA is used to find out the potential dimensions of the construct of 
 86 
interest (Pett et al., 2003; Polit, 2010; Tabachnick & Fidell, 2012). To determine the 
factorability of the present data and sampling adequacy, preliminary analyses were 
conducted as described in this section. First, correlation matrices were inspected to 
examine whether the values of the correlation coefficients were greater than .25 and less 
than .90 (Pett et al., 2003; Polit, 2010). One assumption of factor analysis is that variables 
in a factor should be correlated; if variables are not significantly intercorrelated, factor 
analysis is not appropriate (Polit, 2010), but if the variables correlate too well (r ≥ .90), 
multicollinearity may occur. The correlation matrices presented many coefficients of 
value 0.25 or above but not exceeding .90 (Table R-1; Appendix R). 
The second diagnostic information used to evaluate the factorability in the present 
dataset was Bartlett’s test of sphericity, which tests the null hypothesis that variables in 
the matrices are orthogonal; failure to reject the null hypothesis indicates that factor 
analysis is not feasible in this sample (Polit, 2010). The result of Bartlett’s test of 
sphericity was statistically significant (p = .000; Table 11). Lastly, the KMO test of 
sampling adequacy was computed to assess how suitable the sample size was for factor 
analysis; a KMO value greater than .80 is considered meritorious (Beavers et al., 2013, 
Table 11). The results indicated that the sample size was sufficient, and the data are 
factorable (Pallant, 2013; Tabachnick & Fidell, 2012). 
Table 11 
KMO Test and Bartlett’s Test 
KMO Measure of Sampling Adequacy .82 
Bartlett’s Test of Sphericity Approx. Chi-Square 1786.93 
df 406 
Sig. .000 
Note. N = 153. 
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Initial Factor Analysis 
The investigator performed PAF to identify the underlying factor structure of the 
29-item KT-SM. The PAF is the most commonly used extraction method in research, 
with Kaiser’s criterion, the eigenvalue-greater-than-1 rule, and Cattell’s (1966) scree test 
the most commonly used factor extraction criteria (Gable & Wolf, 1993; Pallant, 2013). 
The initial factor extraction yielded 9 factors that accounted for 67.25% of the total 
variance based on the eigenvalue-greater-than-1 rule (Table 12). The scree plot reveals 
that 4 factors should be retained (Figure 3), which is consistent with the hypothesis that 
the KT-SM scale would be composed of four subscales. Experts indicate that Kaiser’s 
eigenvalue-greater-than-one rule is more likely to over-extract factors (Beavers et al., 
2013; Pallant, 2013). Therefore, another factor retention criterion was employed: the 5% 
criterion, which is determined by percent of variance extracted, that is, one factor that 
accounts for at least 5% of variance will be retained (Pett et al., 2003). As Table 12 
depicts, the first 3 factors that met the 5% criterion were 7%, 9.20%, and 7.12%, 
respectively. The fourth factor was 4.83%, which is close to 5%; therefore, 3 or 4 factors 
were attainable. Hence, 4 factors were extracted throughout the whole EFA process.  
Table 12 
Initial Eigenvalues of the 29-Item KT-SM Scale without Varimax Rotation 
Factor Eigenvalues % of Variance Cumulative % 
1 7.70 26.53 26.53 
2 2.58 8.91 35.44 
3 2.03 6.98 42.43 
4 1.40 4.83 47.25 
5 1.36 4.70 51.95 
Table continues 
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6 1.20 4.14 56.09 
7 1.13 3.91 60.00 
8 1.07 3.71 63.70 
9 1.03 3.55 67.25 
Note. N = 153. Extraction Method: PAF. 
 
Figure 3. Scree Plot of the 29-Item KT-SM Scale. 
To facilitate factor interpretation, varimax rotation was performed after data 
extraction (Hatcher, 2013; Pallant, 2013; Tabachnick & Fidell, 2012). The goal of factor 
rotation is to achieve a simple and interpretable factor structure (Netemeyer et al., 2003). 
After varimax rotation, all variables are uncorrelated, and the items with high loadings 
are strengthened while the items with low factor loadings are diminished, thus enhancing 
the interpretability of factors (Polit, 2010; Tabachnick & Fidell, 2012). When a sample 
size ranges between 150 and 200, a factor loading value of .40 or above is considered 
statistically significant; therefore, only items with factor loadings ≥ .40 were retained and 
interpreted (Netemeyer et al., 2003).  
In addition, extraction communalities and item correlation matrix were assessed 
to determine if items needed to be removed. Determinant and reproduced matrices were 
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examined to see if the final factor solution is adequate (Hatcher, 2013; Pallant, 2013). 
The item reduction procedure was taken one step at a time, and the factor analytic 
procedure was conducted after each item deletion occurred until the optimal factor 
solution was reached, and extraction communality became stable. The following sections 
describe the steps of item reduction.  
Step 1. The EFA results for the 29-item KT-SM Scale showed that 47.25% of the 
variance was explained by 4 factors. As shown in Table 13, for ease of interpretation, 
items with loadings < .32 were suppressed. Items that did not load significantly on any 
factor and had low communality values were considered first for deletion. Communalities 
are “the amount of variance in each item accounted for by the solution” (Gable & Wolf, 
1993, p. 123). Item communality values have been used for additional diagnostic 
information in determining item deletion in scale development research (Pallant, 2013). 
An item that has low communality (less than .30; Pallant, 2013) or is not an important 
contributor to the whole instrument should be eliminated (Pett et al., 2003). Nine items 
did not have factor loading ≥ .40 and were removed from further analysis. In addition, 
extraction communalities for most of these items tended to be low. This step of the 
analyses left 20 items in the KT-SM scale. 
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Table 13 
Rotated Factor Matrix for the 29-Item KT-SM 
29-Items of the KT-SM Factor  
Item 1 2 3 4 h2 
1. I take my antirejection pills as instructed by my 
transplant doctor 
 
.77 
  .64 
2. I call my transplant team if my antirejection pills 
make me sick 
 .77   .64 
3. I do not change the number of antirejection pills  .35   .21 
4. I use a pill box or other reminder to remember to 
take my pills 
    .12 
5. I tell my transplant doctor about problems and 
concerns with my antirejection pills 
 .69 .34  .63 
6. If any doctor other than my transplant doctor 
gives me a new medication, I will call my 
transplant doctor to make sure it is safe to take 
 .37 .34  .32 
7. I avoid taking nonsteroidal anti-inflammatory 
drugs (NSAIDS) 
   0.34 .21 
8. I avoid eating sweets, fried foods and other high 
calorie foods most of the time 
.70    .55 
9. I eat low fat foods like chicken, poultry, lean 
meats, or low-fat dairy products most of the 
time. 
.56    .41 
10. I watch how much salt I eat .38    .33 
11. I read food labels most of the time .49    .31 
12. I exercise at least 5 times per week .57    .35 
13. I limit alcoholic drinks to no more than one drink 
per day 
  .52  .32 
14. I take my blood pressure medication as 
instructed 
    .17 
15. I look at my feet and ankles to check for swelling 
as instructed 
    .22 
16. I call my transplant team if I gain more than 3 
pounds in one day 
.33  .46  .42 
17. I call my transplant doctor if I pee less than usual  .33 .51  .46 
Table continues
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18. I keep every appointment with my transplant 
doctor 
   .71 .58 
19. I keep my blood test appointments    .69 .57 
20. I call my transplant doctor when I have signs of 
an infection 
  .80  .70 
21. I take my temperature as instructed by my doctor .43  .32  .38 
22. I drink at least eight 8-ounce glasses of water 
every day 
.39    .25 
23. I avoid close contact with people who are sick .33    .27 
24. I wash my hands after using the bathroom  .43  .61 .57 
25. I wash my hands before meals   .42  .36 
26. I use sunscreen when outdoors .58    .38 
27. I wear a hat to protect my skin when I am outside .42    .21 
28. I examine (look at carefully) my skin and lips at 
least once a month 
.60    .49 
29. I call my doctor if there is a suspicious lesion on 
my skin 
.55   .33 .46 
Eigenvalues 7.70 2.58 2.03 1.40  
% of Variance 26.53 8.91 6.98 4.83  
Note. Items with loadings of .40 or greater are in boldface. Items with loadings < .32 
were suppressed. H2 = communality. Extraction method: PAF. Rotation method: varimax 
with Kaiser normalization. 
 
Step 2. The EFA results for the 20-item KT-SM scale indicate that 57.12% of the 
total variance was explained by 4 factors. All items loaded strongly with loading  
size > .40 except item 27, “I wear a hat to protect my skin when I am outside,” which had 
the lowest communality of .23 (Table 14) and was thus deleted, leaving 19 items in the 
scale.  
Table 14 
Rotated Factor Matrix for PAF with Varimax Rotation of 20-Item KT-SM. 
20-Items of the KT-SM Factor  
Item 1 2 3 4 h2 
1. I take my antirejection pills as instructed by 
my transplant doctor 
 
.76 
  
.63 
Table continues 
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2. I call my transplant team if my antirejection 
pills make me sick 
 
.80 
  
.70 
5. I tell my transplant doctor about problems and 
concerns with my antirejection pills 
 
.64 
  
.58 
8. I avoid eating sweets, fried foods and other 
high calorie foods most of the time 
.67 
   
.51 
9. I eat low fat foods like chicken, poultry, lean 
meats, or low-fat dairy products most of the 
time. 
.52 
   
.38 
11. I read food labels most of the time .47 
   
.29 
12. I exercise at least 5 times per week .56 
   
.33 
13. I limit alcoholic drinks to no more than one 
drink per day 
  
.55 
 
.35 
16. I call my transplant team if I gain more than 3 
pounds in one day 
  
.45 
 
.42 
17. I call my transplant doctor if I pee less than 
usual 
  
.53 
 
.47 
18. I keep every appointment with my transplant 
doctor 
   
.75 .63 
19. I keep my blood test appointments 
   
.73 .62 
20. I call my transplant doctor when I have signs 
of an infection 
  
.81 
 
.72 
21. I take my temperature as instructed by my 
doctor 
.44 
   
.41 
24. I wash my hands after using the bathroom 
 
.42 
 
.60 .55 
25. I wash my hands before meals 
  
.41 
 
.34 
26. I use sunscreen when outdoors .59 
   
.38 
27. I wear a hat to protect my skin when I am 
outside 
.43 
   
.23 
28. I examine (look at carefully) my skin and lips 
at least once a month 
.60 
   
.50 
29. I call my doctor if there is a suspicious lesion 
on my skin 
.55 
   
.47 
Eigenvalues 6.02 2.26 1.86 1.28  
% of Variance 30.12 11.30 9.32 6.38  
Note. Items with loadings < .38 were suppressed. h2 = communality. Rotation converged 
in seven iterations.  
Step 3a. The PAF with varimax rotation was performed again on the 19-item 
scale (Table 15), which accounted for 58.79% of the total variance. Item 25, “I wash my 
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hands before meals,” was eliminated due to a loading size less than .40, resulting in 18 
items retained in the KT-SM scale.  
Table 15. 
Rotated Factor Matrix for PAF with Varimax Rotation of 4-Factor Solution of 19-Item 
KT-SM 
19-Items of the KT-SM Factor  
Item 1 2 3 4 h2 
1. I take my antirejection pills as instructed by 
my transplant doctor 
 .76   .63 
2. I call my transplant team if my antirejection 
pills make me sick 
 .80   .70 
5. I tell my transplant doctor about problems 
and concerns with my antirejection pills 
 .64   .59 
8. I avoid eating sweets, fried foods and other 
high calorie foods most of the time 
.70    .53 
9. I eat low fat foods like chicken, poultry, lean 
meats, or low-fat dairy products most of the 
time. 
.58    .44 
11. I read food labels most of the time .49    .30 
12. I exercise at least 5 times per week .52    .30 
13. I limit alcoholic drinks to no more than one 
drink per day 
  .53  .32 
16. I call my transplant team if I gain more than 3 
pounds in one day 
  .47  .42 
17. I call my transplant doctor if I pee less than 
usual 
  .54  .49 
18. I keep every appointment with my transplant 
doctor 
   .75 .63 
19. I keep my blood test appointments    .74 .62 
20. I call my transplant doctor when I have signs 
of an infection 
  .79  .69 
21. I take my temperature as instructed by my 
doctor 
.45    .41 
24. I wash my hands after using the bathroom  .43  .60 .56 
25. I wash my hands before meals   .39  .34 
26. I use sunscreen when outdoors .55    .34 
Table continues 
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28. I look at carefully my skin and lips at least 
once a month 
.60    .50 
29. I call my doctor if there is a suspicious lesion 
on my skin 
.54    .48 
Eigenvalues 5.91 2.20 1.79 1.27  
% of Variance 31.12 11.56 9.44 6.67  
Note. Items with loadings < .38 were suppressed. Rotation converged in seven iterations. 
h2 = communality. 
Step 3b. The rotated factor matrix of the 18 items is presented in Table 16. A total 
of 60.11% of the variance is explained by the fixed 4-factor solution. While looking at 
the factor matrix, most of the grouped items were conceptually related, except items 21 
and 24. Experts suggest that items should be deleted if they cross- or multi-load strongly 
or if there is difficulty in interpreting their meanings and results (Pett et al., 2003; Polit, 
2010). The characteristics of the items in factor 1 are related to CV risk reduction and 
skin cancer prevention, except for item 21, “I take my temperature as instructed by my 
doctor,” which did not share anything in common with the other items in factor 1. 
Furthermore, item 24, “I wash my hands after using the bathroom,” loaded on both 
factors 2 and 3 strongly, yet conceptually it is irrelevant to items in these two factors. 
Therefore, these two items were removed, resulting in 16 items retained in the KT-SM 
scale. Whether item 21 and item 24 were deleted together or one-by-one, the results were 
the same. 
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Table 16 
Rotated Factor Matrix for PAF with Varimax Rotation of 4-Factor Solution of 18-Item 
KT-SM 
18-Items of the KT-SM Factor  
Item 1 2 3 4 h2 
1. I take my antirejection pills as instructed by my 
transplant doctor 
 .76   .62 
2. I call my transplant team if my antirejection pills 
make me sick 
 .80   .72 
5. I tell my transplant doctor about problems and 
concerns with my antirejection pills 
 .63  .38 .59 
8. I avoid eating sweets, fried foods and other high 
calorie foods most of the time 
.70    .53 
9. I eat low fat foods like chicken, poultry, lean meats, 
or low-fat dairy products most of the time. 
.59    .45 
11. I read food labels most of the time .49    .30 
12. I exercise at least 5 times per week .52    .30 
13. I limit alcoholic drinks to no more than one drink 
per day 
   .50 .29 
16. I call my transplant team if I gain more than 3 
pounds in one day 
   .51 .45 
17. I call my transplant doctor if I urinate (pee) less 
than usual 
   .56 .50 
18. I keep every appointment with my transplant doctor   .77  .65 
19. I keep my blood (lab) test appointments   .74  .63 
20. I call my transplant doctor when I have signs of an 
infection like fever, flu-like symptoms 
   .74 .62 
21. I take my temperature as instructed by my doctor .45    .42 
24. I wash my hands after using the bathroom  .43 .59  54 
26. I use sunscreen when outdoors .55    .33 
28. I examine (look at carefully) my skin and lips at 
least once a month 
.60    .50 
29. I call my transplant doctor if there is a change or 
suspicious lesion on my lips or skin 
.54    .49 
Eigenvalues 5.58 2.20 1.79 1.26  
% of Variance 31.0 12.2 9.92 6.99  
Note. Items with loadings < .38 were suppressed. Rotation converged in 7 iterations.  
h2 = communality. 
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Finalization of EFA. The EFA results for the remaining 16 items indicated that a 
total of 61.58% of the total variance is explained by the 4-factor solution. Table 17 
displays the factor structure and communality estimates for the 16-item KT-SM. 
Examining the rotated factor matrix further, one item with cross-loading on two factors 
was noted. Experts suggest that if an item cross-loads on more than one factor, it should 
be assigned to the factor that has the higher loading value or be allocated to the factor that 
is conceptually related (Pett et al., 2003; Polit, 2010). Item 29, “I call my doctor if there is 
a suspicious lesion on my skin,” is conceptually related to the skin cancer items that were 
grouped in factor 1 and thus was assigned to factor 1. After the allocation, items 16 and 
17 were left in factor 4. Likewise, items that related to healthy diet and lifestyle and skin 
cancer prevention were grouped into one factor. Therefore, the investigator believed a  
3- or 5-factor solution might be tenable.  
Table 17 
Varimax-Rotated Factor Structure: Final Communalities, Eigenvalues, Percentage of 
Variance, and Reliability for the 16-Item KT-SM Scale 
16-Items of the KT-SM Factor  
Items 1 2 3 4 h2 
1. I take my antirejection pills as instructed by my 
transplant doctor 
 .73   .55 
2. I call my transplant team if my antirejection 
pills make me sick 
 .84   .77 
5. I tell my transplant doctor about problems and 
concerns with my antirejection pills 
 .68   .64 
8. I avoid eating sweets, fried foods and other 
high calorie foods most of the time 
.70    .53 
Table continues 
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9. I eat low fat foods like chicken, poultry, lean 
meats, or low-fat dairy products most of the 
time. 
.58    .42 
10. I read food labels most of the time .51    .33 
11. I exercise at least 5 times per week .53    .31 
12. I limit alcoholic drinks to no more than one 
drink per day 
  .53  .31 
16. I call my transplant team if I gain more than 3 
pounds in one day 
  .48  .42 
17. I call my transplant doctor if I urinate (pee) less 
than usual 
  .56  .49 
18. I keep every appointment with my transplant 
doctor 
   .81 .70 
19. I keep my blood (lab) test appointments    .69 .57 
20. I call my transplant doctor when I have signs of 
an infection like fever, flu-like symptoms 
  .74  .62 
26. I use sunscreen when outdoors .54    .33 
28. I examine (look at carefully) my skin and lips 
at least once a month 
.60    .51 
29. I call my transplant doctor if there is a change 
or suspicious lesion on my lips or skin 
.53   .38 .49 
Eigenvalue 4.92 2.08 1.60 1.25  
% of Variance 30.78 12.98 10.00 7.83  
Note. Items with loadings < .40 were suppressed. h2 = communality. 
However, the EFA results did not support the 3-factor solution, and items 16 and 
17 loaded on factor 3 alone while the rest of the items were clustered in two factors, 
making interpretation of the results even more problematic. The 5-factor solution does 
successfully separate the three skin cancer-related items to factor 5, and 67.18% of the 
variance was explained by the solution (Table 18). Item 26 had a slightly low loading 
value of .39, but it was kept because using sunscreen outdoors is recommended by KT 
guidelines (Kasiske et al., 2010). 
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Table 18 
Five Factor Structure: Final Communalities, Eigenvalues, Percentage of Variance, and 
Reliability for the 16-item KT-SM Scale 
16-Items of the KT-SM Factor  
Items 1 2 3 4 5 h2 
1. I take my antirejection pills as instructed 
by my transplant doctor 
.73     .55 
2. I call my transplant team if my 
antirejection pills make me sick 
.84     .77 
5. I tell my transplant doctor about 
problems and concerns with my 
antirejection pills 
.68     .64 
8. I avoid eating sweets, fried foods and 
other high calorie foods most of the time 
 .85    .76 
9. I eat low fat foods like chicken, poultry, 
lean meats, or low-fat dairy products 
most of the time. 
 .52    .42 
10. I read food labels most of the time  .49    .33 
11. I exercise at least 5 times per week  .49    .31 
12. I limit alcoholic drinks to no more than 
one drink per day 
  .52   .32 
16. I call my transplant team if I gain more 
than 3 pounds in one day 
  .49   .45 
17. I call my transplant doctor if I urinate 
(pee) less than usual 
  .58   .52 
18. I keep every appointment with my 
transplant doctor 
   .89  .86 
19. I keep my blood (lab) test appointments    .62  .51 
20. I call my transplant doctor when I have 
signs of an infection like fever, flu-like 
symptoms 
  .73   .61 
26. I use sunscreen when outdoors  .39   .39 .32 
28. I examine (look at carefully) my skin 
and lips at least once a month 
    .73 .70 
29. I call my transplant doctor if there is a 
change or suspicious lesion on my lips or 
skin 
    .57 .55 
Table continues 
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Eigenvalue 4.92 2.08 1.60 1.25 .90  
% of Variance 30.78 12.98 10.00 7.83 5.60  
Cronbach’s alpha .83 .70 .72 .77 .72  
Note. Items with loadings < .40 were suppressed. h2 = communality. 
To determine if the final 5-factor solution was adequate, the following 
information was used to evaluate model fit. Determinants of the correlation matrix and 
reproduced matrices were inspected (see Tables R-2 and R-3, respectively). As shown in 
the Table R-2 note, the determinant is .002, which is greater than .00001, indicating that 
no multicollinearity and singularity exist (Leech, Barrett, & Morgan, 2014). The numbers 
of the reproduced correlations (Table R-3) were close to the original correlations (Table 
R-2), and values in the residual correlation matrix were small, indicating good model fit 
(Tabachnick & Fidell, 2012; Yong & Pearce, 2013). As noted in Table R-4, there are nine 
(7.0%) nonredundant residuals that have absolute values greater than .05; nonredundant 
residuals less than 50% are preferable (Johnson & Morgan, 2016). Each of these analyses 
support the adequacy of the 5-factor solution. 
Factor naming. Items were grouped per factor as shown in Table 19. Items in 
four of the five factors were consistent with the hypothesized subscales and used the 
original names: “medication adherence” for factor 1, “CV risk reduction” for factor 2, 
“protecting the new kidney” for factor 3, and “skin cancer prevention” for factor 5. Items 
“I keep every appointment with my transplant doctor” and “I keep my blood (lab) test 
appointments” in factor 4 were originally developed for the subscale “protecting the new 
kidney,” but the EFA results revealed that these items belonged to factor 4 alone and had 
higher loading values of .89 and .62, respectively. High loadings indicate that items are 
unique. The rationale for kidney recipients’ keeping doctor and lab appointments is to 
adjust immunosuppressant doses based on lab results and to monitor graft function and/or 
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signs of infection (Kasiske et al., 2009). To achieve optimal post-KT results, recipients 
are expected to make a commitment to be active in their own care by keeping doctor and 
lab appointments. In addition, ownership of post-transplant care requires effective 
doctor–patient communications. Hence, factor 4 was given the name, “ownership 
(partnership) of post-KT care.”  
Table 19 
Reduced 16-Item KT-SM Scale and Its Subscales 
Subscale 
F1 Medication Adherence (3 items) 
I call my transplant team if my antirejection pills make me sick 
I take my antirejection pills as instructed by my transplant doctor  
I tell my transplant doctor about problems and concerns with my antirejection pills 
F2 Cardiovascular disease risk reduction (4 items)  
I eat low fat foods like chicken, poultry, lean meats, or low-fat dairy products most 
of the time 
I avoid eating sweets, fried foods and other high calorie foods most of the time 
I read food labels most of the time 
I exercise at least 5 times per week  
F3 Protecting the new kidney (5 items)  
I limit alcoholic drinks to no more than one drink per day 
I call my transplant doctor if I urinate (pee) less than usual 
I call my transplant team if I gain more than 3 pounds in one day 
I call my transplant doctor when I have signs of an infection like fever, flu-like 
symptoms 
F4 Ownership of post-transplant self-care (2 items)  
I keep every appointment with my transplant doctor 
I keep my blood (lab) test appointments 
F5 Skin cancer prevention (3 items) 
I use sunscreen when outdoors 
I examine (look at carefully) my skin and lips at least once a month 
I call my transplant doctor if there is a change or suspicious lesion on my lips or 
skin 
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Summary. The PAF with varimax rotation identified the underlying factor 
structure of the 29 items from the KT-SM scale using IBM SPSS version 24. Prior to 
performing factor analysis, the KMO measure of sampling adequacy and Bartlett’s test of 
sphericity were conducted. The KMO was .82, and Bartlett’s test of sphericity was 
statistically significant, indicating the sample size was adequate and the data are 
factorable. The EFA results supported that the 16-item KT-SM scale is a 
multidimensional scale and contains five domains. All 16 items load strongly on 5 
factors: medication adherence, CV risk reduction, protecting the new kidney, ownership 
(partnership) of post-KT care, and skin cancer prevention. Loading sizes ranged from 
.49–.89, except one, which was .39. The investigator concluded that H5 and H6 are 
supported. 
Sequential Multiple Regression 
Aim 4: Estimate construct validity of the KT-SM scale guided by the conceptual 
model by exploring relationships between the KT-SM scale and the SEMCD, the  
PAM-13, and the KTQ-25.  
To determine the strength and direction of each proposed theoretical relationship 
in the framework, sequential multiple regression was conducted for the variables of  
self-efficacy, patient activation, KT SM behavior, and HRQoL. Relevant assumptions are 
examined and described in the following sections.  
First, sample size and power needed for multiple regression analysis were 
computed. Based on the rule of thumb: N ≥ 50 + 8k (k represents number of predictor 
variables; Tabachnick & Fidell, 2012), a total of 153 subjects was considered sufficient to 
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run the analysis, which achieved a power of .99 and α = .05 with an effect size of .34 
(Polit, 2010).  
The second assumption was that there was no multicollinearity; that is, predictor 
variables in the model must be uncorrelated. Correlation coefficients of all independent 
variables (Ivs) were examined and were less than .80 (Cohen, Cohen, West, & Aiken, 
2013), indicating that the assumption was met. In addition, the Variance Inflation Factor 
(VIF) and tolerance for all Ivs ranged from 1.59–1.96 and .51–.73, respectively. The VIF 
values less than 10 or tolerance greater than .10 indicate no multicollinearity; therefore, 
the results show that multicollinearity did not occur (Cohen et al., 2003; Tabachnick & 
Fidell, 2012).  
Residual plots for dependent variables were inspected to assess homoscedasticity. 
The residual plots scattered around the diagonal line from the bottom to the top left, 
indicating that no heteroscedasticity was present. Multivariate outliers were evaluated by 
checking the Mahalanobis distance and Cook’s distance for all cases. Critical values of 
chi square (χ2) were estimated to identify outliers. The critical χ2 for this sample was 
16.92, which was estimated based on α = .05 and degree of freedom of 9 (Tabachnick & 
Fidell, 2012). As presented in Table 20, the maximum value of the Mahalanobis distance 
is 32.02. This exceeds 16.92, suggesting that outliers exist. Table 21 presents the outlier 
statistics in the 10 cases with the largest distances. Four cases have values > 16.92 and 
are considered multivariate outliers. The Cook’s distances of these cases were examined 
to see if they influenced the model results. The maximum value of Cook’s distance is .06 
(Table 21), which is lower than 1, suggesting no influence (Tabachnick & Fidell, 2012). 
Therefore, these four cases were retained in the data file. 
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Table 20 
Residuals Statistics 
Distance Min. Max. M SD N 
Mahalanobis 
Distance 
2.71 33.25 9.94 4.22 153.00 
Cook’s Distance 0.00 0.08 0.01 0.03 153.00 
 
Table 21 
Outlier Statistics 
 Cases with 
the Largest 
Distances 
Case 
Number 
Statistic 
Mahalanobis 
Distance 
1 147 33.25 
 2 63 23.13 
 3 28 20.53 
 4 73 19.93 
 5 1 18.55 
 6 153 18.24 
 7 91 17.35 
 8 83 16,85 
 9 50 16.15 
 10 75 15.89 
 
Lastly, a visual inspection was done to examine the data distribution of all 
variables. The SCQ, year of transplant, and year of dialysis were skewed; square root 
transformation was done on these variables.  
H4: A significant amount of variance in KT SM as measured by the 16-item  
KT-SM scale and five subscales will be explained by self-efficacy and patient activation, 
after controlling for demographic and clinical variables. 
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H4 was partially supported by results from sequential multiple regressions 
conducted to investigate the proportion of variance of the KT-SM scale and five domains 
explained by SEMCD and PAM-13. The six regression equations and findings were 
examined further per outcome and presented in the section, Screening for categorical 
variables using MANOVA.  
Model building is a crucial step for successful regression analysis (Mendenhall, 
Sincich, & Boudreau, 2003). An overfitting model (incorporating redundant variables) 
leads to poor predictions of outcomes and complicates the interpretation process, while 
an underfitting model omits the effects of important predictor variables and leads to 
questions about the predictability of included variables (Chatterjee & Simonoff, 2013). 
For this study, prior to conducting sequential multiple regression analyses, bivariate 
correlations were examined for predictor variables and criterion variables, and the 
MANOVA univariate F statistic was used to screen categorical variables to be entered 
into the regression equation. Only variables with significant Pearson r values (p < .05) or 
statistically significant F test results were entered into the regression equation. 
Categorical variables including education, marital status, and employment status had 
unequal cell sizes and thus were combined and recoded into fewer categories and 
presented as follows. Education was condensed into four levels: high school and under  
(n = 21), some college (n = 46), college graduate (n = 46), and post graduate (n = 40). 
Marital status had three categories: married (n = 88), living with a partner (n = 16), and 
single/divorced (n = 49). Employment status was regrouped as retired or receiving 
supplemental security income (n = 41), unemployed (n = 30), and employed (n = 82). 
Categorical variables that had statistically significant F test results were dummy coded 
 105 
with numerals per the recommendation from Tabachnick and Fidell (2012) before being 
entered in the regression model. 
Screening for continuous variables using Pearson r. As depicted in Table 22, 
KT recipients’ age was significantly positively correlated with KT-SM total score as well 
as with scores on four of the five domains (r = .21 to .41, p < .05; except domain 
protecting kidney). Years post-transplant was significantly inversely correlated to overall 
KT-SM (r = -.22, p < .01) and to the subscales medication adherence (r = -.19, p < .05) 
and protecting kidney (r = -.25, p < .01). Years of pre-transplant dialysis was found to be 
positively related to medication adherence (r = .20, p < .05) but negatively associated 
with skin cancer prevention (r = -.19, p < .05). The predictor variables SEMCD and 
PAM-13 were positively correlated with the KT-SM total scale score and the five 
subscales (medication adherence, cardio risk reduction, protecting new kidney, 
ownership, and skin cancer) with ranges of r = .22 to .50, p < .01 and r = .31–.52, p < .01, 
respectively (see Table 23). Therefore, age, square root-transformed years  
post-transplant, square root-transformed years of pre-transplant dialysis, square  
root-transformed SCQ score, PAM-13, and SEMCD (measuring self-efficacy) were 
entered in the regression equation accordingly.  
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Table 22 
Intercorrelations for Overall and Dimensions of KT-SM Scale and Six Independent 
Variables 
KT-SM and 
domains 
Age Sqrt Years 
Post-
Transplant 
Year of 
Dialysis 
Sqrt 
SCQ  
SEMCD PAM-
13 
KT-SM total .35** -.22** -.05 -.11 .50** .52** 
Medication 
adherence 
.35** -.19* .20* -.01 .31** .41** 
CV risk reduction .21* -.14 -.16 -.09 .38** .31** 
Protecting kidney .16 -.25** .03 -.04 .22** .39** 
Ownership .41** .01 .01 -.23** .42** .36** 
Skin cancer .23** -.12 -.19* -.09 .48** .37** 
PAM-13 .16 -.04 .04 -.18* .53** - 
SEMCD .24** .01 -.09 -.34** - .53** 
Note. N = 153. Sqrt = Square root. 
*p < .05. **p < .01. ***p < .001. 
Table 23 
Multivariate and Univariate Analysis of Variance on Discrete Socioeconomic Factors 
and KT-SM Scale and Five Domains 
Factors Multi-
variate F 
 Univariate F 
   KT-SM 
Overall 
Meds 
Adher-
ence 
CV 
risk 
Reduc
-tion 
Protect
-ing 
Kidney 
Owner-
ship 
Skin 
Can-
cer 
Gendera .75  .06 .03 .03 .24 1.07 .72 
Maritalb 2.43**  3.10 1.94 .34 .96 11.48*** 2.32 
Racec .88  1.68 .05 3.52 .08 .55 2.05 
Ethnicityd 2.44*  .99 .81 2.33 .15 3.09 .60 
Educatione 1.31  1.49 .82 1.65 1.89 2.33 .74 
Table continues 
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Employmentf .98  .64 1.60 .33 .04 1.77 1.16 
Tx typeg 1.79  5.65** 4.60 3.83 3.95 1.30 1.20 
Note. Multivariate F values were obtained from Pillai’s statistics.  
aMultivariate df (5, 146). bdf (10, 294). cdf (5, 147). ddf (5, 145). edf (15, 441). fdf (10, 
294). gdf (5, 146). 
*p < .05. **p < .01. ***p < .001. 
Screening for categorical variables using MANOVA. Separate one-way 
multivariate analysis of variance (MANOVA) tests were conducted to investigate the 
effects of gender, marital status, race, ethnicity, education, employment, history of  
pre-transplant dialysis, and transplant type differences in the overall KT-SM and the five 
domain scores. Pillai’s criterion was used as it is more robust than Wilks’ lambda, 
Hostelling’s trace, and Roy’s largest root and produces more accurate results when cell 
sizes are unequal (Hatcher, 2013; Tabachnick & Fidell, 2012).  
Variables that had nonsignificant multivariate F test results indicated no main 
effect on the overall dependent variables and were therefore screened for first. Table 24 
shows that multivariate F tests for gender (p = .59), race (p = .49), education (p = .19), 
transplant type (p = .06), and employment status (p = .46) were nonsignificant. However, 
the p value for the main effect of transplant type approached significance, and the 
univariate F test result for the overall KT-SM scale was statistically significant,  
F(2, 150) = 5.65, p = .004, indicating that KT recipients who received a living 
nonrelative kidney had the highest mean score on the overall KT-SM scale compared to 
non-living donor and living-related donor. Tabachnick and Fidell (2012) suggest that if 
only a single dependent variable is measured in a study, the univariate F effect can still 
be considered significant. This is not the case for this study, hence, the variables 
transplant type, gender, race, education, and employment status were first excluded from 
the sequential multiple regression equations. 
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Table 24 
Variables to be Entered in the Sequential Multiple Regression Equations Displayed per 
Outcome Variable 
Outcome 1st Block 2nd Block 
KT-SM Overall Age, r = .35** 
years post-transplant sqrt, r = .22** 
PAM-13, r = .52** 
SEMCD, r = .50**  
Meds adherence Age, r = .35** 
Years post-transplant sqrt, r = -.14* 
Years of dialysis sqrt, r = -.16* 
PAM-13, r = .41** 
SEMCD, r = .31** 
CV risk Age, r = .21** 
Years of dialysis sqrt, r = -.19** 
Years post-transplant sqrt, r = -.25** 
PAM-13, r = .31** 
SEMCD, r = .38** 
Protecting kidney Years post-transplant sqrt, r = -.25** PAM-13, r = .39** 
SEMCD, r = .22** 
Ownership Age, r = .41** 
SCQ-sqrt, r = -.23** 
Marital status, F = 11.48, α < .000 
PAM-13, r = .36** 
SEMCD, r = .42** 
Skin cancer Age, r = .23** 
Years of dialysis sqrt, r = -.19** 
PAM-13, r = .37* 
SEMCD, r = .48** 
*p < .05. **p < .01. ***p < .001. 
The multivariate F test for marital status [F(10, 294) = 2.43, p = .009] and 
ethnicity [F(5, 145) = 2.44, p = .04] were statistically significant, hence, the univariate F 
tests for individual dependent variables overall KT-SM scale and the five domains were 
examined further. The univariate F tests using a Bonferroni adjusted alpha value of .008 
(α = .05/6 dependent variables) demonstrated a large effect of marital status on ownership 
of post-KT care, F(2, 150) = 11.48, 
2
pη  = .13, p < .001. The result of the multivariate F 
test for ethnicity was statistically significant, but the univariate F tests results were 
nonsignificant, demonstrating that ethnicity had no effects on overall KT-SM scale or the 
five domains (see Table 23).  
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Six pre-test regression models. To test H4, a series of sequential multiple 
regressions were conducted to investigate how well the PAM-13 and SEMCD scores 
explained the variation in the overall KT-SM scale and five domains after controlling for 
the effects of demographic and clinical factors. Continuous and categorical variables 
including age, marital status, square root-transformed years of dialysis, square  
root-transformed comorbidity score, and square root-transformed years post-transplant 
accordingly were put into the six regression equations to control for their effects on the 
criterion variables. In the last step, SEMCD and PAM-13 were added to the regression 
equation (Table 24).  
Overall KT-SM. Means, standard deviations, and intercorrelations for the 
variables to be entered in the regression equation are reported in Table 25. 
Table 25 
Descriptive Statistics and Intercorrelations for Overall KT-SM Scale and Predictor 
Variables 
Variable M SD Age Year Tx sqrt PAM-13 SEMCD 
KT-SM Total 67.02 8.33 .35*** -.22** .52*** .50*** 
Age 46.63 12.19  .13 .24** .16* 
Year Tx-sqrt 2.22 1.29 .13  -.04 .01 
PAM-13 77.89 15.71 .16 -.04   
SEMCD 7.44 1.80 .24 .01 .53***  
Note. Tx = transplant. Sqrt = Square root-transformed. 
* p < .05. ** p < .01. *** p < .001. 
Table 26 presents the results for the overall KT-SM scale as an outcome variable. Age 
and years post-transplant were added in the first block; these explained 20% of the 
variation in the overall KT-SM scale, R2 = .20, F(2, 150) = 18.15, p < .001. After step 2, 
with all predictor variables included, 45% of the variance in the overall KT-SM scale was 
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explained by the model as a whole, R2 = .45, F(4, 148) = 30.22, p < .001. The variables 
SEMCD and PAM-13 explained an additional 26% of the variance in the overall KT-SM 
scale (R2 change = .26, sig. F change = .000) after controlling for age and years  
post-transplant. In examining the final model, all predictor variables made unique 
significant contributions in explaining the variation in the overall KT-SM scale, with 
PAM-13 recording a higher beta value (β = .32, p < .001) than SEMCD (β = .28,  
p < .001), age (β = .27, p < .001), and years post-transplant (β = -.25, p < .001). Positive 
beta values indicate positive relationships among variables, whereas negative beta values 
represent negative relationships. 
Table 26 
Sequential Multiple Regression Analysis for Variables Predicting Overall KT-SM Score  
Predictor R2 ΔR2 B SEB β t 
Step 1       
Age   .26 .05 .39*** 5.23 
Sqrt-Year 
transplant 
  -1.76 .48 -.27** -3.67 
 .20 .20***     
Step 2       
Age   .18 .04 .27*** 4.23 
Sqrt-Year 
transplant 
  -1.58 .40 -.25*** -4.0 
SEMCD   1.28 .34 .28*** 3.76 
PAM-13   .17 .04 .32*** 4.39 
 .45 .26***     
*p < .05. **p < .01. ***p < .001. 
Correlation coefficients for all variables presented in Table 27 support the direction of the 
relationships. Correlation coefficients for variables age, PAM-13, and SEMCD range 
between .35 and .52 (p < .01), indicating positive, moderate relationships with the overall 
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KT-SM scale (Table 27). Years post-transplant was inversely related to overall KT-SM 
scale (r = -.22, p < .05).  
Table 27 
Descriptive Statistics and Intercorrelations for Subscale Medication Adherence Scale 
and Predictor Variables 
Variable M SD M. Adherence Age Sqrt-Year 
transplant 
PAM-13 
M. Adherence 4.60 .72     
Age 46.63 12.19 .35**    
Sqrt-Year transplant 2.22 1.29 -.19* .13   
Dialysis-sqrt  1.04 1.01 .20* .03 -.21**  
PAM-13 77.89 15.71 .41*** .16 -.09  
SEMCD 7.44 1.80 .31*** .24** .01 .53*** 
*p < .05. **p < .01. ***p < .001. 
Medication adherence. Table 27 provides the means, standard deviations, and 
bivariate correlations for the variables to be entered in the regression model. To test the 
ability of SEMCD and PAM-13 to explain the variation in the KT-SM domain 
medication adherence, age, square root-transformed years post-transplant and square 
root-transformed years of dialysis were entered in the first step. As presented in Table 28, 
these three variables explained 20% of the variance in medication adherence,  
F(3, 149) = 12.08, p < .001. In the second step, adding SEMCD and PAM-13 in the 
model accounted for an additional 12% of the variance, F(2, 147) = 13.00, p < .001. 
Including all the variables in the final model explained a total of 32% of the variance. 
However, adding SEMCD (β = .10, p = .24) in the final model did not help predict the 
medication adherence score. Thus, the investigator concluded that nearly one-third of the 
variability in medication adherence was predicted by age (β = .30, p < .001), PAM-13  
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(β = .29, p < .001), years post-transplant (β = -.19, p < .01), and years of pre-transplant 
dialysis (β = .15, p < .05). The variables age, years of pre-transplant dialysis, and  
PAM-13 are positively correlated to medication adherence (r =.20 to .41, p < .01), 
whereas years post-transplant (r =.19, p < .01) is inversely correlated to medication 
adherence.  
Table 28 
Sequential Multiple Regression Analysis Summary for Variables Predicting Subscale 
Medication Adherence Score (N = 153) 
Variable R2 ΔR2 B SEB β t 
Step 1       
Age   .02 .00 .37*** 4.96 
Sqrt-Year 
transplant 
  -.12 .04 -.21** -2.74 
Sqrt-Year dialysis   .01 .06 .15 1.94 
 .20 .23**     
Step 2       
Age   .02 .00 .30*** 4.71 
Sqrt-Year 
transplant 
  -.10 .04 -.19** -2.64 
Sqrt-Year dialysis   .11 .05 .15* 2.10 
SEMCD   .04 .03 .10 1.19 
PAM-13   .01 .00 .29*** 3.62 
 .32 .12***     
*p < .05. **p < .01. ***p < .001. 
CV risk reduction. Sequential multiple regression was conducted again to 
investigate the ability of SEMCD and PAM-13 to explain the variation of the KT-SM 
domain CV risk reduction. Descriptive statistics and bivariate correlations for testing 
variables are presented in Table 29. 
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Table 29 
Descriptive Statistics and Intercorrelations for the KT-SM Subscale CV Risk Reduction 
Variable M SD CV risk reduction Age PAM-13 
CV risk reduction 3.56 .82    
Age 46.63 12.19 .21**   
Years post KT 6.19 6.59 -.14*   
Year of pre-dialysis 2.10 3.11 -.16*   
PAM-13 77.89 15.71 .31*** .16  
SEMCD 7.44 1.80 .38*** .24** .53*** 
*p < .05. **p < .01. ***p < .001. 
In the first step, adding the variables age, years post-KT, and years of pre-transplant 
dialysis explained 11.1% of the variance in the domain, F(3, 149) = 6.19, p < .001  
(see Table 30). After step 2, with the variables PAM-13 and SEMCD included in the 
equation, the total variance explained as a whole was 23%, F(2, 147) = 11.32, p < .001. 
The introduction of PAM-13 and SEMCD accounted for an additional 12% (sig. F 
change = .000) of the variance in explaining CV risk reduction after controlling for age, 
years post-KT, and years of pre-transplant dialysis. The final model incorporated the 
variables age (β = .16, p < .05), years post-KT (β = -.19, p < .05), years of pre-transplant 
dialysis (β = -.18, p < .05), and SEMCD (β = .25, p < .01). Years post-KT and years of 
pre-transplant dialysis were negative predictors of CV risk behavior, which means that 
longer years post-KT and longer duration of pre-transplant dialysis were correlated with 
high likelihood not to practice CV risk reduction behaviors. The results of bivariate 
correlational analysis displayed in Table 29 show a positive association between PAM-13 
and CV risk reduction, yet the PAM-13 did not reach statistical significance in predicting 
CV risk reduction scores. However, SEMCD made a statistically significant contribution 
to the model in predicting CV risk reduction score.  
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Table 30 
Sequential Multiple Regression Analysis Summary for Variables Predicting Subscale CV 
Risk Reduction Score  
Variable R2 ΔR2 B SEB β t 
Step 1       
Age   .02 .01 .24** 3.09 
Years post-KT   -.13 .05 -.21** -2.65 
Year of  
pre-dialysis 
  -.17 .06 -.21* -2.61 
 .11 .11***     
Step 2       
Age   .01 .01 .16* 2.05 
Years post-KT   -.12 .05 -.19* -2.55 
Year of  
pre-dialysis 
  -.15 .06 -.18* -2.45 
SEMCD   .13 .04 .28** 3.15 
   PAM-13   .01 .01 .14 1.59 
 .23 .12***     
*p < .05. **p < .01. ***p < .001. 
Protecting kidney. Correlation coefficients of the predictor variables and 
outcome variable range between r = -.25 and .39, p < .01 (Table 31). Adding square  
root-transformed years post-transplant in the first block explained 6.3% of the variance in 
protecting kidney, F(1, 151) = 10.23, p < .01.  
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Table 31 
Descriptive Statistics and Intercorrelations for KT-SM Subscale Protecting Kidney and 
Predictor Variables 
Variable M SD Protecting 
kidney 
Year Tx 
sqrt 
PAM-13 
Protecting kidney 4.36 .69    
Sqrt-Year transplant 2.22 1.29 -.25***   
PAM-13 77.89 15.71 .39** -.09  
SEMCD 7.44 1.80 .22*** .01 .53*** 
*p < .0.5 **p < .01. ***p < .001. 
After step 2, with the variables PAM-13 and SEMCD included, 20.6% of the variance in 
protecting kidney was explained by the model as a whole (Table 32). Adding PAM-13 
and SEMCD explained an additional 13.36% of variance (sig. F change =.000) after 
controlling for the effect of years post-transplant. In the final model, two of the three 
variables have statistically significant β-values: PAM-13 (β = .36, p < .001) and years 
post-transplant (β = -.24, p < .01). PAM-13 is the stronger positive predictor in predicting 
the protecting kidney score, whereas years post-transplant may be used to predict the 
inverse outcome. The more years post-transplant, the lower the score on protecting 
kidney is expected to be. In other words, the longer a person has had a KT, the less likely 
he or she is to perform kidney-protecting behaviors. 
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Table 32 
Sequential Multiple Regression Analysis Summary for Variables Predicting Subscale 
Protecting Kidney Score (N = 153) 
Predictor R2 ΔR2 B SEB β t 
Step 1       
Sqrt-Year 
transplant 
  -.14 .04 -.28** -3.20 
 .06 .06**     
Step 2       
Sqrt-Year 
transplant 
  -.13 .04 -.24** -3.24 
SEMCD   .00 .03 .03 .35 
PAM-13   .02 .00 .36*** 4.18 
 .21 .14***     
*p < .05. **p < .01. ***p < .001. 
Ownership. Marital status was dummy coded into three categories: married, 
living with a partner, and single/divorced, with married as the reference group. In step 1, 
living with a partner, single/divorced, age, and square root-transformed SCQ were 
entered in the first block; these explained 29.4% of the variance in ownership (see Table 
33).  
Table 33 
Descriptive Statistics and Intercorrelations for KT-SM Subscale Ownership and 
Predictor Variables (N = 153) 
Variable M SD Ownership 
Ownership 4.69 .63 - 
Married 4.83 .35 .27*** 
Living with a partner 4.91 .27 .12 
Single/divorced 4.36 .91 -.36*** 
Age 46.63 12.19 .41*** 
Table continues 
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Sqrt-SCQ 2.00 .98 -.23** 
PAM-13 77.89 15.71 .42*** 
SEMCD 7.44 1.80 .36*** 
*p < .05. **p < .01. ***p < .001. 
After adding SEMCD and PAM-13 in the second block, 37.2% of the total variance was 
explained by the model as a whole, F(6, 146) = 14.40, p < .001. PAM-13 and SEMCD 
explained an additional 8% of the variance in ownership, after controlling for marital 
status, age, and square root-transformed SCQ, ΔR2 = .08, F change (2, 146) = 9.05, p < 
.001. In the final adjusted model, age, single/divorced, and SEMCD were statistically 
significant, with age (β = .29, p < .001) recording a higher beta weight value than 
single/divorced (β = -.24, p < .001), and SEMCD (β = .20, p < .05). (See Table 34.) 
Table 34 
Sequential Multiple Regression Analysis Summary for Variables Predicting Subscale 
Ownership Score (N = 153) 
Predictor R2 ΔR2 B SEB β t 
Step 1       
Living with a 
partner 
  .13 .15 .06 .86 
single/divorced   -.33 .10 -.25** -.33 
Age   .02 .00 .36*** 4.99 
Sqrt-SCQ   -.14 .05 -.22** -3.08 
 .29 .29**     
Step 2       
Living with a 
partner 
  .08 .14 .04 .56 
single/divorced   -.32 .09 -.24** -3.37 
Age   .02 .00 .29*** 4.04 
Sqrt-SCQ   -.08 .05 -.12 -1.72 
SEMCD   .07 .03 .20* 2.42 
PAM-13   .01 .00 .15 1.88 
 .37 .08***     
*p < .05. **p < .01. ***p < .001. 
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Skin cancer prevention. Table 35 presents the descriptive statistics and bivariate 
correlations for variables to be tested in the regression model. 
Table 35 
Descriptive Statistics and Intercorrelations for KT-SM Subscale Skin Cancer Prevention 
and Predictor Variables 
Variable M SD Skin cancer I 
Skin cancer 4.04 .80 - 
Age 46.63 12.19 .23** 
Sqrt- Year dialysis 1.04 1.01 -.19** 
SEMCD 7.44 1.80 .48*** 
PAM-13 77.88 15.71 .37*** 
*p < .05. **p < .01. ***p < .001. 
As shown in Table 36, in Step 1, age and square root-transformed years of pre-transplant 
dialysis were entered in the first block, explaining 9% of the variance in skin cancer. 
After entering SEMCD and PAM-13 in the second block, 29% of the total variance was 
explained by the model as a whole, F(4, 148) = 14.96, p < .001. PAM-13 and SEMCD 
explained an additional 20% of the variance in skin cancer, after controlling for age and 
square root-transformed years of pre-transplant dialysis, ΔR2 = .20, F change (2, 148) = 
20.48, p < .001. In the final model, years of pre-transplant dialysis, PAM-13, and 
SEMCD were statistically significant, with SEMCD (β = .34, p < .001) recording a 
higher beta value than PAM-13 (β = .18, p < .05) and years of pre-transplant dialysis  
(β = -.17, p < .05). Years of pre-transplant dialysis has a negative value, indicating a 
negative relationship with the domain skin cancer; this finding was consistent with the 
result of the bivariate intercorrelations of skin cancer prevention and years of  
pre-transplant dialysis presented in Table 35. 
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Table 36 
Sequential Multiple Regression Analysis Summary for Variables Predicting Subscale 
Skin Cancer Prevention Score (N = 153) 
Predictor R2 ΔR2 B SEB β t 
Step 1       
Age   .02 .01 .23** 2.98 
Sqrt-Year 
dialysis 
  -.16 .06 -.20* -2.54 
 .09** .09**     
Step 2       
Age   .01 .01 .12 1.73 
Sqrt-Year 
dialysis 
  -.14 .06 -.17* -2.45 
SEMCD   .15 .04 .34*** 4.05 
PAM-13   .01 .00 .18* 2.13 
 .29*** .20***     
Note. ΔR2 = R2 change. 
*p < .05. **p < .01. ***p < .001 
In summary, intercorrelations for the five domains ranged from r = .19 to .55, p < 
.05. Pearson correlation coefficients for the KT-SM overall score and five domains were 
moderate to strong, r = .51 to .76, p < .01. The six regression models composed of 
socioeconomic variables, clinical factors, PAM-13, and SEMCD explained significant 
amounts of variation (see Table 37) in the overall KT-SM (45%) and the domains 
medication adherence (32%), CV risk reduction (18%), protecting kidney (21%), 
ownership (37%), and skin cancer prevention (29%). Based on further examination of the 
final models, the PAM-13 was not statistically significant in predicting scores for the 
domains CV risk reduction and ownership, and SEMCD was not a significant predictor of 
protecting kidney behavior. Therefore, H5 was partially met.  
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Table 37 
Six Equation Models for Predicting Scores on Overall KT-SM and 5 Domains 
Outcome Predictor % of variance 
explained 
KT-SM total β0 (constant) + β1 (age) + β2 (years post transplant) + 
β3 (PAM-13) + β4 (SEMCD) 
45% 
M. adherence β0 + β1 (age) + β2 (years post transplant) + β 3 (PAM-
13)  
32% 
CV risk  β0 + β1 (age) + β2 (years post transplant) + β3 (years 
of pre-transplant dialysis) + β4 (SEMCD)  
23% 
Protecting 
kidney 
β0 + β1 (years post transplant) + β2 (PAM-13) 21% 
Ownership β0 + β1 (single/divorced) + β2 (age) + β3 (SEMCD) 37% 
Skin cancer β0 + β1 (years of pre-transplant dialysis) + β2 (PAM-
13) + β 3 (SEMCD) 
29% 
 
H5: Controlling for demographic and clinical variables, a significant amount of 
variance in HRQoL will be explained by self-efficacy, patient activation, and KT-SM 
behavior. 
H5 was partially supported. The six regression models composed of 
characteristics, clinical factors, and SEMCD explained significant amounts of variation in 
the overall KTQ-25 (47%) and the subscales physical symptoms (42%), fatigue (43%), 
uncertainty/fear (19%), appearance (26%), and emotion (33%). The PAM-13 and KT-SM 
scores were not statistically significant in predicting scores for the overall KTQ-25 and 
four of the five subscales, except KT-SM domain CV risk reduction. 
Prior to conducting sequential multiple regression, categorical and continuous 
variables were screened using MANOVA F statistics and Pearson’s product-moment 
correlation, respectively. Categorical variables that had insignificant F test values and 
continuous variables that were not statistically significantly correlated to criterion 
variables were excluded from the regression equation.  
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Table 38 presents results of the one-way MANOVA. Using Pillai’s trace (Λ) 
criterion, there were significant differences in the combined dependent variables of the 
KTQ-25 overall and the five subscales for gender, F(5, 146) = 3.33, p = .007; Λ = .10; 
education, F(15, 441) = 2.66, p < .001; Λ = .10; and employment status, F(10, 294) = 
2.18, p < .05; Λ = .14. Given the statistically significant results of the multivariate tests, 
univariate tests of between-subject effects were conducted on gender, education, and 
employment differences separately.  
Table 38 
Multivariate and Univariate Analysis of Variance for KTQ-25 and 5 Subscales 
 Multi-
variate F 
Univariate F 
  KTQ 
Overall 
Physi-
cal 
Fatigue Uncer-
tainty 
Appear-
ance 
Emotion 
Gendera 3.33** 4.82** 4.82 10.5** 3.70 11.31** 2.65 
Maritalb 1.43 .64 .35 1.64 2.99 .14 .80 
Racec 1.60 1.32 1.42 .17 4.00 1.19 2.28 
Ethnicityd .58 .55 .03 .23 2.14 .05 1.18 
Educatione 2.66** 3.16 6.12** 1.62 2.91 .34 2.66 
Employ-
mentf 
2.18* 4.85 4.91 2.67 4.13 1.27 3.69 
Tx typeh .28 .21 .12 .32 .29 .50 .04 
Note. Multivariate F values were obtained from Pillai’s statistics.  
adf (5, 146). bdf (10, 294). cdf (5, 147). ddf (5, 145). edf (15, 441). fdf (10, 294).  
gdf (5, 146). hdf (10, 294).  
* p < .05. ** p < .01.*** p < .001. 
Using a Bonferroni corrected alpha value of .008, univariate F tests results were 
further examined on gender, education, and employment status. The results presented in 
Table 39 show that there were significant gender differences on the overall KTQ-25,  
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F = (1, 150) = 9.39, p = .003; fatigue F = (1, 150) = 10.5, p = .001; and appearance, F = 
(1, 150) = 11.31, p = .001. 
Table 39 
Mean- Post Hoc Tests 
Groups KTQ-
25 
Total 
Physical 
Symptoms 
Fatigue Uncertainty Appearance Emotion 
Gender M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) 
Female 4.73 
(1.15) 
- 4.29 
(1.55) 
- 5.52 (1.20) - 
Male 5.29 
(.95) 
- 5.12 
(1.43) 
- 6.14 (.89) - 
Education       
High school 
and under 
 4.26 
 (1.89)*** 
    
Some 
college 
 4.34 
(1.59)*** 
    
College & 
graduate 
 4.90  
(1.37) 
    
Post 
graduate 
 5.64 
(1.53)*** 
    
Note. Independent variables had no significant effects on KTQ and five subscales are left 
blanks. 
*p < .05. **p < .01. ***p < .001 
Females reported lower scores than men on the overall KTQ-25 and the subscales fatigue 
and appearance (see Table 40); a higher score indicates perceived less or no distress and a 
better quality of life. Univariate F test results indicated that education level had an effect 
on the KTQ-25 subscale physical symptoms, F = (3, 149) = 6.12, p = .001. Employment 
status had effects on overall KTQ-25, F = (3, 149) = 5.21, p = .002; physical symptoms, 
F = (3, 149) = 5.56, p = .001; and uncertainty/fear, F = (3, 149) = 4.92, p = .003. Post-hoc 
multiple comparisons using Tamhane’s T2 test revealed that mean scores for the 
employed group were statistically significantly higher than for the unemployed group on 
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overall KTQ-25 (M = 5.24, SD = .96), the physical symptoms subscale (M = 5.32, SD = 
1.44), and the uncertainty subscale (M = 5.0, SD = 1.32).  
Based on the MANOVA test results, the categorical variables gender and 
education that had statistically significant F test results were entered into the first block 
of the sequential regression model.  
Intercorrelations. Table 40 presents the intercorrelations for overall and each 
dimension of the KTQ-25 with four clinical variables, SEMCD, and PAM-13. Age was 
significantly positively related to overall KTQ-25 and three of the five subscales (except 
physical symptoms and fatigue), with Pearson’s r ranging between .23–.28; p < .01. 
Years post-transplant was not statistically significantly correlated with overall KTQ-25 or 
its five subscales. Years of dialysis was only significantly inversely associated with 
emotion (r = -.16, p < .05). Comorbidity scores (square root-transformed SCQ) were 
negatively related to scores on the overall KTQ-25 and five subscales (r = -.17 to  -.40,  
p < .05). SEMCD was positively correlated with overall KTQ and five subscales  
(r = .35 to .61), while PAM-13 was only positively related to KTQ overall and the 
subscales physical symptoms and emotion (r = .20 to .24). 
Table 40 
Intercorrelations for Overall and Dimensions of KTQ-25 and Six Predictor Variables 
KTQ-25 and 
subscales 
Age Sqrt years 
post 
transplant 
Sqrt 
year of 
dialysis 
Sqrt 
SCQ  
SEMCD PAM-
13 
KTQ-25 overall .24** .04 -.15 -.40** .61** .22** 
Physical symptom .12 .11 -.15 -.36** .52** .20* 
Fatigue .15 -.07 -.09 -.44** .54** .16 
Uncertainty/fear .23** .05 -.15 -.17* .40** .13 
Table continues 
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Appearance .24** .04 .04 -.28** .35** .24** 
Emotion .28** .01 -.16* -.25** .50** .16 
Note. N = 153. Sqrt = Square root. 
*p < .05. **p < .01. ***p < .001. 
Intercorrelations for overall and each dimension of the KT-SM and KTQ-25 are 
displayed in Table 41. KT-SM total was positively correlated with KTQ total and four of 
the five subscales (r = .23 to 32, p < .01), except subscale uncertainty/fear. Medication 
adherence was positively related to KTQ total and the subscales physical symptoms and 
appearance with Pearson’s r ranging between .16 and .24. CV risk reduction was 
positively related to all subscales except uncertainty/fear, and r ranged from .25 to .34. 
Protecting kidney was not statistically significantly related to overall KTQ-25 and its 
subscales. Ownership was correlated with overall KTQ-25 and five subscales, with 
Pearson’s r ranging from .17 to .31. Skin cancer was positively related to KTQ-25 total, 
physical symptoms, fatigue, and emotion subscales (r = .21 to 33).  
Table 41 
Intercorrelations for Overall and Dimensions of KTQ-25 and KT-SM Scale 
KTQ-25 and 
subscales 
KT-
SM 
Total 
Medication 
adherence 
CV risk 
reduction 
Protecting 
kidney  
Ownership Skin 
cancer 
KTQ-25 total .32** .20* .30** .07 .31** .27** 
Physical 
symptom 
.30** .16* .25** .07 .29** .33** 
Fatigue .27** .16 .26** .07 .29* .21* 
Uncertainty/fear .10 .07 .11 -.09 .17* .16 
Appearance .23** .24** .20* .07 .23* .11 
Emotion .32** .16 34** .16 .20* .23* 
*p < .05. **p < .01. ***p < .001. 
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In summary, the variables entered in the six sequential multiple regression models 
for testing H6 are summarized and displayed in Table 42. 
Table 42 
Variables to be Entered in the Sequential Multiple Regression Equations Displayed per 
Outcome KTQ-25 and Five Subscales  
Outcome 1st Block 2nd Block 3rd Block 
KTQ total Gender, F = 4.82, α = .003 
Age, r = .40** 
SCQ, r = -.15* 
SEMCD, r = 
.60**  
PAM-13, r = 
.22** 
KT-SM Total, r = .32** 
KTQ-1 
physical 
Education, F = 3.16, α = 
.001 
SCQ, r = .15* 
Year dialysis, r = .20* 
SEMCD, r = 
.52** 
PAM-13, r = 
.20* 
Meds adherence, r = 
.16* 
CV risk, r = .25** 
Ownership, r = .29** 
Skin cancer, r = .33** 
KTQ-2 
Fatigue 
Gender, F = 10.5, α = .001 
SCQ, r = -.44** 
SEMCD, r = 
.54** 
CV risk, r = .26** 
Ownership, r = .29** 
Skin cancer, r = .21* 
KTQ-3 
Uncertainty 
Age, r = .23** 
SCQ, r = -.17* 
SEMCD, r = 
.40** 
Ownership, r = .17* 
KTQ-4 
Appearance 
Gender, F = 11.31, α = .001 
Age, r = .24** 
SCQ, r = -.28** 
SEMCD, r = 
.35** 
PAM-13, r = 
.24** 
Meds adherence, r = 
.24** 
CV risk, r = .20* 
Ownership, r = .23** 
KTQ-5 
Emotion 
Age, r = .28** 
Year of dialysis, r = -.16* 
SCQ, r = -.25** 
SEMCD, r = 
.50** 
CV risk, r = -.34** 
Ownership, r = -.20** 
Skin cancer, r = -.23** 
*p < .05. **p < .01. ***p < .001. 
Overall KTQ-25 scale as outcome. Age, gender, and square root-transformed 
SCQ were introduced in the first block to control for the effects. As presented in Table 
43, introducing these three variables explained 26% of the variance in the KTQ-25 total 
score, R2 = .26, F(3, 147) = 17.02, p < .001. PAM-13 and SEMCD scores were then 
entered in the second block; adding these explained an additional 21% of the variance in 
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the KTQ-25 total score, R2 change (ΔR2) = .21, F(5, 145) = 25.92, sig. F change = .000. 
KT-SM total was added in the last block, and 47% of the variability in the KTQ-25 total 
score was explained by the model as a whole, R2 = .47, F(6, 144) = 21.65, p = .000. 
However, adding the total KT-SM scale in Model 3 had no explanatory power in the 
proportion of the variance explained in the overall KTQ-25 scale (R2 change = .00, sig. F 
change = .48), after controlling for age, gender, SCQ, PAM-13, and SEMCD.  
Table 43 
Sequential Multiple Regression Analysis Summary for Variables Predicting Overall KTQ 
Predictor R2 ΔR2 B SE β t 
Step 1       
Gender   .48 .17 .21 2.89** 
Age   .02 .01 .23 3.27** 
Sqrt-SCQ   -.44 .08 -.39 -5.42** 
 .26** .26**     
Step 2       
Gender    .46 .14 .20 3.26** 
Age   .01 .01 .11 1.80 
Sqrt-SCQ   -.24 .07 -.21 -3.24** 
PAM-13   -.01 .01 -.09 -1.18 
SEMCD   .34 .05 .55 7.12** 
 .47** .21**     
Step 3       
Gender   .46 .14 .20 3.27** 
Age   .01 .01 .10 1.53 
Sqrt-SCQ   -.24 .07 -.21 -3.28** 
PAM-13   -.01 .01 -.11 -1.39 
SEMCD   .33 .05 .54 6.67** 
KT-SM Total   .01 .01 .06 .80 
 .47 .00     
* p < .05. **p < .01. ***p < .001. 
When the six independent variables were included in the final model, only 
SEMCD (β = .54, p < .001), square root-transformed SCQ (β = -.21, p < .001), and 
gender (β = .20, p < .001) made significant contributions in predicting overall KTQ-25 
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score. The SEMCD is the most important predictor, explaining 24.5% of the variation in 
the KTQ-25 total score. Square root-transformed SCQ had negative beta values, 
indicating an inverse relationship between scores on comorbid conditions and post KT 
quality of life (r = -.40, p < .000).  
KTQ-25 subscale physical symptoms. Education was dummy coded into four 
levels and entered in the first step with the variables square root-transformed years of 
dialysis and square root-transformed SCQ (Table 44); these explained 22% of the 
variance in the physical symptoms subscale, F change (5, 146) = 8.27, p < .001. 
Introducing PAM-13 and SEMCD in step 2 resulted in an additional 15% of the variance 
explained in the physical symptoms subscale, F change (7, 144) = 13.20, p < .001. In the 
last step, four of five domains of the KT-SM scale (medication adherence, CV risk 
reduction, ownership, and skin cancer prevention) were added in the equation to 
determine their ability to predict KTQ-25 subscale physical symptoms, and nearly 42% 
of the variability in the KTQ physical symptoms subscale was explained by the model as 
a whole, F(11, 140) = 9.03, p< .001. Nevertheless, the inclusion of these four KT-SM 
domains resulted in no improvement in R2 change, ΔR2 = .02, sig. F change = .28. 
In examining the regression coefficients for each predictor variable in the final 
model, beta weights for college/graduate degree (p = .15), years of pre-transplant dialysis 
(p = .70), PAM-13 (p = .30), and the KT-SM domains medication adherence (p = .29), 
CV risk reduction (p = .76), ownership (p = .50), and skin cancer prevention (p = .22) 
were not statistically different from zero. The variables SEMCD (β = .37, p < .001), 
received some college education (β = -.34, p < .001), SCQ score (β = -.21, p < .05), and 
received high school education or less (β = -.19, p < .005) significantly contributed to 
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predicting KTQ-25 physical symptoms. Participants who perceived a higher level of  
self-efficacy reported fewer physical symptoms and experienced less distress from the 
physical symptoms; a higher score on the KTQ-25 physical symptoms subscale indicated 
no symptoms or distress at all. The SCQ score, received some college education, and 
received high school or less education were negatively related to physical symptoms.  
Table 44 
Sequential Multiple Regression Analysis Summary for Variables Predicting Subscale: 
Physical Symptoms 
Predictor R2 ΔR2 B SEB β t 
Step 1       
High school/under   -1.14 .40 -.24** -2.83 
Some college   -1.16 .32 -.33*** -3.59 
College graduate   -.65 .32 -.18* -2.04 
Sqrt-year dialysis   -.10 .12 -.06 -.85 
Sqrt-SCQ   -.54 .12 -.32*** -4.41 
 .22 .22**     
Step 2       
High school/under   -.90 .36 -.19* -2.49 
Some college   -1.08 .29 -.31** -3.75 
College graduate   -.43 .29 -.12 -1.50 
Sqrt-year dialysis   -.06 .11 -.04 -.53 
Sqrt-SCQ   -.30 .12 -.18* -2.59 
PAM-13   .00 .01 -.04 -.50 
SEMCD   .42 .08 .47** 5.59 
 .39 .17**     
Step 3       
High school/under   -.94 .36 -.20** -2.58 
Some college   -1.16 .29 -.33*** -4.02 
College graduate   -.41 .29 -.11 -1.41 
Sqrt-year dialysis   -.04 .11 -.03 -.38 
Sqrt-SCQ   -.32 .12 -.19** -2.75 
PAM-13   -.01 .01 -.12 -1.38 
SEMCD   .35 .08 .39*** 4.39 
Table continues 
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M. adherence   .18 .17 .08 1.06 
CV risk reduction   .04 .16 .02 .27 
Ownership   .19 .20 .07 .94 
Skin cancer   .23 .18 .11 1.27 
 .42 .02     
Note. N = 152. 
*p < .05. **p < .01. ***p < .001.  
KTQ-25 subscale fatigue. The variables gender and square root-transformed 
SCQ were entered in the first block and accounted for 25% of the variance in the subscale 
fatigue, F(2, 148) = 24.48, p < .001 (see Table 45). The SEMCD was then introduced in 
the second block, explaining an additional 17% of the variance in the subscale fatigue, 
after controlling for gender and square root-transformed SCQ, F(3, 147) = 35.55, p < 
.001. In the last step, the three KT-SM domains, CV risk reduction, ownership, and skin 
cancer prevention were added to the equation; 43% of the total variance was explained by 
the model as a whole, after controlling for the other variables previously entered, F(6, 
144) = 18.07, p < .001. Nevertheless, adding the three KT-SM variables resulted in no 
improvement in the R2 increment, ΔR2 = .01, sig. F change = .52. As shown in the final 
model presented in Table 45, SEMCD (β = .43, p < .001) was the most important 
contributor in predicting fatigue score, suggesting that KT recipients who perceived 
higher self-efficacy experienced less fatigue. Square root-transformed SCQ (β = -.27, p < 
.001) and gender (β = .21, p < .01) had significant negative coefficients, indicating that 
kidney recipients with more comorbidities or who were female were prone to experience 
more fatigue.  
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Table 45 
Sequential Multiple Regression Analysis Summary for Variables Predicting Subscale: 
Fatigue 
Predictor R2 ΔR2 B SEB β t 
Step 1       
Gender    .75 .23 .23** 3.23 
Sqrt-SCQ   -.67 .11 -.43** -5.95 
 .25 .25**     
Step 2       
Gender   .73 .20 .22*** 3.56 
Sqrt-SCQ   -.43 .11 -.27*** -4.08 
SEMCD   .38 .06 .44** 6.60 
 .42 .17**     
Step 3       
Gender   .69 .21 .21** 3.35 
Sqrt-SCQ   -.42 .11 -.27*** -3.91 
SEMCD   .37 .07 .43** 5.41 
CV risk reduction   .20 .15 .10 1.36 
Ownership   .12 .18 .05 .64 
Skin cancer   -.18 .16 -.09 -1.10 
 .43 .01     
Note. n = 151. 
*p < .05. **p < .01. ***p < .001.  
KTQ-25 subscale uncertainty/fear. As shown in Table 46, age and square  
root-transformed SCQ were entered in the first block and accounted for 8% of the 
variance in the KTQ subscale uncertainty/fear, F(2, 149) = 6.63, p < .01. Introducing the 
variable SEMCD in the second step explained an additional 10% of variance in the 
subscale uncertainty/fear, F(3, 148) = 11.06, p < .001 after other variables were 
controlled. The inclusion of ownership in the final model explained a total of 19% of 
variance by the model as a whole, F(4, 147) = 8.42, p < .001. Nonetheless, including 
ownership did not improve R2 change, ΔR2 = .00, sig. F change = .45. In the final model, 
only age and SEMCD were important predictors of uncertainty/fear, and the SEMCD  
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(β = .37, p < .001) had higher beta weight than age (β = .17, p < .05). Knowing the 
kidney recipient’s age and perception of self-efficacy in taking care of the new kidney 
only explained a small proportion of the variance in uncertainty/fear.  
Table 46 
Sequential Multiple Regression Analysis Summary for Variables Predicting Subscale: 
Uncertainty/Fear 
Predictor R2 ΔR2 B SE B β t 
Step 1       
Age   .03 .01 .23** 2.96 
Sqrt-SCQ   -.24 .11 -.18* -2.24 
 .08 .08**     
Step 2       
Age   .02 .01 .14 1.87 
Sqrt-SCQ   -.07 .11 -.05 -0.64 
SEMCD   .27 .06 .35*** 4.29 
 .18 .10**     
Step 3       
Age   .02 .01 .17* 2.01 
Sqrt-SCQ   -.08 .11 -.06 -.75 
SEMCD   .28 .06 .37*** 4.32 
Ownership   -.14 .19 -.07 -.76 
 .19 .00     
Note. n = 151. 
 *p < .05. **p < .01. ***p < .001.  
KTQ-25 subscale appearance. The first block was composed of gender, age, 
and square root-transformed SCQ; it accounted for 19% of the variance in appearance, 
F(3, 147) = 11.34, p < .001 (Table 47). SEMCD was then added in the second block, but 
it explained only an additional 6% of the variance in appearance, F(3, 147) = 11.34, p < 
.001, after controlling for gender, age, and square root-transformed SCQ. The KT-SM 
scale subdomains medication adherence, CV risk reduction, and ownership were put in 
the last block, and the total vaariance explained by the model as a whole was 26%,  
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F(8, 142) = 6.10, p < .001. However, the R2 change was not significantly improved by 
entering any of these three variables, ΔR2 = .00, sig. F change = .64. Looking at the final 
model in Table 47, only gender (β = .25, p < .001) and square root-transformed SCQ  
(β = -.19, p < .05) had statistically significant beta coefficients. The results suggest that 
subjects’ gender and comorbidity score were predictors for appearance. Male participants 
cared less about transplant-related appearance changes than females, while participants 
who reported higher scores on comorbidity (SCQ) also were dissatisfied with their 
appearance.  
Table 47 
Sequential Multiple Regression Analysis Summary for Variables Predicting Subscale: 
Appearance 
Predictor R2 ΔR2 B SE β t 
Step 1       
Gender   .56 .18 .24** 3.15 
Age   .02 .01 .23** 3.02 
Sqrt-SCQ   -.31 .09 -.26*** -3.55 
 .19 .19***     
Step 2       
Gender    .60 .17 .25** 3.44 
Age   .01 .01 .15* 2.03 
Sqrt-SCQ   -.20 .09 -.17* -2.24 
PAM-13   .01 .01 .14 1.57 
SEMCD   .10 .06 .16 1.76 
 .25 .06**     
Step 3       
Gender   .60 .18 .25** 3.42 
Age   .01 .01 .14 1.62 
Sqrt-SCQ   -.22 .09 -.19* -2.38 
Table continues 
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PAM-13   .01 .01 .10 1.04 
SEMCD   .10 .06 .15 1.54 
M. adherence   .16 .14 .10 1.14 
CV risk   .06 .11 .05 .57 
Ownership   -.06 .16 -.03 -.37 
 .26 .01     
Note. n = 152. 
*p < .05. **p < .01. ***p < .001.  
KTQ-25 subscale emotion. To determine the best equation model for predicting 
scores on the emotion subscale, three model compositions and results are presented in 
Table 48. Model 1 comprises variables of age, years of pre-transplant dialysis, and SCQ, 
explaining 16% of the variance in the emotion subscale, F(3, 147) = 9.71, p < .001. 
PAM-13 and SEMCD then were added in the model and accounted for 30% of the 
variance, F(5, 145) = 12.16, p < .001. Model 3 incorporated eight predictors including 
the KT-SM subdomains CV risk reduction, ownership, and skin cancer prevention and 
accounted for a total of 33% of the variance, F(8, 142) = 8.90, p < .001. Including the 
three KT-SM variables in the model slightly improved the R2 increment, ΔR2 = .04, sig. F 
change < .05. Examining the final model, SEMCD (β = .44, p < .001), age (β = -.21, p < 
.01), and CV risk reduction (β = .21, p < .05) had statistically significant beta 
coefficients; SEMCD had the heaviest beta weight, meaning it had more impact than the 
other two variables. Recipients who were younger or performed more CV risk reduction 
behaviors reported experiencing less emotional distress. 
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Table 48 
Sequential Multiple Regression Analysis Summary for Variables Predicting Subscale: 
Emotion 
Predictor R2 ΔR2 B SE β t 
Step 1       
Age   .03 .01 .28** 3.74 
Year of dialysis   -.18 .09 -.14 -1.91 
Sqrt-SCQ   -.33 .10 -.26** -3.44 
 .17 .17***     
Step 2       
Age   .02 .01 .19** 2.63** 
Year of dialysis   -.14 .09 -.11 -1.58 
Sqrt-SCQ   -.15 .10 -.11 -1.51 
PAM-13   -.01 .01 -.11 -1.29 
SEMCD   .32 .07 .46*** 4.91 
 .30 .13***     
Step 3       
Age   .02 .01 .21** 2.67 
Year of dialysis   -.12 .09 -.10 -1.41 
Sqrt-SCQ   -.17 .10 -.13 -1.72 
PAM-13   -.01 .01 -.09 -.98 
SEMCD   .31 .07 .44*** 4.62 
CV risk   .33 .13 .21* 2.55 
Ownership   -.18 .19 -.08 -.95 
Skin cancer   -.20 .15 -.12 -1.34 
 .33 .04*     
Note. N = 151 
*p < .05. **p < .01. ***p < .001. 
In summary, the six regression models composed of characteristics, clinical 
factors, and SEMCD explained significant amounts of variation in the overall KTQ-25 
(47%) and the subscales physical symptoms (42%), fatigue (43%), uncertainty/fear 
(19%), appearance (26%), and emotion (33%). The results are depicted in Table 49. 
However, the PAM-13 and KT-SM scale were not statistically significant in predicting 
scores for the overall KTQ-25 and four of the five subscales, except KT-SM domain CV 
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risk reduction. It is noteworthy that the subscale appearance was predicted by gender and 
SCQ (number of comorbidities) only; PAM-13, SEMCD, and KT-SM did not explain any 
variability in the subscale appearance. Although adding the KT-SM and PAM-13 in the 
regression did not reach statistical significance in explaining the variation in the overall 
KTQ-25 and four of the five subscales, as presented in Table 49, a significant amount of 
variance in the KTQ and five subscales were explained by six regression models. 
Therefore, the investigator concluded that H5 was partially met.  
Table 49 
Six Equation Models for Predicting Overall KTQ-25 and 5 Subscales 
Outcome Predictor % of variance 
explained 
Overall KTQ-25 β0 (constant) + β1 (Gender) + β2 (SCQ) + β3 
(SEMCD) 
47% 
Physical 
symptoms 
β0 + β1 (high school or less) + β2 (some college 
degree) + β 3 (SCQ) + β 4 (SEMCD) 
42% 
Fatigue  β0 + β1 (gender) + β2 (SCQ) + β 3 (SEMCD) 43% 
Uncertainty/fear  β0 + β1 (Age) + β2 (SEMCD) 19% 
Appearance  β0 + β1 (gender) + β2 (SCQ) 26% 
Emotion  β0 + β1 (Age) + β2 (SEMCD) + β 3 (CV risk 
reduction) 
33% 
H6. Criterion-related validity will be supported as the 16-item KT-SM total scale 
and five domain scales are statistically significantly correlated with the PAM-13, 
SEMCD, and KTQ-25 and 5 subscales. 
H6 about criterion-related validity was partially supported. Bivariate correlation 
coefficients of the KT-SM and the five domains with SEMCD and PAM were adequate, 
ranging from r =.22 to .53 (p < .01), and r = .31 to .52 (p < .01), respectively. KT-SM 
total was positively correlated with KTQ total and four of the five subscales (r = .23 to 
32, p < .01), except the subscale uncertainty/fear. KT-SM domain medication adherence 
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was positively related to KTQ total and the subscales physical symptoms and appearance 
(r = .16 to 24, p < .05). The KT-SM domain CV risk reduction was positively related to 
all subscales except uncertainty/fear, and r ranged from .25 to .34. Protecting kidney was 
not statistically significantly related to the overall KTQ-25 and its subscales. Ownership 
was positively correlated with overall KTQ-25 and the five subscales, with Pearson’s r 
ranging from .17 to .31, p < .05. Skin cancer was positively correlated with KTQ total 
and the physical symptoms, fatigue, and emotion subscales (r = .21 to 33, p < .05). Based 
on the results reported above, hypothesis 6 is determined to be partially supported. 
Summary. The six models comprised of subject characteristics, clinical variables, 
PAM-13, SEMCD, and the overall KT-SM scale and five domains explained 47%, 42%, 
43%, 19%, 26%, and 33% of the variance in the overall KTQ-25, physical symptoms, 
fatigue, uncertainty/fear, appearance, and emotion subscales, respectively (Table 50). 
Overall, only one KT-SM domain (CV risk reduction) significantly contributed to 
predicting the KTQ emotion subscale, β = .21, p < .05. PAM-13 was not statistically 
significant in predicting overall KTQ or any of the subscales in the six equation models. 
SEMCD was the strongest predictor for predicting overall KTQ-25 scale and four of the 
five subscales except the subscale appearance. For ease of further discussion in the next 
chapter, the six best-fitting models for predicting the overall KTQ-25 scale and five 
subscales are presented in Table 49. Summary tables for evaluating the psychometric 
properties of the KT-SM scale and five domains are displayed in Table 50 and Table 51.  
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Table 50 
Evaluation of Psychometric Properties of KT-SM Scale and 5 Domains 
Outcome Cronbach 
alphaa 
Inter-item 
correla-
tionb 
Item-
total 
correla-
tionc 
Factor 
analysisd 
Criterion 
validitye: 
PAM-13 
Criterion 
validitye: 
SEMCD 
KT-SM total X X X X X X 
M. 
adherence 
X X X X X X 
CV risk  X X X X X X 
Protecting 
kidney 
X X X X X X 
Ownership X X X X X X 
Skin cancer X X X X X X 
aCronbach’s alpha > .70. bIIC > 3.4. cItem-to-total correlation > 3.8. dloading size > .40.  
er =  .22 to  .53, p < .05. 
Table 51 
Evaluation of Psychometric Properties of KT-SM Scale and 5 Domains: Sequential 
Multiple Regression 
Testing variable Construct validity:  
Multiple regressiona 
Construct validity:  
Multiple regressionb 
KT-SM total X  
Meds adherence X  
CV risk reduction X X 
Protecting kidney X  
Ownership X  
Skin cancer X  
aTesting hypothesis 7 with PAM-13 and SEMCD; variances explained by the regression 
models were 45%, 32%, 18%, 21%, 37%, and 29%, respectively; p < .05. bTesting 
hypothesis 8, KTQ-25 as outcome; CV risk domain alone explained 5% of the variance in 
the KTQ-25 subscale emotion. 
Summary 
Chapter Four described the recruitment process and presented the results of the 
study beginning with a description of the data collection methods. Using SPSS, the 
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investigator examined the participant surveys for missing data and checked for outliers 
and data distribution. The aims, hypotheses, and research questions were discussed, and 
the factor analysis presented. Each section concluded with an analysis summary for 
variables predicting subscales. The concluding chapter, Chapter Five, discusses the study 
findings including the cost and effectiveness of Facebook recruitment for studies. It 
concludes with study limitations, implications for future research, and conclusions. 
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CHAPTER FIVE 
DISCUSSION 
This chapter begins with a summary of the study findings, followed by 
discussions of the cost and effectiveness of Facebook recruitment; issues related to the 
online survey; sample composition and clinical characteristics; Aim 1: content validity; 
Aim 2: internal consistency reliability; Aim 3: EFA results; and Aim 4: construct validity. 
The limitations of the study, implications for future research, and conclusions are 
presented as well. 
Summary 
The KT-SM scale, developed as part of this study to measure post-transplant SM 
behaviors in U.S. kidney recipients (N = 153 recruited from Facebook), demonstrates 
adequate internal consistency reliability as well as content and construct validity. The  
16-item KT-SM scale is a multi-dimensional scale that contains five domains: medication 
adherence, protecting kidney, CV risk reduction, ownership, and skin cancer prevention. 
The KT-SM scale uses a 5-point Likert-type scale format with responses ranging from 1 
(strongly disagree) to 5 (strongly agree). Items are summed to produce an overall SM 
score (16 items) as well as five subscale scores to represent the five domains.  
The ability to assess KT recipients’ SM behaviors is critically important for 
clinicians and researchers; thus, the development of a psychometrically sound instrument 
has widespread research and clinical implications. The best treatment option for people 
with end-stage kidney failure is KT, but life after KT is complex and patients may be 
unprepared or underprepared to manage post-transplant health conditions. The 10-year 
allograft survival rate has not significantly improved over the past several decades 
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(Wekerle et al., 2017); thus, there is a critical need to promote KT SM behaviors and 
assess the relationships between SM behaviors and long-term graft outcomes. It is 
expected that the psychometrically sound KT-SM instrument developed in this study will 
allow researchers to collect and evaluate data related to SM behaviors, which is 
particularly important for testing interventions that aim to improve post-transplant SM 
behaviors.  
The second purpose of the study was to evaluate construct validity via 
hypothesized relationships among sSM, self-efficacy, patient activation, and HRQoL. As 
hypothesized, greater self-efficacy and high patient activation level were positively 
correlated to post-KT SM behavior and quality of life. The multivariate regression 
analysis results indicated that SM behaviors may be predicted by knowing a KT 
recipient’s patient activation level and perceived self-efficacy. Higher levels of patient 
activation and self-efficacy result in better SM behaviors. Thus, interventions that are 
designed to improve patient activation and/or self-efficacy may result in improved SM 
behaviors. Given the study results using the adapted conceptual model as a guide, there 
may be multiple areas (SM, patient activation, and self-efficacy) to intervene in 
improving SM behaviors. Designing and evaluating an intervention that may have 
particular effects on a specific outcome may be difficult without fully understanding the 
phenomenon related to KT SM. The framework adapted for KT SM serves as a map that 
may guide the design and implementation of interventions and systematically evaluate 
intervention outcomes on KT SM behavior, patient activation, and self-efficacy (De Silva 
et al, 2014; Hurley et al., 2015; Van Belle, Marchal, Dubourg, & Kegels, 2010). 
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Effectiveness of Facebook Recruitment and Survey Incentive 
Participants were recruited mainly by means of paid Facebook ads (51%; Figure 
S-1; Appendix S), pay-to-promote study page (Appendix J) and recruiting posts (7.8%), 
and recruiting messages (Figure T-1; Appendix T) on three targeted KT Facebook 
support groups (34%). The pay-to-promote study page and pay-to-boost recruiting post 
function were not as effective in recruiting participants as standard Facebook ads in this 
study. The Kidney Transplant Facebook study page reached 1,933 people, generated 164 
likes, was shared by 21 Facebook users, and received 15 clicks on the study link during 
the 5-week data collection period, but only 12 respondents self-reported that they found 
our study via the Facebook study page.  
A total of 538 respondents who saw the Facebook ads visited the REDCap 
Kidney Transplant Study survey page (Appendix M), and 292 read the study information 
sheet and submitted a valid email address. Of these 292 respondents, 9% declined to 
participate in the study, leaving 265 respondents who agreed to be informed and screened 
for eligibility. A total of 153 usable and completed surveys were generated within a  
5-week recruitment period. Of these, the mean missing item rate of these surveys was less 
than 5%. The study results showed that Facebook recruitment using standard ads 
combined with a small guaranteed post-paid incentive did facilitate a shorter subject 
recruitment time and a lower missing item rate. The overall yield rate of 28% (n = 
153/538) is acceptable and consistent with recent reported online survey response rates of 
22.89–23.43% (Tustin, Crowcroft, & Gesink, 2017). Tustin et al. (2017) collected 1,096 
completed surveys in 4 weeks using CPM (cost per 1,000 impressions) with a lifetime 
budget of Canadian $1,500 (approximately U.S. $1,170); however, Tustin et al.’s target 
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sample was the general population and their campaign budget was 6.69 times higher than 
the present study’s budget. When the targeted participants come from the general 
population, Facebook ads using CPM seem to reach more potential participants 
effectively. However, when the research subjects come from a hard-to-reach or small 
population, pay-per-click (PPC) appears to be more cost effective for subject recruitment 
per the present study findings. 
Cost of Facebook Recruitment 
The total cost for Facebook standard ads and the Kidney Transplant Survey study 
page promotion was $206. Of that, $35 was paid for the Facebook study page promotion 
and post-boosting service. The average costs for acquiring each valid survey were $2.19 
through Facebook standard ads and $2.92 from the study page (see Table 52). As noted 
previously, the Facebook standard ad was pay-per-click; therefore, payment was made 
only when users clicked the ad. Page promotion and post-boost were impression-based. 
By Facebook’s definition, each time the study page or posts about the study page were 
displayed in Facebook users’ newsfeed counts as impressions. Reach is the number of 
people who saw the page or page post (Facebook Help Center, n.d.). Even though the 
study page reached 1,933 people, only 12 respondents were recruited from the study 
page. In addition, the Facebook study page required more time to create and maintain. 
When taking time and cost into consideration, the Facebook page and post promotion 
were not as cost- and time-efficient as the pay-per-click-based Facebook standard ads. 
Still, the study results supported findings from previous studies that Facebook is a viable, 
cost-efficient subject recruitment tool for hard-to-reach populations in health-related 
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research (Carter-Harris, Ellis, Warrick, & Rawl, 2016; Jones, Lacroix, & Porcher, 2017; 
Lohse & Wamboldt, 2013). 
Table 52 
Cost for 5 Weeks Facebook Standard Ads, Post Boosting, and Page Promotion 
Promotion type Number of 
surveys 
acquired 
Cost Cost per 
person 
Facebook standard ads 78 $171 $2.19 
Pay-to-promote Facebook study 
page + Pay-to-boost post  
12 $35 $2.92 
Issues Related to REDCap Online Survey 
Although Facebook recruitment of respondents was adequate, several issues arose 
that future studies should address. The reminder messages did not work as effectively as 
expected. This could be attributed to two reasons. First, the REDCap system requires two 
different 6-digit codes for two-step verification to resume a survey. Although a  
step-by-step procedure with screenshots was provided in the reminder emails, 
respondents could still have considered that it was a burden to resume the survey. 
Second, according to the monthly report sent from the Facebook business department, 
95% of this study’s respondents saw the Facebook ads while using mobile devices and 
only 5% saw the ads while using laptop or desktop computers. It was highly likely that 
the survey respondents were taking the survey on tablets or smartphones. Because the 
survey design included scrolling and visual display not optimized for mobile devices, 
survey fatigue may have resulted due to the smaller mobile device screen. 
Studies have shown that mobile device users have a higher survey dropout rate, 
more missing items, longer survey response times, and shorter answers to open-ended 
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questions, and they are more likely to be distracted by other things than computer users 
(Antoun, Couper, & Conrad, 2017; Lugtig & Toepoel, 2016; Wenz, 2017). The trend of 
using mobile devices to take internet surveys is growing, and modifications of survey 
tools for mobile devices are necessary (Antoun et al., 2017; Revilla, Toninelli, Ochoa, & 
Loewe, 2016; Wang et al., 2017). For future studies, online survey design should be 
optimized for mobile devices to account for different screen sizes, web browsers, and 
operating systems to attract and retain the highest number of participants (Leiner, 2013; 
Revilla et al., 2016). 
Threats to Validity: Misrepresentation, Response Time, and Response Pattern 
Offering a guaranteed post-paid incentive without precautions to prevent 
unqualified participants from taking the survey to obtain the incentive could be a threat to 
online survey data quality. For example, the PI noticed that a respondent took repeated 
surveys, submitting 25 surveys with 25 different Gmail addresses during a 1.5-hour 
period. Observing the survey start and end times showed that each survey submission was 
in sequence with a short break in between. The mean completion time of these surveys 
was between 1–3 minutes. These 25 surveys had a similar response pattern, and the 
provided emails had similar naming conventions. Those surveys were found to use a 
random pattern or picking middle response option on most of the scales and demonstrated 
logical inconsistency. These surveys also were identified as extreme outliers by statistical 
procedures and eliminated from the data set. If this potential participant had submitted 
surveys at different times (as opposed to a relatively short period of time) it is unlikely 
that he/she would have been identified as having submitted multiple surveys instead of 
just one.   
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Survey response time and response pattern are the major indicators for assessing 
internet data quality. REDCap is a powerful data-collecting platform that can export data 
directly into formats that are compatible with major statistical packages and, therefore, 
reduce data entry error. However, in this case, lack of internet protocol tracking and 
blocking functions made the data cleaning procedure take longer. The PI had foreseen 
these problems and made every effort to prevent misrepresentation. These precautions 
included putting screening questions in the survey to eliminate unqualified respondents, 
including screening questions with multiple choices, and limiting each respondent to one 
email address only. As internet-based survey methods are used increasingly in  
health-related research, the experience/knowledge gained from past traditional survey 
methods such as postal survey or phone survey may not be entirely applicable to this 
field. Experts suggest that putting screener questions or bogus items in the survey could 
help identify careless responses or respondents who are misrepresenting as eligible 
(Meade & Craig, 2012; Oxtoby, King, Sheridan, & Obst, 2016). A screener question asks 
for a specific answer format for a question; a respondent who fails to answer correctly 
could be considered a careless survey respondent. Similarly, a bogus item is a question 
with a clear answer, such as “are there 31 days in February?” Meade and Craig (2012) 
suggest incorporating a bogus item for every 50 items but not exceeding more than 3 
such items in a survey. Carter-Harris et al. (2016) utilized a simple but effective method 
to prevent misrepresentation: they used a traditional postal mail survey reward to the 
addresses provided. Further studies are needed to help researchers to identify and prevent 
misrepresentation, to set gold standards for survey response time, and to decide what 
types of response patterns can be considered meaningless data. 
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Sample Composition and Clinical Characteristics 
Most participants in this study were married, female, White, employed, and had 
received higher education. The study results are consistent with results reported in 
previous KT studies except for gender. The KT literature has shown that there are gender 
and racial disparities in access to KT. Specifically, men, Whites, and individuals with a 
college degree are more likely to get a KT (Epstein et al., 2005; Goldfarb‐Rumyantzev  
et al., 2012). Nearly 65% of participants in this study were female, which is consistent 
with recent studies using Facebook as recruiting tool that reported ranges of 56% to 
80.8% female (Kayrouz et al., 2016; Nelson, Hughes, Oakes, Pankow, & Kulasingam, 
2014; Thornton, Harris, Baker, Johnson, & Kay-Lambkin, 2016). This may be because 
females engage more often in activities on social network sites such as Facebook and are 
more willing to participate in online survey than males (Adam, Manca, & Bell, 2016; 
Shepherd, 2016). In addition, African Americans have been found to be less likely to 
participate in internet surveys than those of other races (Keusch, 2015). 
The average years post-transplant for the present sample was 6.94 years (SD = 
6.65), and nearly 73% of subjects had a history of pre-transplant dialysis, with an average 
of 2.89 years (SD = 3.2). About 54% (n = 84) of the present subjects received kidneys 
from living donors. Approximately 92% of respondents reported having at least one 
comorbidity, and the average number of comorbidities reported was 2.46 (SD = 1.86). 
The present study’s results are consistent with previous observations; 47%–91% of 
kidney recipients reported at least one comorbidity in previous studies (Hollisaaz et al., 
2007; Machnicki et al., 2011).  
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A total of 55% of participants in this study reported having back pain or arthritis 
pain. Masajtis‐Zagajewska and colleagues (2011) conducted a study on the prevalence 
and characteristics of pain in KT recipients and found that 64% of the KT recipients in 
their study (n = 73) reported pain, and 93% of KT participants reported pain intensity that 
was moderate to severe. The most common pain locations were calf (44%), abdomen 
(34%), head (30%), and back (29%). Among those who reported having pain, 41% of KT 
recipients did not take any pain relievers but just endured the pain. Failure to treat pain 
can negatively impact HRQoL, but little is known about the prevalence, characteristics, 
and intensity of pain in this population. How KT recipients manage their pain also 
remains understudied (Masajtis‐Zagajewska et al., 2011). A large-scale study of pain in 
this population is needed. 
Aims 
Aim 1 
The first aim was to evaluate content validity. The original 40-item scale was 
reviewed by four content experts for concept definition, item relevance, wording clarity, 
and item appropriateness. The CVI for the final 29 items was .93 after removing 11 items 
with CVI scores less than .75. Some items with CVI = .75 were modified for wording and 
kept because they were theoretically important and generated based on KT practice 
guidelines. The KT-SM is comprehensive but concise and does not place undue burden 
on participants.  
Aim 2 
The second aim of this study was to estimate the internal consistency reliability of 
a new instrument, the KT-SM scale, among adult KT recipients. The overall coefficient 
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alphas for the initial 29- and reduced 16-item KT-SM Scale were .89 and .84, 
respectively. The alpha coefficients for the 16-item scale were .83, .70, .72, .77, and .72 
for the subscales medication adherence, CV risk reduction, protecting the new kidney, 
ownership (partnership) in post-transplant care, and skin cancer prevention, respectively, 
demonstrating adequate internal consistency reliability. It is recommended to report  
item-to-total correlation, inter-item correlation, and internal coefficient reliability per 
subscale for a multidimensional scale (Netemeyer et al., 2003). The corrected  
item-to-total correlation coefficients were greater than .38 for all items in each subscale. 
The mean inter-item correlation coefficients for the five subscales were in the range of 
.38 to .63, which suggests strong correlation among items yet no multicollinearity present 
(Pallant, 2013). It is well known that Cronbach’s alpha value is affected by scale length, 
but the short version of the 16-item KT-SM scale still achieved a desirable alpha value of 
.84. The item analysis results support the reliability of the reduced 16-item KT-SM scale. 
However, there is a concern pertaining to reliability. 
The reliability concern is that a ceiling effect was noted in the present sample. A 
ceiling effect occurs if an item has more than 33% of responses reaching the highest 
possible score (Paxton, Fithian, Stone, & Silva, 2003). Some items present a higher 
ceiling effect but were retained in the scale for this study phase based on the following 
rationales. One measure administered in different settings and populations can result in 
variance in the psychometric proprieties. For example, Bot et al. (2004) reported ceiling 
effects for the United Kingdom Shoulder Disability Questionnaire when it was 
administered to people with shoulder pain from a community sample but saw no ceiling 
effects among patients who sought care in the primary care setting. Furthermore, 
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respondents recruited from the internet tend to select extreme response options such as 
strongly agree, resulting in a ceiling effect. Leach, Butterworth, Poyser, Battham, and 
Farrer (2017) investigated physical and mental health issues in postpartum women, using 
internet recruitment (n = 1,083) and face-to-face recruitment as part of a nationwide study 
(n = 579). The study result showed that participants recruited from the internet tend to 
provide an overestimate compared to the national sample. Subjects from the internet 
sample reported more physical and mental health problems than the national 
representative sample after adjusting for socio-economic factors. The present study is 
exploratory in nature and the sample was recruited from Facebook, so further testing with 
a larger sample size and recruiting from various settings is recommended (Bruce, Fries, 
Lingala, Hussain, & Krishnan, 2013; Hinkin, 1995).  
Aim 3 
The third aim of this study was to estimate the dimensionality of the KT-SM scale 
through EFA. As presented in Chapter Four, the EFA results demonstrated that the  
KT-SM scale consisted of five factors with loadings ranging between .39 and .89. 
However, the 16 items did not load exactly as hypothesized in the the five domains; only 
medication adherence and protecting kidney domains remained the same. The item “limit 
alcohol” was originally developed for the hypothesized subscale, CV risk reduction, as 
CV disease is a leading cause of death in the KT population (Mathur et al., 2017). Yet, 
the item “limit alcohol” was grouped in the subscale, protecting kidney, per EFA results. 
Excessive alcohol consumption leads to developing CV disease as well as decreases 
kidney function (Nakagawa & Hasebe, 2017; Shankar, Klein, & Klein, 2006). A failing 
transplanted kidney can result in returning to dialysis, and dialysis means losing freedom 
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because of the need for dialysis several times weekly (Gill & Lowes, 2014). Perhaps that 
was the reason why the survey participants prioritized preserving allograft function.  
The items “I keep every appointment with my transplant doctor” and “I keep my 
blood (lab) test appointments” formed a new domain. These two items initially were 
placed in the hypothesized subscale, protecting kidney. The two items are unique in that 
they are not correlated with any items in the scale. Based on the characteristics of these 
two items, the domain was “ownership (partnership) in post kidney transplant care” 
(Bodenheimer, Wagner, & Grumbach, 2002) There has been little research on KT 
recipients’ perception about ownership (partnership). For future study, a clear conceptual 
definition of ownership (partnership) in this population will be required. Moreover, two 
items may insufficient to capture the meaning of ownership from KT recipients’ 
perspective; therefore, items pertaining to the concept need to be added to the subscale 
for further testing. 
Aim 4 
The fourth aim of this study was to estimate the criterion validity and construct 
validity of the KT-SM scale. Criterion-related validity was evidenced by significant 
correlations of the KT-SM and domains with SEMCD (r =.22 to .53, p = .01), PAM (r = 
.31 to .52, p = .01), and the overall KTQ (r = .20 to .32, p = .01) except for one KT-SM 
domain: protecting kidney. Construct validity was supported by multivariate regression 
analysis results. The linear combination of age, patient activation, and self-efficacy 
explained 45% of the variance in KT-SM behaviors, while 47% of the variance in KTQ 
(measuring quality of life) was predicted by age, comorbidity, and self-efficacy. The 
detailed discussions are divided into two sections: criterion validity–bivariate correlations 
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among all study variables and construct validity–factors/variables that predict overall  
KT-SM and five domains and overall KTQ-25 and five subscales. 
Criterion validity of the 16-item KT-SM scale was evidenced by significant 
correlation with PAM-13 (r = 52, p < .001), SEMCD (r = .50, p < .001), and KTQ-25 
total scores (r = .32, p < .001). In addition, the intercorrelations of the domains 
medication adherence (r = .59, p < .001), CV risk reduction (r = .76, p < .001), protecting 
kidney (r = .75, p < .001), ownership (r = .51, p < .001), and skin cancer prevention (r = 
.76, p < .001) with the KT-SM total scale were statistically significant. These findings 
that SM behavior is positively associated with patient activation (PAM-13), self-efficacy, 
and HRQoL are consistent with those of studies conducted in heart failure, diabetes, 
multiple sclerosis, chronic kidney disease, and KT populations (Goodworth et al., 2016; 
Jacobson et al., 2017; Johnson et al., 2016; Tharavanij et al., 2008; Weng et al., 2013, 
Young et al., 2017; Zimbudzi, Lo, Ranasinha, Kerr, Polkinghorne et al., 2017). Because 
the KT-SM scale and KTQ-25 are multidimensional scales, the investigator further 
examined and highlight the findings from bivariate correlations of the KT-SM’s five 
domains with the KTQ-25 subscales specifically. 
Bivariate correlations of KT-SM five domains with KTQ-25 subscales. In all, 
the KT-SM and five domains were partially correlated with the KTQ-25 and its five 
subscales. In particular, “medication adherence” related positively to the KTQ-25 
subscales physical symptoms (r = .16, p < .05) and appearance (r = .24, p < .05). 
Previous studies have shown that perceiving fewer medication and cosmetic side effects 
is positively associated with long-term treatment adherence (Chisholm‐Burns, Pinsky  
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et al., 2012; Gonzalez et al., 2007). Moreover, KT recipients who experience poor life 
quality tend to be nonadherent to medications (Chisholm‐Burns, Erickson et al., 2012).   
KT-SM domain CV risk reduction was positively related to the KTQ-25 subscales 
physical symptoms, fatigue, appearance, and emotion, ranging from r = .20 to .34, p < 
.05. Items in domain CV risk reduction are related to exercising regularly, healthy diet, 
and lifestyle modification. Multiple studies have shown that exercising regularly is 
associated with better emotional well-being, less depressive syndrome, better sleep 
quality, improved muscle strength and physical function, and ultimately improved quality 
of life in KT recipients (Barroso et al., 2016; Bernstein & McNally, 2017; Chan et al, 
2016; Galanti et al., 2016; Latimer-Cheung et al., 2013; Takahashi et al., 2018). In 
addition, regular exercise can help maintain healthy weight and increase self-esteem and 
body esteem (Homan & Tylka, 2014; Klaassen et al., 2017). The present study results 
were not different from previous reports. 
KT-SM domain ownership correlated to all the KTQ-25 subscales, ranging 
between r = .17 and .31, p < .05. As mentioned previously, little is known about 
ownership/partnership of post-transplant SM in this population. Chisholm‐Burns, 
Erickson et al. (2012) conducted a study with 512 adult KT recipients to examine factors 
related to medication non-adherence, and the results suggested that lower life satisfaction, 
feeling a loss of control over one’s life, and being less satisfied with care received and 
care providers were associated with IS medication non-adherence. By contrast, KT 
recipients who had greater control over their lives, such as the ability to manage daily 
routines and keep medications refilled, were satisfied with their lives, care quality, and 
care providers, and therefore, adherent to treatments.  
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KT-SM domain skin cancer prevention was related positively to the KTQ-25 
subscales physical symptoms (r = .33, p < .01), fatigue (r = .21, p < .05), and emotion  
(r = .23, p < .01). The relationships among these variables seem illogical. However, the 
key words in the domain skin cancer prevention include outdoor activity, sun, and 
sunscreen, and all these link to exercise or physical activity. As noted previously, the 
benefits of exercise include increased emotional well-being, decreased physical fatigue, 
and improved physical functioning. In the present study results, the more kidney 
recipients practiced skin cancer precaution, the less likely they were to complain of 
physical symptoms, fatigue, and emotional distress.  
KT-SM domain protecting kidney was not correlated with any subscale of the 
KTQ-25. The purpose of practicing kidney-protecting behavior is to preserve allograft 
function, and allograft function is tied to post-transplant quality of life. Upon further 
examination of each item in the KTQ-25 and the domain protecting kidney, the KTQ-25 
is more likely to measure physical symptoms rather than to assess kidney recipients’ 
perceived quality of life, so future study should be conducted on the relationships 
between HRQoL and kidney-protecting behaviors using different scale measures such as 
the SF-12/SF-36. 
Bivariate correlations of PAM-13, SEMCD, and KTQ-25. The relationship 
between PAM-13 and SEMCD was statistically significant, r = .53, p < .001, which is 
consistent with the recent study by Young et al. (2017). Nevertheless, the bivariate 
correlational analysis for PAM-13 and KTQ-25 and its five subscales indicated that 
PAM-13 was only weakly related to the KTQ-25 total scale (r = .22, p < .01) and its 
subscales physical symptoms (r = .20, p < .05) and appearance (r = .24, p < .01). In 
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contrast, there were moderate to strong associations of SEMCD with the five KTQ 
subscales, ranging from r = .35 to r = .61, p < .01. The prior study results for the 
relationships of PAM-13 and HRQoL were mixed. Hibbard et al. (2007) and Magnezi  
et al. (2014) reported a positive relationship between quality of life and PAM-13. 
Conversely, Goodworth et al. (2016) found that patient activation was not statistically 
significantly related to HRQoL in the multiple sclerosis population.  
Overall, the correlation coefficients for KT-SM and its five domains, PAM-13, 
and SEMCD were statistically significant. However, while estimating correlation 
coefficients with outcome variable HRQoL (KTQ-25), the KT-SM scale and its five 
domains was partially correlated with KTQ-25 and its five subscales, and PAM-13 was 
weakly related to KTQ-25 total and two subscales.  
Construct Validity 
KT SM Behavior as Outcome 
KT-SM overall. The linear combination of age (β = .27; p < .001), years  
post-transplant (β = -.25; p < .001), SEMCD (β = .28; p < .001), and patient activation  
(β = .32; p < .001) explained 45% of the variance in the overall KT-SM scale scores. In 
other words, KT recipients’ SM behavior was predicted by knowing their age, patient 
activation level, and perceived self-efficacy level. In contrast, the longer the time  
post-transplant, the less recipients were performing self-managing behavior. Knowledge, 
skills, and social support are essential elements for individuals to engage in SM behavior 
(Ryan & Sawin, 2009). For future study, adding knowledge and social support in the 
regression may help to explain additional proportions of the variance in KT-SM behavior. 
To the best of the investigator’s knowledge, this is the first study to examine the 
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associations among patient activation, self-efficacy, and SM behaviors in kidney 
recipients. Still, further testing is needed with a large-scale sample and including 
measures of knowledge and social support will further understanding of relation between 
SM behaviors and quality of life. 
Variables that predict medication adherence score. The final equation model 
for predicting medication adherence containing age (β = .30; p < .001), years  
post-transplant (β = -.19; p = .009), years of pre-transplant dialysis (β = .15; p < .05), and 
PAM-13 (β = .29; p < .001) accounted for 32% of the variance in medication adherence, 
p < .001. These results were not different from those previously reported in the research 
on diabetes, oncology, and KT (Griva et al., 2012; Parchman, Zeber, & Palmer, 2010; 
Salgado et al., 2017).  
Variables that predict CV risk reduction score. Age, years post-KT, duration 
of pre-transplant dialysis, and self-efficacy were found to significantly predict CV risk 
reduction practice, accounting for 23% of the variance in CV risk reduction score. This 
result is consistent with the results of other studies that a higher level of perceived  
self-efficacy was associated with lifestyle modification including exercising regularly and 
eating a well-balanced diet (Alharbi et al., 2017; Greco et al., 2014; Steca et al., 2013; 
Zelber-Sagi et al., 2017). Mathur et al. (2017) investigated all causes of post-KT 
hospitalization (n = 103,118) from 2005 to 2011 and found that 26.5% of incidences were 
related to CV disease. Diabetes and high blood pressure are well-known risk factors for 
CV disease; in the present sample, 60.8% (n = 93) of the participants reported having 
high blood pressure, 25.7% had diabetes, and 11.8% had heart disease; this is not 
different from other recent findings (Ballesteros et al., 2017). CV risk increases over time 
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after transplant and is the leading cause of death in KT patients. However, the importance 
of post-KT CV risk factors is less addressed with KT recipients, and education to 
increase awareness of post-transplant CV disease and risk factors in the KT population is 
crucial (Ballesteros et al., 2017) 
Variables that predict protecting kidney score. The final regression model 
composed of years post-transplant (β = -.24, p < .01) and patient activation (β = .36, p < 
.001) explained 21% of the variance in the protecting kidney score. Years post-transplant 
is a well-known risk factor for non-adherence behaviors in this population (Dew, Dabbs, 
& DiMartini, 2017), and the findings of this study is consistent with previously reported 
findings. Recent study results suggest that higher PAM level is associated with better 
control of diabetes clinical indicators such as blood pressure, cholesterol, and triglyceride 
level (Sacks et al., 2017). Maintaining behavioral change is always challenging. KT 
recipients need specific knowledge and confidence in self-managing lifetime  
post-transplant care. Intervention to increase patient activation level may help strengthen 
and sustain KT recipients’ medication adherence and kidney-protecting behaviors. 
Variables that predict ownership. The regression model demonstrated that age 
(β = .29, p < .001), being single/divorced (β = -.24, p < .001), and SEMCD (β = .20, p < 
.001) made unique contributions in predicting the ownership score, accounting for 37.2% 
of the variance. The domain ownership incorporated two items: “keep doctor’s 
appointments” and “keep blood test appointments”; these two items have a meaning of 
but are not limited to “appointment adherence.” Appointment adherence is an 
independent risk factor for allograft loss, while allograft function is positively related to 
HRQoL (Taber et al., 2017). Appointment adherence can be detected by clinicians and is 
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considered a more reliable method to assess medication adherence (Taber Fleming et al., 
2017). The current study indicated that being single or divorced was a negative predictor 
for ownership of post-transplant care. KT recipients who are single or divorced are 
usually considered to lack social support, perceive more stress, experience lower quality 
of life, and tend to be more less adherent to treatment than those who are married/living 
with a partner (Frazier, Davis-Ali, & Dahl, 1995; Ladin, Daniels, Osani, & Bannuru, 
2018). In addition, older age and greater self-efficacy were positively associated with 
ownership. These findings are consistent with the previous literature (Kauric-Klein et al., 
2017; Náfrádi, Nakamoto, & Schulz, 2017). The current study results suggest that 
interventions targeted at promoting patient activation and self-efficacy may increase KT 
recipients’ perceived post-KT ownership. 
Variables that predict skin cancer prevention. Years of pre-transplant dialysis 
(β = -.17, p < .05), self-efficacy (β = .34, p < .001), and patient activation (β = .18, p < 
.05) make unique contributions to predict the score of skin cancer prevention and 
accounted for 29% of the variance. In the present study, participants who had been on 
pre-transplant dialysis longer performed fewer skin cancer precautions. Long-term 
dialysis is associated with deterioration of physical function because of fatigue, 
decreasing muscle mass, not being encouraged to exercise due to concerns about leak and 
hernia associated with the peritoneal dialysis catheter, and a gradually more sedentary 
lifestyle (Findlay & Mark, 2017; Johansen, 2007; Morishita, Tsubaki, & Shirai, 2017; 
Thangarasa, Imtiaz, Hiremath, & Zimmerman, 2017). Some KT recipients may 
mistakenly believe that because they stay indoors most of time there is no need to 
practice skin cancer prevention behavior. Nonetheless, KT recipients, patients with 
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ESRD, and dialysis recipients who have an immunosuppressed/immunocompromised 
status are at higher risk of immune-deficiency-related cancers (Stewart et al., 2009).  
Little is known about the associations between patient activation, self-efficacy, 
and preventive health behaviors. The present study results show that patient activation is 
related to skin cancer preventive behavior (r = .37, p < .0001) and is one of three 
independent contributors in predicting skin cancer prevention behavior. More studies are 
needed to confirm the relation. Findings of Heckman et al.’s study (2011) affirmed that 
skin cancer preventive behavior was predicted by greater perceived self-efficacy (β = .17, 
t = 2.55, p = .012). Other recent study findings showed that an intervention to increase 
skin cancer prevention knowledge (β = .24, p < .05) predicted the frequency of practicing 
cancer-preventive behaviors (DiMillo et al., 2017; Werk, Hill, & Graber, 2017). 
However, transplant recipients’ knowledge and awareness regarding transplant-related 
cancer risk and preventive behavior are still understudied (Patel et al., 2017). 
Interventions to increase cancer awareness and knowledge, motivate patients to perform 
monthly skin self-exams, and prolong the intervention effect in this population are 
crucial.  
Post-Transplant Quality of Life (KTQ-25) as Outcome 
The purpose of the present study is to psychometrically test the KT-SM scale. The 
sequential regression analysis results showed that self-efficacy is a strong predictor of 
scores on the KTQ-25 overall and its five subscales, but the KT-SM total score and four 
of the five domain scores and the PAM-13 did not reach statistical significance in 
predicting the KTQ-25 score. Therefore, this discussion is focused only on results 
pertaining to the KT-SM scale. 
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The KTQ emotion score was predicted by a linear combination of age (β = .21,  
p < .01), self-efficacy (β = .44, p < .001), and KT-SM domain CV risk reduction (β = .21, 
p < .05). The present results are no different from prior findings (Calia et al., 2017). 
Emotional distress has been found to impede diabetes patients from performing SM 
behavior (Schinckus, Dangoisse, Van den Broucke, & Mikolajczak, 2017). Similarly, in 
KT patients, emotional distress is associated with negative health behaviors including 
missing clinic and lab appointments and medication non-adherence (Griva, Neo, & 
Vathsala, 2018; Penkower et al., 2003); therefore, reducing emotional distress may result 
in better SM behaviors (including CV risk reduction practice) and consequently improve 
transplant outcomes. However, the ways KT recipients identify stressors and adapt to 
distress remain understudied. Early and routine screening for emotional distress such as 
depression may help to identify problems early and thereby provide the support KT 
recipients need to manage emotion (Griva et al., 2018; Ndemera & Bhengu, 2017;  
Veater & East, 2016).  
Theoretical and Research Implications 
The contributions of the study include the following highlights. First, the results 
of the analyses show that KT SM is a multidimensional construct; in particular, the EFA 
results showing five domains support the multidimensionality of the KT-SM scale. 
Moreover, the KT-SM scale provides researchers a means to capture specific post-KT 
SM behaviors so that more effective and individualized interventions can be designed and 
delivered to kidney recipients accordingly. This will ultimately improve long-term KT 
outcomes. Second, the present study is the first to investigate and identify the significant 
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relationships among the five domains of post-KT SM behaviors, patient activation,  
self-efficacy for managing chronic disease, and HRQoL. 
While there has been increasing attention paid to KT SM, there was very little 
framework/theory that could be used to describe SM and HRQoL in this population at the 
time of study preparation. Nevertheless, the framework used to guide the study was found 
to be useful in predicting/explaining phenomena in KT SM behavior and quality of life. 
In this framework, KT recipients’ perceived self-efficacy and patient activation level 
were hypothesized to be positively related to SM behaviors, and engaging in SM 
behaviors was hypothesized to ultimately result in improved HRQoL. The hypothetical 
links of the study variables were evidenced by the results of bivariate correlational 
analysis and multivariate regression analysis.  
Still, two important variables are not included in this conceptual model: 
knowledge and social support. Skills, knowledge, and social support are crucial 
components for individuals to engage in and sustain SM behavior (Ryan & Sawin, 2009). 
Inclusion of knowledge may help explain an additional proportion of variance in KT SM 
behavior, as previous study results indicated that KT recipients are underprepared for 
their post-transplant care by the current discharge program, especially in terms of 
knowledge regarding IS medication, CV risk reduction, skin cancer prevention, and 
protecting kidney behaviors (Ghadami, Memarian, Mohamadi, & Abdoli, 2012; Patel  
et al., 2017; Vasquez, Tanzi, Benedetti, & Pollak, 2003; Williams, Tong et al., 2012).  
Social support is an indicator of allograft outcomes and medication adherence; 
inadequate social support will make a person ineligible for a transplant. Some researchers 
simply use marital status as a measure of social support, but many factors have been 
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found to be negatively related to kidney recipients’ marital status following transplant, 
such as the complex treatment regimen, appearance changes due to medication side 
effects, sexual dysfunction, emotional distress due to fear of rejection, and the financial 
burden from the high cost of IS medications (Crawford, Low, Manias, & Williams, 2017; 
Evans et al., 2010; Pisanti, et al., 2017; van Ek et al., 2017). In the present study results, 
being single or divorced was a negative predictor of the domain ownership. A possible 
explanation for this is that ownership of post-KT care included keeping doctor’s and lab 
appointments and may require a spouse/relative/partner to help with transportation or 
household chores when the recipient is away from home. Researchers have suggested that 
social support is equally important in post-transplant evaluation as in pre-transplant 
assessment (Ladin et al., 2018). Incorporating knowledge and social support in the 
framework guiding future studies may help further the understanding of factors that may 
hinder or enhance KT recipients’ SM behavior and quality of life after transplant. 
Lastly, the EFA results revealed a new domain ownership, but this topic has not 
been thoroughly investigated in KT research. The investigator’s bivariate correlational 
analysis results indicated that ownership of post-KT care was positively significant 
related to KTQ-total (r =.31; p < .01 ) and the subscales physical symptoms (r =.29; p < 
.01), fatigue (r =.29; p < .01), uncertainty/fear (r =.17; p < .05), appearance (r =.23; p < 
.05), emotion (r =.20; p < .05); PAM-13 (r =.42; p < .001), and SEMCD (r =.36; p < 
.001). This means that KT recipients who perceive a higher level of ownership of  
post-KT care scored higher on overall HRQoL, reported fewer physical symptoms, 
experienced less fatigue, were more satisfied with their appearance, were not as 
emotionally distressed, adapted and engaged in post KT SM behavior, and perceived 
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greater self-efficacy. Moreover, ownership is impacted negatively by more comorbidities 
and by being divorced/single. Based on results from the present study, further testing and 
interventions targeting post KT care will warrant further investigation in KT SM and 
quality of life.  
Research and Clinical Implications 
The 16-item KT-SM scale has the following advantages for clinical practice. 
First, the statistical analysis results provided preliminary evidence of the reliability and 
validity of the 16-item KT-SM. Second, the KT-SM scale is concise but comprehensive, 
incorporating five domains necessary to detect post-KT SM behaviors. Third, the item 
wordings, meanings, and 5-point Likert-type response options are straightforward, easy 
to read and respond to, and can be completed by KT recipients within 3 minutes. Lastly, 
items in the scale were evidence-based and generated per recommendations of the 
KDIGO Clinical Practice Guideline for the Care of KT Recipients (Kasiske et al., 2010) 
and from the National Kidney Foundation, thus, there are no culture adaptation issues, 
which means the scale has potential to be used in countries outside the U.S.  
Risk factors associated with non-adherence behavior and being less likely to 
perform SM behaviors were identified in the present study, which may help clinicians to 
target individuals who are at high risk of non-adherence. Utilizing the KT-SM scale 
design, a post-KT care plan can be tailored according to each individual’s skill. 
Moreover, the current study results have shown that more years post-transplant is 
associated with medication non-adherence and less practice of kidney-protecting 
precautions and overall SM behavior. Interventions focused on prolonging the 
intervention effect and helping KT recipients maintain the recommended health behaviors 
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will be crucial. Future studies to identify a cutoff score to separate those with adequate 
verus inadequate SM behaviors may be helpful for targeted and tailored interventions.  
Limitations 
This study has some limitations that must be acknowledged. First, this is a  
cross-sectional study with a convenience sample of 153 subjects recruited from 
Facebook. The study was not intended to identify causality, so the investigator does not 
consider the cross-sectional design to be a study limitation. Still, as most of the 
participants were female, selection bias could be an issue. Another limitation is that 
nearly 45% of subjects were recruited from two Facebook KT support groups and one KT 
exercise group. People who perceived more social support and who exercise regularly 
have been found to have greater self-efficacy and higher confidence levels, and this may 
affect the interpretation of the results. Third, all data were self-reported, and the study 
results/estimations could be inflated. Fourth, concurrent validity cannot be supported as 
there is no other KT SM scale specifically developed for KT recipients in the U.S. 
Finally, the last hypothesis was only minimally supported. The variation in HRQoL was 
not explained by PAM-13 and four of the five domains of the KT-SM scale. However, 
this could be attributed to the outcome measure selected.  
Future Directions 
Given the exploratory nature of this study, two types of future research should be 
pursued: psychometric testing of the 16-item KT-SM scale and theory testing. Scale 
refinement may be required to include other domains. This study’s results suggest that 
pain is still an issue for KT recipients, so incorporating pain management in the KT-SM 
scale may give some indications of how to help improve KT recipients’ quality of life. 
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Moreover, the ownership of post-KT care is an important concept that has not been 
adequately addressed in KT research. A clear conceptual definition of ownership is 
needed so that items can be generated based on the definition and added into the domain 
for testing. To further test the psychometric properties of the KT-SM scale, confirmatory 
factor analysis and test-retest reliability analysis with a large sample recruited from 
clinical settings is required. In addition, a cut-off value for predicting adequate post-KT 
SM behaviors needs to be identified.  
The present study results show that 55% of the proportion of variance in KT SMt 
behaviors was not explained by the regression model: the linear combination of  
β0 (constant) + β1 (age) + β2 (years post-transplant) + β3 (PAM-13) + β4 (SEMCD). 
Adding measures of knowledge and social support for further testing may push 
understanding of post-KT SM even further. The causal relationships for the variables of 
the adapted KT framework need to be further identified using path analysis. In addition, 
the statistical analysis suggests that self-efficacy mediated the effects of patient activation 
and SM behavior on HRQoL. It is not clear if the mediating effect is caused by an 
unobserved confounding of variable or variables, so future testing using path analysis is 
strongly recommended.  
Conclusion 
The KT-SM is a newly developed instrument to evaluate SM behaviors in U.S. 
kidney recipients. The study results provide beginning evidence of reliability as well as 
content and construct validity. Instruments like this will provide a means to capture the 
SM behaviors of the KT population, which is critical for future work on interventions. In 
addition, the framework guiding this study was found to be useful in explaining 
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phenomena in KT SM. Designing and implementing interventions and evaluating 
outcomes using a theory-driven approach will ensure that the intervention is effective for 
kidney recipients 
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APPENDIX A 
PERMISSIONS TO USE 
 
Figure A-1. Permission to Use Zimmerman (and Young) Framework.
 
Figure A-2. Permission to Use the PAM. 
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Figure A-3. Permission to Use the KTQ-25 
 
 
Figure A-4. Permission to Use the SCQ. 
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APPENDIX B 
SURVEY 5: DEMOGRAPHIC 
1. What is your age? _____________ years old 
2. What is your gender? 
o Male 
o Female 
3. What is your current marital status? 
o Married 
o Living with a partner 
o Never married 
o Separated/divorced  
o Widowed 
4. What is your race/ethnicity? 
o African-American 
o Asian/Pacific Islander 
o Caucasian/White 
o Hispanic/Latin 
o Other, please specify:______________ 
5. What is the highest level of education you have completed? 
o Less than high school 
o High school, diploma, or GED 
o Some college 
o College graduate 
o Some graduate work 
o Graduate degree 
6. What is your current employment status? 
o Retired 
o Unemployed 
o Employed full-time 
o Employed part-time 
o Other. Please specify: ______________ 
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APPENDIX C 
SURVEY 6: MEDICAL HISTORY 
1. How long were you on dialysis before your kidney transplant surgery? 
Please specify: ______________ 
 
2. How many years has it been since you had your kidney transplant?  
Please specify: ______________ 
 
3. What type of kidney transplant did you have? 
o Living donor-Related 
o Living donor-Non-Related 
o Non-living donor 
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APPENDIX D 
SURVEY 7: THE SELF-ADMINISTERED COMORBIDITY QUESTIONNAIRE 
The following is a list of common medical problems. If you have been told by a medical doctor that you 
have any of these problems, please indicate it in the first column. If you do not have the problem, skip to 
the next problem. 
If you do have the problem, please indicate in the second column if you receive medications or some other 
type of treatment for it. 
In the third column, please indicate if the problem limits any of your activities. 
Finally, indicate any medical conditions you may have that are not listed under “other medical problems” at 
the bottom of this page. 
Problem Do you have the 
problem? 
Do you receive 
treatment for it? 
Does it limit your 
activities? 
 No (0) Yes (1) No (0) Yes (1) No (0) Yes (1) 
Heart disease such as heart 
attack or poor heart function 
      
High blood pressure       
Lung disease       
Diabetes       
Ulcer or stomach disease       
Liver disease       
Anemia or other blood 
disease 
      
Cancer       
Depression       
Osteoarthritis or 
degenerative arthritis 
      
Back pain       
Rheumatoid arthritis       
Other medical condition 1       
Other medical condition 2       
Other medical condition 3       
 
Your completed questionnaire has been received. Thank you! 
Please leave your email address below so that your Amazon eGift Card can be 
delivered through email. 
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APPENDIX E 
KIDNEY TRANSPLANT SELF-MANAGEMENT ITEM POOL: RESULTS OF 
COGNITIVE INTERVIEWING 
Table E-1 
Kidney Transplant SM Item Pool: Results of Cognitive Interviewing 
Items Feedback from think-aloud 
interview 
Decision 
Medication Management 
1. I take my antirejection pills as 
instructed by my transplant 
doctor. 
All participants agreed that the 
statement is easy to understand 
and answer. 
Item retained 
2. I call my transplant team when I 
have new side effects from my 
antirejection pills. 
M1 and M2: It would be more 
clear if it can be written more 
specifically, like side effects: 
rashes, dry throat, dizzy, 
headache, fever, etc. 
M2 and F2 said that they have 
never experienced any side 
effects. 
F1 suggested using “anything 
different,” “I am not used to,” or 
“my med makes me sick.”  
F2 suggested using “I don’t feel 
well after taking my pills” to 
replace “side effects.” 
According to “Prograf” 
(medication manufacturer), 
transplant patients should call 
if they have: fever, flu 
symptoms, sore throat, short of 
breathing, pain on urinating, 
blood in urine, etc.  
Two participants claimed that 
they have never experienced 
any side effects, so they don’t 
know what the side effects of 
the pills are. In addition, 
patients may not be able to 
remember all medication side 
effects; therefore, “anything 
different”, “I am not used to”, 
or “my med makes me sick” 
would be easy for most people 
to answer. 
3. I change the number of 
antirejection pills when my 
kidney is working well. 
All participants agreed that the 
statement is easy to understand 
and answer. But one participant 
rated this item as not important 
because no transplant patient 
should  
self-medicate without doctor’s 
approval. 
Item revised based on the 
following reasons: 
1. Response item for this item 
is opposite from that of 
other items, needs add extra 
SAS syntax for this item.  
2. Easy for participants to 
answer since other items are 
“positive wording.” 
Table continues 
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  3. “I do not change the 
number of antirejection 
pills even when my kidney 
is working well:” Two 
participants rated this 
revised item as better than 
the old version. 
4. I use a method, like a pillbox or 
reminder, to remind me to take 
my antirejection pills. 
5 participants use a pillbox or 
phone reminders to help them 
remember to take medications. 
M1 is a young man, and only 
underwent dialysis for 3 years. He 
has no comorbidities, so he 
simply takes immunosuppressive 
medication once in the morning, 
once at night. 
M3 said, “I use my memory.” 
Item retained 
5. I refill my prescriptions on time. 
(How do you define on time? 
How easy or difficult is it for 
you to remember to refill your 
meds?) 
M1 defined “on time” as refilling 
one week before running out of 
antirejection pills. And CVS calls. 
M2 said that the university 
hospital pharmacy delivers all 
medication to his door every 
single month. “I put meds at four 
locations: car, office, home, and 
backpack” and “reserve extra 
meds.” 
M3 & F3: “3 to 4 days before it 
ran out.” “Pharmacy calls.” 
F1: Pharmacy calls, but 
“sometimes I forgot.” 
F2: “reserve at least 2 weeks 
meds” and “easy to figure out 
from the pillbox” 
Item retained 
6. I never forget to take my 
antirejection pills. 
M1: “Never” but admitted taking 
pills at times that are slightly 
different from what the doctor 
prescribed. 
M2: Never 
M3: Forgot to take pills 
sometimes, about “3 times per 
year” 
Item retained 
Table continues 
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 F1: “Yes, I did forget” but “my 
husband helps me to 
remember.”  
F2: only forgot once many 
years ago 
 
7. I tell my transplant doctor about 
problems and concerns with my 
pills during every clinic visit. 
M3: sometimes negotiates with 
the transplant doctor to see if 
his antirejection pills dose can 
be decreased. “If the doctor 
disagreed, I will still take meds 
as prescribed.” 
M2 & F2 have never had any 
side effects from antirejection 
pills, but they agreed that they 
will tell their doctors if they 
have something uncommon.  
F3: “Absolutely” 
Item retained 
8. I avoid taking herbs and 
NSAIDS like ibuprofen and 
Motrin. 
All participants suggested that 
using the full name 
“nonsteroidal anti-
inflammatory drugs” would be 
better. And provide an example 
of an herb to help them answer 
this question. 
A double-barreled question, 
revising item 
9. I avoid eating and drinking 
grapefruit and grapefruit juice  
This new item was suggested 
by 4 participants 
Grapefruit increases the levels 
of immunosuppressant in the 
blood and can mislead 
transplant doctors’ decision on 
medication dosing.  
Diet Management 
1. I eat a low cholesterol diet. None of the participants could 
tell the difference between low 
cholesterol and low fat diets. 
Items 1 and 2 are confusing to 
them. 
Item 1 removed and use “I eat 
low-calorie foods” instead. 
Weight gain is a big issue after 
kidney transplant; studies have 
shown that weight gain can be 
prevented or manage with diet 
management, 
2. I eat a low fat diet.  Item 2 is kept and provided 
with examples 
3. I eat a low sodium(salt) diet. F1: No MSG 
F2: low sodium food is fresh 
food, no canned food, no frozen 
food 
F3: “I eat fresh food,” “I avoid 
canned food.” 
According to the National 
Kidney Foundation, most 
transplant recipients still need 
to limit salt intake, but it 
depends on their conditions and 
what their doctors told them.  
Table continues 
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  Immunosuppressive medication 
such as steroids may cause 
fluid retention and raise blood 
pressure, therefore the item is 
kept but revision is needed. 
4. I monitor how much sodium I 
eat. 
M1 monitors sodium intake 
amount because he used to be a 
dialysis patient. 
M2: never because “my kidney 
is working well” 
Item 3 and 4 are very similar, 
so item 4 removed 
5. I read food labels. F2: “If I am going to eat at a 
restaurant, I pick low salt with 
no extra sauce on it.” She pays 
attention to sodium content 
when she prepares food or eats 
at restaurant. 
M1: reads food label. 
F3: reads food labels only if it 
is canned food, but she avoids 
canned food most of time  
It is not required for kidney 
transplant recipients to read 
food labels unless they are told 
to. 
6. I avoid raw and undercooked 
food such as: meats, seafood, 
salad bar, and eggs, etc. 
M1: “medium well steak, I like 
pink inside” 
M2: “Avoid salad bar” 
All participants were able to 
provide correct examples of 
raw and undercooked food.  
Item retained 
 
Lifestyle Modification 
1. I exercise 3 times per week for 
20 minutes. 
M1 exercises 5 days per week.  
M2 exercises 25 minutes every 
day and agreed that adding “at 
least” would be better. 
F2 exercises once or twice a 
week. 
F3 exercises 3–5 times per 
week depending on how busy 
she is during the week: “I 
exercise because I don’t want 
to gain weight.” 
National Kidney Foundation 
suggests exercise 5 times per 
week for 30 minutes.  
Item revised.  
Table continues 
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2. I avoid alcoholic drinks. All participants refrained from 
alcohol except F2, who is an 
occasional drinker, less than 2 
oz every 2 weeks. She suggested 
the item could be revised as “I 
limit my alcoholic drinks.” 
I have discussed this with the 
transplant coordinator. From 
their standpoint, all transplant 
patients should refrain from 
alcohol consumption. 
Guidelines say “limit alcohol 
intake.” 
Graft Function Monitoring   
1. I check my feet or ankles for 
swelling every day. 
M1 & M2 check feet or ankle 
swelling every day. 
F1: “I don’t check it everyday, 
but I know if my shoes are tight 
 
2. I take my blood pressure every 
day. 
M3 & F2 don’t check items 2–4 
every day because they had their 
transplants done more than 10 
years ago, but they agreed that 
for new transplant patients these 
items should be checked daily. 
 
3. I take my temperature every day. M2, M3, F2, F3 never check 
temperature, or only check if 
they don’t feel well 
 
4. I check my weight every day. Only 2 participants check their 
weight everyday 
KT recipients are asked to 
call if they have gained 2-3 
pounds in one day or 5-7 lbs. 
within 3-5 days. Item revision 
is needed.  
5. I call my transplant doctor if my 
urine output changes. 
M2: “yes, I keep track of how 
much I lose”. He suggested that 
urine color change should be 
added into the item pool as well. 
F1: Defined urine output change 
as: “how much I am going to the 
bathroom.” 
F3: Did not really know how 
many times she urinates 
everyday 
“Urine output” is more like a 
medical term; meaning of 
changes can refer to decrease 
or increase. Item needs to be 
revised. 
Table continues 
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Infection Prophylaxis 
1. I keep track of symptoms of 
infections when I have them. 
(What, to you, are the symptoms 
of infection?) 
M1: fever 
M2: running temp 
M3: “skin infection”, “not 
feeling well” 
F1: “fever”, “UTI”, “pain on 
urinating.” Stated that she has 
been hospitalized for UTI in the 
past.  
F2: “hard to answer” 
“Keep track of symptoms of 
infections” was confusing 
patients, additional 
explanations were given for 
all participants  
2. I drink at least eight 8-ounce 
glasses of water (2 liters) every 
day. 
All participants agreed this item 
is clear and easy to answer. 
F3 drinks a lot of fluids 
including tea, coffee, and water 
but does not know how much 
water she takes every day. 
Item retained 
3. I avoid close contact with people 
who are sick. 
M2: Avoid handshake with sick 
people. Use sanitizer if needed.  
M3: Avoid coughing people. “I 
wear a mask if necessary.”  
F2: “stay away from coughing 
people”, “not shake their hands” 
Item retained 
4. I wash my hands after using the 
bathroom and before meals. 
M2 uses sanitizer as needed. 
F3 washes her hands with soap 
and water before preparing 
meals and after cooking. 
Standard hand washing is 
washing hands with soap and 
water 
5. I keep appointments with my 
transplant doctor. 
All participants agreed items 10 
& 11 are important. 
No change needed 
6. I keep my lab test appointments. 
(What were you thinking when I 
asked this item?) 
M2 also checks lab results at the 
hospital website or through 
hospital smartphone application. 
No change needed 
Table continues 
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 M3: “Blood tests” 
F2: “It helps the doctor to know 
what is going on” 
F3 stated that without lab data, 
there is not much the doctor can 
do during the appointment. 
“creatinine levels” 
 
Skin Cancer Prevention 
1. I use sunscreen when outdoors.  All participants agreed this is 
important 
 
2. I wear a hat to protect my skin 
when outdoors. 
All participants agreed this is 
important 
 
3. I wear protective clothing to 
protect my skin when outdoors. 
All participants agreed this is 
important 
 
4. I self-check my whole body skin 
every month. 
All participants agreed this is 
important 
 
5. I have my annual skin exam 
check by a dermatologist.  
None of them have done this. Retained because this is 
recommended by kidney 
transplant practice guidelines 
& National Kidney 
Foundation 
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APPENDIX F 
KT-SM RESULTS OF EXPERT REVIEW (Total CVI = 0.931) 
Table F-1 
KT-SM Results of Expert Review (Total CVI = 0.931) 
Proposed Items CVI 
Medication management (7 items)  
1. I take my antirejection pills as instructed by my transplant doctor.  1.00 
2. I call my transplant team if my antirejection pills make me sick. 1.00 
3. I do not change the number of antirejection pills, even when my kidney is working 
well. 
1.00 
4. I use a pill box or other reminder to remember to take my antirejection pills. 1.00 
5. I tell my transplant doctor about problems and concerns with my antirejection 
pills. 
1.00 
6. If any doctor other than my transplant doctor gives me a new medication, I will 
call my transplant doctor to make sure it is safe to take. 
1.00 
7. I avoid taking nonsteroidal anti-inflammatory drugs (NSAIDS) like ibuprofen, 
naproxen, or Motrin. 
1.00 
Diet Recommendation (5 items)  
8. I avoid eating sweets, fried foods and other high calorie foods most of the time. 0.75 
9. I eat low fat foods like chicken, poultry, lean meats, or low-fat dairy products most 
of the time. 
0.75 
10. I watch how much sodium (salt) I eat. 0.75 
11. I read food labels most of the time. 1.00 
Lifestyle Modification (2 items)  
12. I exercise for at least 30 minutes 5 times per week. 0.75 
13. I limit alcoholic drinks to no more than one drink per day.  1.00 
Graft Monitoring (6 items)  
14. I take my blood pressure as instructed by my doctor. 1.00 
15. I look at my feet and ankles to check for swelling as instructed by my doctor. 1.00 
16. I call my transplant team if I gain 2–3 pounds in one day. 0.75 
17. I call my transplant doctor if I urinate (pee) less than usual. 1.00 
18. I keep almost every appointment with my transplant doctor. 1.00 
19. I keep my blood (lab) test appointments. 1.00 
Infection prophylaxis (6 items)  
20. I call my transplant doctor when I have signs of an infection like fever, flu-like 
symptoms, pain on urinating or a cough. 
1.00 
21. I take my temperature as instructed by my doctor. 1.00 
22. I drink at least eight 8-ounce glasses of water (2 liters) every day. 1.00 
23. I avoid close contact with people who are sick. 1.00 
24. I wash my hands with soap and water after using the bathroom. 1.00 
25. I wash my hands with soap and water before meals. 1.00 
Table continues 
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Skin Cancer Prevention (6 items)  
26. I use sunscreen when outdoors.  1.00 
27. I wear a hat to protect my skin when I am outside. 0.75 
28. I examine (look at carefully) at my skin and lips at least once a month. 0.75 
29. I call my transplant doctor if there is a change or suspicious lesion on my lips or 
skin. 
0.75 
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APPENDIX G 
SURVEY 3: SELF-EFFICACY FOR MANAGING CHRONIC DISEASE 6-ITEM SCALE 
Table G-1 
Survey 3: Self-Efficacy for Managing Chronic Disease 6-Item Scale 
We would like to know how confident you are in doing certain activities. For each of the following questions, please choose the number that corresponds to your 
confidence that you can do the tasks regularly at the present time. 
 
1 
Not at all 
confident 
2 3 4 5 6 7 8 9 10 
Totally 
Confident 
1. How confident do you feel that you can keep the fatigue 
caused by your disease from interfering with the things 
you want to do? 
1 2 3 4 5 6 7 8 9 10 
2. How confident are you that you can keep the physical 
discomfort or pain of your disease from interfering with 
the things you want to do? 
1 2 3 4 5 6 7 8 9 10 
3. How confident are you that you can keep the emotional 
distress caused by your disease from interfering with the 
things you want to do? 
1 2 3 4 5 6 7 8 9 10 
4. How confident are you that you can keep any other 
symptoms or health problems you have from interfering 
with the things you want to do? 
1 2 3 4 5 6 7 8 9 10 
5. How confident are you that you can do the different 
tasks and activities needed to manage your health 
condition so as to reduce you need to see a doctor? 
1 2 3 4 5 6 7 8 9 10 
6. How confident are you that you can do things other than 
just taking medication to reduce how much your illness 
affects your everyday life? 
1 2 3 4 5 6 7 8 9 10 
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APPENDIX H 
25-ITEM KIDNEY TRANSPLANT QUESTIONNAIRE 
This questionnaire is designed to learn how you have been feeling during the last two weeks. You will be 
asked about how tired you have been feeling, how your mood has been, and what physical symptoms or 
problems you have experienced. 
Please mark up to 6 problems or symptoms from the list that follows that you have experienced frequently 
during the last two weeks. If you have experienced more than 6, please mark the 6 that were most 
troublesome. 
1) Loss of weight and muscle 
2) Decreased mental ability 
3) Itchy/dry skin 
4) Infections 
5) Hypotension 
6) Embarrassment caused by appearance or access site 
7) Aching, tired legs 
8) Coughing during day or night 
9) Very little strength 
10) Side-effects from medications 
11) Forgetfulness 
12) Confusion 
13) Aching bones 
14) Trouble getting to sleep 
15) Regulating bowel movements 
16) Constipation or diarrhea 
17) Vomiting 
18) Headaches 
19) Nausea or upset stomach 
20) Shivering 
21) Waking up during the night 
22) Loss of appetite 
23) Lightheadedness or dizziness during daily activities 
24) Shortness of breath in daily activities 
25) Decreased sexual ability 
26) Difficulty focusing attention 
27) Difficulty concentrating 
28) Need to rest frequently because of shortness of breath 
29) Increased appetite 
30) Excessive weight gain 
31) Acne 
32) Trouble getting a good night’s sleep 
33) Muscle pain 
Other: ____________________ 
1. Of the 6 items that you listed, please choose the problem that troubles you most and indicate how 
much trouble or distress you have had during the last two weeks by choosing one of the following 
options: 
1) A very great deal of trouble or distress 
2) A great deal of trouble or distress 
3) A good deal of trouble or distress 
4) A moderate amount of trouble or distress 
5) Some trouble or distress 
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6) Very little trouble or distress 
7) No trouble or distress 
2. Of the 6 items that you listed, please choose the problem that troubles you the second most and 
indicate how much trouble or distress you have had during the last two weeks by choosing one of the 
following options: 
1) A very great deal of trouble or distress 
2) A great deal of trouble or distress 
3) A good deal of trouble or distress 
4) A moderate amount of trouble or distress 
5) Some trouble or distress 
6) Very little trouble or distress 
7) No trouble or distress 
3. Of the 6 items that you listed, please choose the problem that troubles you the third most and indicate 
how much trouble or distress you have had during the last two weeks by choosing one of the following 
options: 
1) A very great deal of trouble or distress 
2) A great deal of trouble or distress 
3) A good deal of trouble or distress 
4) A moderate amount of trouble or distress 
5) Some trouble or distress 
6) Very little trouble or distress 
7) No trouble or distress 
4. Of the 6 items that you listed, please choose the problem that troubles you the fourth most and indicate 
how much trouble or distress you have had during the last two weeks by choosing one of the following 
options: 
1) A very great deal of trouble or distress 
2) A great deal of trouble or distress 
3) A good deal of trouble or distress 
4) A moderate amount of trouble or distress 
5) Some trouble or distress 
6) Very little trouble or distress 
7) No trouble or distress 
5. Of the 6 items that you listed, please choose the problem that troubles you the fifth most and indicate 
how much trouble or distress you have had during the last two weeks by choosing one of the following 
options: 
1) A very great deal of trouble or distress 
2) A great deal of trouble or distress 
3) A good deal of trouble or distress 
4) A moderate amount of trouble or distress 
5) Some trouble or distress 
6) Very little trouble or distress 
7) No trouble or distress 
6. Of the 6 items that you listed, please choose the problem that troubles you the sixth most and indicate 
how much trouble or distress you have had during the last two weeks by choosing one of the following 
options: 
1) A very great deal of trouble or distress 
2) A great deal of trouble or distress 
3) A good deal of trouble or distress 
4) A moderate amount of trouble or distress 
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5) Some trouble or distress 
6) Very little trouble or distress 
7) No trouble or distress 
7. In the last two weeks, how much trouble or distress have you had because of excessive appetite? 
1) A very great deal of trouble or distress 
2) A great deal of trouble or distress 
3) A good deal of trouble or distress 
4) A moderate amount of trouble or distress 
5) Some trouble or distress 
6) Very little trouble or distress 
7) No trouble or distress 
8. In the last two weeks, how much trouble or distress have you had because of excessive hair growth? 
1) A very great deal of trouble or distress 
2) A great deal of trouble or distress 
3) A good deal of trouble or distress 
4) A moderate amount of trouble or distress 
5) Some trouble or distress 
6) Very little trouble or distress 
7) No trouble or distress 
9. In the last two weeks, how much trouble or distress have you had because of excessive weight? 
1) A very great deal of trouble or distress 
2) A great deal of trouble or distress 
3) A good deal of trouble or distress 
4) A moderate amount of trouble or distress 
5) Some trouble or distress 
6) Very little trouble or distress 
7) No trouble or distress 
10. In the last two weeks, how much trouble or distress have you had because of acne? 
1) A very great deal of trouble or distress 
2) A great deal of trouble or distress 
3) A good deal of trouble or distress 
4) A moderate amount of trouble or distress 
5) Some trouble or distress 
6) Very little trouble or distress 
7) No trouble or distress 
11. During the past two weeks, how often have you felt weak?  
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
6) Hardly any of the time 
7) None of the time 
12. How often during the past two weeks have you felt sluggish? 
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
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6) Hardly any of the time 
7) None of the time 
13. During the past two weeks, how much trouble or difficulty have you had because of having very little 
strength? 
1) A very great deal of trouble or difficulty 
2) A great deal of trouble or difficulty 
3) A good deal of trouble or difficulty 
4) A moderate amount of trouble or difficulty 
5) Some trouble or difficulty 
6) Very little trouble or difficulty 
7) No trouble or difficulty at all 
14. During the past two weeks, how much trouble or difficulty have you had because of increased 
tiredness? 
1) A very great deal of trouble or difficulty 
2) A great deal of trouble or difficulty 
3) A good deal of trouble or difficulty 
4) A moderate amount of trouble or difficulty 
5) Some trouble or difficulty 
6) Very little trouble or difficulty 
7) No trouble or difficulty at all 
15. During the past two weeks, how often have you felt low in energy? 
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
6) Hardly any of the time 
7) None of the time 
16. How often during the past two weeks have you felt fear or panic related to rejection of the kidney? 
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
6) Hardly any of the time 
7) None of the time 
17. How often during the past two weeks have you felt uncertain about your future? 
8) All of the time 
9) Most of the time 
10) A good bit of the time 
11) Some of the time 
12) A little of the time 
13) Hardly any of the time 
14) None of the time 
18. How often during the past two weeks have you felt worried? 
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
 185 
6) Hardly any of the time 
7) None of the time 
19. How often during the past two weeks have you felt protective of your transplant? 
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
6) Hardly any of the time 
7) None of the time 
20. How often in the last two weeks have you felt depressed? 
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
6) Hardly any of the time 
7) None of the time 
21. How often during the past two weeks have you felt stubborn? 
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
6) Hardly any of the time 
7) None of the time 
22. How often in the last two weeks have you felt anxious? 
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
6) Hardly any of the time 
7) None of the time 
23. How often during the past two weeks have you felt impatient? 
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
6) Hardly any of the time 
7) None of the time 
24. How often in the last two weeks have you felt irritable or difficult to get along with? 
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
6) Hardly any of the time 
7) None of the time 
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25. How often in the last two weeks have you felt generally frustrated? 
1) All of the time 
2) Most of the time 
3) A good bit of the time 
4) Some of the time 
5) A little of the time 
6) Hardly any of the time 
7) None of the time 
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APPENDIX I 
REVIEW OF EXISTING POST-KT-SM SCALES 
Table I-1 
Review of Existing Post-KT-SM Scales 
Author(s)/Year/
Location 
Items Self-
management 
definition/frame
work 
Subscales Validity & reliability Limitations 
Weng et al., 
2010, Taiwan 
27 items measured 
with a 5-point 
Likert-type scale: 0 
(never) to 4 
(always) 
Yes 
 
Not reported 
1. Problem-solving (10 
items) 
2. Patient-provider 
partnership (4 items) 
3. Self-care behavior (13 
items) 
Cronbach’s α for problem-
solving, patient-provider 
partnership, and self-care 
behavior were 0.80, 0.70, and 
0.81 respectively. 
1. Construct validity statistic 
not reported 
Only 1 item to measure medication 
adherence 
1. No graft function monitoring 
2. No diet management 
3. No cancer precaution 
4. Most items written as double or triple-
barreled questions  
5. Translation quality 
Kosaka et al., 
2013, Japan 
24 items measured 
with a 4-point 
Likert-type scale: 1 
(not applied) to 4 
(strongly applied) 
Yes 
 
No framework 
used 
1. Self-monitoring (6 
items) 
2. Self-care behavior in 
daily living (7 items) 
3. Early detecting and 
coping with 
abnormalities after 
kidney transplantation 
(4 items) 
4. Stress management (3 
items) 
1. Cronbach’s α coefficients 
for 4 subscales were from 
0.61 (stress management) to 
0.87. 
2. The kappa coefficients for 
the additional 4 items were 
from 0.33 to 0.72. 
3. Construct validity was 
confirmed. 
 
1. No subscale for IS medication 
adherence, but the first three of four 
additional items are considered 
“medication adherence” items 
2. Most items were too general to 
answer; ex: “I eat well-balanced 
meals” and “I keep my house clean”  
3. No subscale for graft function 
monitoring 
4. No lifestyle modification items such 
as exercise  
Table continues 
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   5.  Four items related to 
clinical importance 
were added to the 
scale 
 5. No cancer precaution items 
6. Translation quality 
Schmid-
Mohler et al., 
2014, 
Switzerland 
44 items assessed 
with yes/no 
response option 
 
Self-management 
tasks in the first 2 
years following 
kidney transplant 
Yes/Yes 
 
Three sets of 
self-
management 
tasks described 
by Corbin and 
Strauss (1988) 
and Lorig 
(2003) 
1. Managing 
medication regimen 
2. New life roles  
3. Emotion 
management  
Mixed-method 
 
No reliability and validity data 
reported. 
1. Focused on emotion management tasks 
2. At very early sate of instrument 
development, no sample questions 
provided in their study.  
Ziegelmann  
et al., 2002, 
England 
24-item transplant 
effects 
questionnaire with 
a 5-point Likert 
scale ranging from 
1 (strongly 
disagree) to 5 
(strongly agree)  
No/No 1. Worry about 
transplant (6 items) 
2. Guilt regarding 
donor (5 items) 
3. Disclosure (3 items)   
4. Adherence (5 items) 
5. Responsibility (4 
items) 
1. Cronbach’s α ranging from 
.72 to .86. Test-retest 
reliability had favorable 
results except for 
“disclosure” (Cronbach’s α 
= .60). 
2. Construct validity supported 
by principal components 
analysis and confirmatory 
factor analysis results. 
4 of 5 subscales mainly focus on 
emotional responses and reactions to 
kidney transplant. Only the medication 
adherence subscale (5 items) is considered 
self-management related. 
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APPENDIX J 
FACEBOOK STUDY PAGE 
 
Figure J-1. Facebook Study Page. 
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APPENDIX K 
FACEBOOK RECRUITMENT PERMISSIONS 
 
 
Figure K-1. Recruitment Permission from Facebook Support Group, Kidney Transplant 
Survivors and Donors. 
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Figure K-2. Recruitment Permission from Facebook Support Group, Kidney Transplant 
and Weight Loss. 
 192 
 
Figure K-3. Recruitment Permission from Facebook Support Group, Kidney Transplant. 
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APPENDIX L 
FACEBOOK MESSAGES 
First Facebook Public Recruitment Message 
Kidney transplant recipients are needed for a study on health self-management conducted 
by a Ph.D. candidate at the Indiana University School of Nursing. Qualified participants 
who complete a 20–25-minute online survey will receive a $5 Amazon e-gift card within 
5 business days. Simply click on the link below to see if you qualify for the study: 
https://redcap.uits.iu.edu/surveys/?s=99FN9AFYAR 
This study is completely anonymous, and we will not ask for any personal identifiable 
information. If you are interested or want more information, please visit the Facebook 
study page or contact Shu-Yu Chung at shuchung@iu.edu or (812) 241-3968. If you 
would like to see a brief summary of the study results, we hope to post them on our 
Facebook study page (www.facebook.KTXSM) and on the Facebook kidney transplant 
support group page in early July. 
Second Public Recruitment Message 
Thank you so much to all who have participated so far in the kidney transplant  
self-management study! If you have completed the online survey, you should be 
receiving your e-gift card very soon if you haven’t gotten it already. In order to 
accurately describe important self-care behaviors and knowledge that may help 
transplanted kidneys last longer, we are still looking for more participants to take the  
20–25-minute online survey. Please click on the link to see if you qualify for the study: 
https://redcap.uits.iu.edu/surveys/?s=99FN9AFYAR 
If you know others who are also kidney recipients, please feel free to pass along the 
link above to them. 
For more information, please visit the Facebook study page or contact Shu-Yu Chung at 
shuchung@iu.edu or (812) 241-3968. 
Public Thank You Message 
Thank you for taking the time to complete this survey. We have collected enough survey 
data to help us understand if kidney recipients are confident about taking care of 
themselves and satisfied with their life after kidney transplant. This understanding will 
help us design better educational programs following transplantation. 
We greatly appreciate all your help and support.  
If you are interested in a summary of the study results, we hope to post them on our 
Facebook study page (www.facebook.KTXSM) and on the Facebook kidney transplant 
support group page in mid-July. 
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APPENDIX M 
REDCAP REMINDERS 
First Reminder 
Subject: Share your post kidney transplant experience with a research team and get a 
$5 Amazon e-gift card) 
Welcome to the Post Kidney Transplant Self-Management Study! 
A week ago we sent you an invitation to access this full survey. If you have already 
completed this survey, thank you very much for your help. If you didn’t have a chance to 
finish it yet, we hope that providing you with a survey link will make it easier for you to 
respond. Please simply click on the link below or copy and paste it into your web 
browser:  
Kidney Transplant Survey 
If you would like to take this survey using your iPad, please use a QR code reader to scan 
the QR code below: 
After completing this survey, which should take about 20–25 minutes, you will receive a 
$5 Amazon e-gift card via email within 5 business days. If you have any questions or 
comments, please contact Shu-Yu Chung, RN, Ph.D. candidate at the Indiana University 
School of Nursing by email at shuchung@iu.edu or by phone at 812-241-3968. 
Thank you in advance for your participation. We look forward to your valuable feedback! 
Second Reminder 
Subject: Help us understand how you take care of your new kidney (Or Help us 
understand your post kidney transplant self-care experience) 
Welcome to the Post Kidney Transplant Self-Management Study! 
Recently we sent you an email asking you to complete a survey about what you know, 
what you do, how confident you are, and how you feel since you began to take care of 
your new kidney. If you have already completed this survey, thank you very much for 
your help.  
If you have not taken the survey yet, please take some time to do so. If you can’t finish 
the survey in one sitting, you can save your progress and return to finish later. It should 
only take about 20–25 minutes to complete. Simply click on the link below to begin the 
survey or copy the link and paste it into your web browser.  
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Kidney Transplant Survey 
Thank you in advance for your help. We look forward to your valuable input. 
As thanks for completing this survey, you will receive a $5 Amazon e-gift card via email 
within 5 business days. 
Third Reminder 
Subject: Reminder: Help us understand how you take care of your new kidney (Or 
Help us understand your post kidney transplant self-care experience) 
Welcome to the Post Kidney Transplant Self-Management Study! 
In __month/date__(date) we contacted you asking for your help with the Post Kidney 
Transplant Self-Management Survey. We are writing to you again because our ability to 
accurately describe important self-care behaviors and knowledge that may help new 
transplanted kidney last longer depends on hearing from those who have not yet 
responded. We need your help to ensure that the results are as precise as possible. 
To complete the survey questions, please click on the link below or copy and paste it into 
your web browser: 
www.redcap.com 
Your responses are completely anonymous. We will not ask for any personally 
identifiable information. You will receive a $5 Amazon e-gift card via email within 5 
business days after completing the survey. If you have any questions or comments, please 
contact Shu-Yu Chung, RN, Ph.D. candidate at Indiana University School of Nursing by 
email at shuchung@iu.edu or by phone at 812-241-3968.  
Thank you for considering our request.  
Many thanks!   
Final Reminder 
Subject: Final Reminder! Help us understand your post kidney transplant experience 
and get a $5 Amazon e-gift card 
We are writing to follow up on the message we sent last week asking you to take the Post 
Kidney Transplant Self-Management Study survey. If you would still like to participate, 
please click the link below and take the 20–25 minute survey:  
www.redcap.com 
If you cannot access the link above, please copy and paste the link into your web 
browser: 
https://redcap.uits.iu.edu/surveys/index.php?s=DII6VDCfqz 
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If you would like to take this survey using your iPad or tablet, please use a QR code 
reader to scan the QR code below: 
In appreciation for your time, respondents who complete the survey will receive a $5 
Amazon e-gift card via email within 5 business days.  
If you are interested in a summary of the study results, we hope to post them on our 
Facebook study page (www.facebook.KTXSM) and through the Facebook pages of 4 
kidney transplant support groups (Transplant Support Group, Kidney Transplant and 
Weight Loss, and Kidney Transplant Survivors and Donors, and Kidney Transplants) in 
early July. We appreciate your help.  
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APPENDIX N 
INCLUSION SCREENING QUESTIONS 
1. Are you aged 18 years old or older? 
o Yes 
o No (Will be excluded from the study) 
2. Did you have more than one organ transplant? 
o Yes (Will be excluded from the study) 
o No 
3. Is your transplanted kidney (allograft) still functioning? 
o Yes 
o No (Will be excluded from the study) 
4. Are you receiving post-transplant follow-up care in the United States? 
o Yes 
o No (Will be excluded from the study) 
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APPENDIX O 
INSTITUTIONAL REVIEW BOARD APPROVAL 
 
Figure O-1. Institutional Review Board Approval. 
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APPENDIX P 
SURVEY 1: KIDNEY TRANSPLANT SELF-MANAGEMENT SCALE 
Please mark the number that corresponds with your level of agreement/disagreement 
Questions Strongly 
Disagree 
1 
Disagree 
2 
Neutral 
3 
Agree 
4 
Strongly 
Agree 
5 
1. I take my antirejection pills as instructed by my transplant doctor.     
2. I call my transplant team if my antirejection pills make me sick.     
3. I do not change the number of antirejection pills, even when my kidney is working well.     
4. I use a method, like a pillbox or reminder, to remind me to take my antirejection pills.     
5. I tell my transplant doctor about problems and concerns with my antirejection pills.     
6. If another doctor other than my transplant doctor adds a new medication, I will call my transplant doctor to see 
if it is safe to take. 
    
7. I avoid taking nonsteroidal anti-inflammatory drugs (NSAIDS) like Ibuprofen, Naproxen, or Motrin.     
8. I avoid high-calorie foods such as sweets and fried foods most of the time.     
9. I eat low-fat food such as chicken, low-fat dairy products, lean meats, poultry or fish most of the time.     
10. I watch how much sodium (salt) I eat.     
11. I read food labels most of the time.     
12. I exercise for at least 30 minutes 5 times per week.     
13. I limit alcoholic drinks to no more than one drink per day.      
14. I take my blood pressure as instructed by my doctor.     
15. I check my feet or ankles for swelling as instructed by my doctor.     
16. I call my transplant team if I gain more than 4 pounds in one day.     
17. I call my transplant doctor if I urinate (pee) less than usual.     
18. I keep almost every appointment with my transplant doctor.     
19. I keep my blood (lab) test appointments.     
20. I call my transplant doctor when I have symptoms of an infection like fever, flu-like symptoms, pain on 
urinating, or cough. 
    
21. I take my temperature as instructed by my doctor.     
22. I drink at least eight 8-ounce glasses of water (2 liters) every day.     
Table continues 
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23. I avoid close contact with people who are sick.     
24. I wash my hands with soap and water after using the bathroom.     
25. I wash my hands with soap and water before meals.     
26. I use sunscreen when outdoors.      
27. I wear a hat to protect my skin when outdoors.     
28. I self-examine my skin and lips at least once every month.     
29. I call my doctor if there is a suspicious lesion on my lips or skin.     
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APPENDIX Q 
13-ITEM PATIENT ACTIVATION MEASURE 
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APPENDIX R 
DATA TABLES 
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Table R-1 
Correlation Matrix for the Initial 29-item KT-SM Scale 
Items 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1. I take my antirejection pills as instructed by 
my transplant doctor 
__ 0.62 0.42 0.29 0.57 0.25 0.20 0.11 0.23 0.26 0.04 -0.04 0.16 0.17 
2. I call my transplant team if my 
antirejection pills make me sick 
0.62 __ 0.23 0.26 0.68 0.38 0.29 0.19 0.32 0.29 0.11 -0.03 0.19 0.14 
3. I do not change the number of antirejection 
pills, even when my kidney is working well 
0.42 0.23 __ 0.06 0.26 0.34 0.20 0.02 0.08 0.09 -0.01 -0.04 0.05 0.28 
4. I use a pill box or other reminder to 
remember to take my antirejection pills 
0.29 0.26 0.06 __ 0.38 0.18 0.11 0.06 0.06 0.04 0.19 0.02 0.13 0.10 
5. I tell my transplant doctor about problems 
and concerns with my antirejection pills 
0.57 0.68 0.26 0.38 __ 0.60 0.27 0.15 0.22 0.37 0.12 0.08 0.27 0.17 
6. If any doctor other than my transplant 
doctor gives me a new medication, I will 
call my transplant doctor to make sure it is 
safe to take 
0.25 0.38 0.34 0.18 0.60 __ 0.24 0.22 0.21 0.29 0.22 0.12 0.19 0.20 
7. I avoid taking nonsteroidal anti-
inflammatory drugs (NSAIDS)  
0.20 0.29 0.20 0.11 0.27 0.24 __ 0.12 0.26 0.21 0.14 0.16 0.25 0.29 
8. I avoid eating sweets, fried foods and other 
high calorie foods most of the time 
0.11 0.19 0.02 0.06 0.15 0.22 0.12 __ 0.50 0.32 0.46 0.44 0.05 -0.05 
9. I eat low fat foods like chicken, poultry, 
lean meats, or low-fat dairy products most 
of the time 
0.23 0.32 0.08 0.06 0.22 0.21 0.26 0.50 __ 0.53 0.32 0.28 0.12 0.14 
10. I watch how much sodium (salt) I eat 0.26 0.29 0.09 0.04 0.37 0.29 0.21 0.32 0.53 __ 0.36 0.27 0.31 0.28 
11. I read food labels most of the time 0.04 0.11 -0.01 0.19 0.12 0.22 0.14 0.46 0.32 0.36 __ 0.28 0.21 -0.03 
12. I exercise at least 5 times per week -
0.04 
-0.03 -0.04 0.02 0.08 0.12 0.16 0.44 0.28 0.27 0.28 __ 0.04 0.02 
13. I limit alcoholic drinks to no more than one 
drink per day 
0.16 0.19 0.05 0.13 0.27 0.19 0.25 0.05 0.12 0.31 0.21 0.04 __ 0.17 
14. I take my blood pressure medication as 
instructed by my doctor 
0.17 0.14 0.28 0.10 0.17 0.20 0.29 -0.05 0.14 0.28 -0.03 0.02 0.17 __ 
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Table R-1 
Correlation Matrix for the Initial 29-item KT-SM Scale (continued) 
Items 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 
1. I take my antirejection pills as 
instructed by my transplant doctor 
0.25 0.22 0.23 0.19 0.27 0.10 0.29 0.19 0.18 0.50 0.28 0.03 0.11 0.21 0.19 
2. I call my transplant team if my 
antirejection pills make me sick 
0.30 0.36 0.34 0.14 0.26 0.30 0.34 0.18 0.20 0.35 0.26 0.02 0.08 0.26 0.18 
3. I do not change the number of 
antirejection pills, 
0.12 0.25 0.16 0.22 0.20 0.13 0.13 0.20 0.07 0.35 0.18 0.01 0.04 0.16 0.24 
4. I use a pill box or other reminder to 
remember to take my pills 
0.26 0.20 0.21 0.16 0.19 0.10 0.20 0.15 0.18 0.13 0.06 0.13 0.08 0.10 0.18 
5. I tell my transplant doctor about 
problems and concerns with my 
antirejection pills 
0.27 0.39 0.38 0.34 0.27 0.39 0.28 0.13 0.22 0.37 0.34 0.10 0.10 0.29 0.20 
6. If any doctor other than my 
transplant doctor gives me a new 
medication, I will call my 
transplant doctor to make sure it is 
safe to take 
0.21 0.36 0.28 0.31 0.18 0.43 0.15 0.30 0.17 0.29 0.33 0.29 0.19 0.23 0.17 
7. I avoid taking nonsteroidal anti-
inflammatory drugs (NSAIDS)  
0.17 0.19 0.09 0.28 0.33 0.12 0.09 0.08 0.13 0.35 0.19 0.20 0.12 0.33 0.26 
8. I avoid high calorie foods most of 
the time 
0.06 0.26 0.31 0.10 0.09 0.31 0.36 0.31 0.29 0.04 0.26 0.31 0.24 0.34 0.35 
9. I eat low fat foods most of the time 0.13 0.26 0.28 0.15 0.29 0.25 0.41 0.28 0.23 0.33 0.37 0.33 0.06 0.44 0.31 
10. I watch how much salt I eat 0.21 0.36 0.34 0.13 0.18 0.30 0.21 0.17 0.21 0.27 0.33 0.23 0.11 0.35 0.22 
11. I read food labels most of the time 0.16 0.33 0.24 0.13 0.01 0.25 0.18 0.22 0.16 0.04 0.20 0.31 0.14 0.29 0.27 
12. I exercise at least 150 minutes per 
week 
-0.03 0.21 0.07 0.19 0.15 0.17 0.19 0.26 0.20 0.05 0.14 0.29 0.35 0.32 0.31 
13. I limit alcoholic drinks to no more 
than one drink per day 
0.21 0.23 0.25 0.24 0.15 0.46 0.15 0.10 0.20 0.21 0.32 -0.04 -0.04 0.12 0.19 
14. I take my blood pressure 
medication as instructed  
0.30 0.20 0.06 0.21 0.18 0.17 0.13 0.15 0.10 0.28 0.24 0.06 0.01 0.13 0.07 
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Table R-1 
Correlation Matrix for the Initial 29-item KT-SM Scale (continued) 
Items 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
15.  I look at my feet and ankles to check for 
swelling as instructed  
0.25 0.30 0.12 0.26 0.27 0.21 0.17 0.06 0.13 0.21 0.16 -0.03 0.21 0.30 
16.  I call my transplant team if I gain more 
than 3 pounds in one day 
0.22 0.36 0.25 0.20 0.39 0.36 0.19 0.26 0.26 0.36 0.33 0.21 0.23 0.20 
17.  I call my transplant doctor if I pee less 
than usual 
0.23 0.34 0.16 0.21 0.38 0.28 0.09 0.31 0.28 0.34 0.24 0.07 0.25 0.06 
18.  I keep every appointment with my 
transplant doctor 
0.19 0.14 0.22 0.16 0.34 0.31 0.28 0.10 0.15 0.13 0.13 0.19 0.24 0.21 
19.  I keep my blood test appointments 0.27 0.26 0.20 0.19 0.27 0.18 0.33 0.09 0.29 0.18 0.01 0.15 0.15 0.18 
20. I call my transplant doctor when I have 
signs of an infection  
0.10 0.30 0.13 0.10 0.39 0.43 0.12 0.31 0.25 0.30 0.25 0.17 0.46 0.17 
21. I take my temperature as instructed by 
my doctor 
0.29 0.34 0.13 0.20 0.28 0.15 0.09 0.36 0.41 0.21 0.18 0.19 0.15 0.13 
22. I drink at least eight 8-ounce glasses of 
water every day 
0.19 0.18 0.20 0.15 0.13 0.30 0.08 0.31 0.28 0.17 0.22 0.26 0.10 0.15 
23. I avoid close contact with people who 
are sick 
0.18 0.20 0.07 0.18 0.22 0.17 0.13 0.29 0.23 0.21 0.16 0.20 0.20 0.10 
24. I wash my hands after using the 
bathroom 
0.50 0.35 0.35 0.13 0.37 0.29 0.35 0.04 0.33 0.27 0.04 0.05 0.21 0.28 
25. I wash my hands before meals 0.28 0.26 0.18 0.06 0.34 0.33 0.19 0.26 0.37 0.33 0.20 0.14 0.32 0.24 
26. I use sunscreen when outdoors 0.03 0.02 0.01 0.13 0.10 0.29 0.20 0.31 0.33 0.23 0.31 0.29 -0.04 0.06 
27. I wear a hat to protect my skin when I 
am outside 
0.11 0.08 0.04 0.08 0.10 0.19 0.12 0.24 0.06 0.11 0.14 0.35 -0.04 0.01 
28. I examine my skin and lips once a 
month 
0.21 0.26 0.16 0.10 0.29 0.23 0.33 0.34 0.44 0.35 0.29 0.32 0.12 0.13 
29. I call my doctor if there is a suspicious 
lesion on my skin 
0.19 0.18 0.24 0.18 0.20 0.17 0.26 0.35 0.31 0.22 0.27 0.31 0.19 0.07 
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Table R-1 
Correlation Matrix for the Initial 29-item KT-SM Scale (continued) 
Items 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 
15.  I look at my feet and ankles to 
check for swelling as instructed  
__ 0.36 0.22 0.17 0.20 0.20 0.32 0.15 0.31 0.30 0.25 0.12 0.06 0.18 0.10 
16.  I call my transplant team if I gain 
more than 3 pounds in one day 
0.36 __ 0.54 0.24 0.22 0.41 0.50 0.15 0.20 0.17 0.29 0.21 0.20 0.40 0.36 
17.  I call my transplant doctor if I pee 
less than usual 
0.22 0.54 __ 0.02 0.05 0.49 0.40 0.11 0.21 0.10 0.33 0.17 0.13 0.24 0.28 
18.  I keep every appointment with 
my transplant doctor 
0.17 0.24 0.02 __ 0.63 0.24 0.23 0.32 0.29 0.47 0.21 0.25 0.25 0.31 0.40 
19.  I keep my blood test 
appointments 
0.20 0.22 0.05 0.63 __ 0.14 0.35 0.27 0.31 0.56 0.17 0.17 0.24 0.35 0.36 
20. I call my transplant doctor when I 
have signs of an infection  
0.20 0.41 0.49 0.24 0.14 __ 0.42 0.25 0.39 0.14 0.48 0.17 0.04 0.27 0.35 
21. I take my temperature as 
instructed by my doctor 
0.32 0.50 0.40 0.23 0.35 0.42 1.00 0.29 0.42 0.27 0.35 0.29 0.20 0.39 0.45 
22. I drink at least eight 8-ounce 
glasses of water every day 
0.15 0.15 0.11 0.32 0.27 0.25 0.29 __ 0.19 0.30 0.28 0.32 0.15 0.33 0.36 
23. I avoid close contact with people 
who are sick 
0.31 0.20 0.21 0.29 0.31 0.39 0.42 0.19 __ 0.18 0.38 0.24 0.27 0.30 0.35 
24. I wash my hands after using the 
bathroom 
0.30 0.17 0.10 0.47 0.56 0.14 0.27 0.30 0.18 __ 0.43 0.19 0.12 0.28 0.24 
25. I wash my hands before meals 0.25 0.29 0.33 0.21 0.17 0.48 0.35 0.28 0.38 0.43 __ 0.32 0.14 0.33 0.28 
26. I use sunscreen when outdoors 0.12 0.21 0.17 0.25 0.17 0.17 0.29 0.32 0.24 0.19 0.32 __ 0.40 0.41 0.38 
27. I wear a hat to protect my skin 
when I am outside 
0.06 0.20 0.13 0.25 0.24 0.04 0.20 0.15 0.27 0.12 0.14 0.40 __ 0.29 0.27 
28. I examine my skin and lips once a 
month 
0.18 0.40 0.24 0.31 0.35 0.27 0.39 0.33 0.30 0.28 0.33 0.41 0.29 __ 0.63 
29. I call my doctor if there is a 
suspicious lesion on my skin 
0.10 0.36 0.28 0.40 0.36 0.35 0.45 0.36 0.35 0.24 0.28 0.38 0.27 0.63 __ 
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Table R-2 
Correlation Matrix for the Reduced 16-item KT-SM Scale  
 Item 1 2 5 8 9 10 11 12 16 17 18 19 20 26 28 29 
1.  I take my antirejection pills as instructed by 
my transplant doctor 
1.00 0.62 .57 .11 .23 .04 -.04 .16 .22 .23 .19 .27 .10 .03 .21 .19 
2.  I call my transplant team if my antirejection 
pills make me sick 
.62 1.00 .68 .19 .32 .11 -.03 .19 .36 .34 .14 .26 .30 .02 .26 .18 
5.  I tell my transplant doctor about problems 
and concerns with my antirejection pills 
.57 .68 1.00 .15 .22 .12 .08 .27 .39 .38 .34 .27 .39 .10 .29 .20 
8.  I avoid eating sweets, fried foods and other 
high calorie foods most of the time 
.11 .19 .15 1.00 .50 .46 .44 .05 .26 .31 .10 .09 .31 .31 .34 .35 
9.  I eat low fat foods like chicken, poultry, lean 
meats, or low-fat dairy products most of the 
time. 
.23 .32 .22 .50 1.00 .32 .28 .12 .26 .28 .15 .29 .25 .33 .44 .31 
10.  I read food labels most of the time .04 .11 .12 .46 .32 1.00 .28 .21 .33 .24 .13 .01 .25 .31 .29 .27 
11.  I exercise at least 5 times per week -.04 -.03 .08 .44 .28 .28 1.00 .04 .21 .07 .19 .15 .17 .29 .32 .31 
12.  I limit alcoholic drinks to no more than one 
drink per day 
.16 .19 .27 .05 .12 .21 .04 1.00 .23 .25 .24 .15 .46 -.04 .12 .19 
16.  I call my transplant team if I gain more than 3 
pounds in one day 
.22 .36 .39 .26 .26 .33 .21 .23 1.00 .54 .24 .22 .41 .21 .40 .36 
17.  I call my transplant doctor if I urinate (pee) 
less than usual 
.23 .34 .38 .31 .28 .24 .07 .25 .54 1.00 .02 .05 .49 .17 .24 .28 
18.  I keep every appointment with my transplant 
doctor 
.19 .14 .34 .10 .15 .13 .19 .24 .24 .02 1.00 .63 .24 .25 .31 .40 
19.  I keep my blood (lab) test appointments .27 .26 .27 .09 .29 .01 .15 .15 .22 .05 .63 1.00 .14 .17 .35 .36 
20.  I call my transplant doctor when I have signs 
of an infection like fever, flu-like symptoms 
.10 .30 .39 .31 .25 .25 .17 .46 .41 .49 .24 .14 1.00 .17 .27 .35 
26.  I use sunscreen when outdoors. .03 .02 .10 .31 .33 .31 .29 -.04 .21 .17 .25 .17 .17 1.00 .41 .38 
28.  I examine (look at carefully) my skin and lips 
at least once a month 
.21 .26 .29 .34 .44 .29 .32 .12 .40 .24 .31 .35 .27 .41 1.00 .63 
29.  I call my transplant doctor if there is a change 
or suspicious lesion on my lips or skin 
.19 .18 .20 .35 .31 .27 .31 .19 .36 .28 .40 .36 .35 .38 .63 1.00 
Note. Determinant = .002. 
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Table R-3 
Reproduced Correlation Matrix for the Reduced 16-item KT-SM Scale (5-Factor Solution) 
 Item 1 2 5 8 9 10 11 12 16 17 18 19 20 26 28 29 
1.  I take my antirejection pills 
as instructed by my 
transplant doctor 
.554a .63 .55 .10 .23 .03 -.02 .12 .24 .22 .19 .28 .14 .03 .22 .15 
2.  I call my transplant team if 
my antirejection pills make 
me sick 
.63 .768a .67 .19 .30 .10 -.01 .21 .35 .38 .15 .25 .28 .03 .25 .18 
5.  I tell my transplant doctor 
about problems and 
concerns with my 
antirejection pills 
.55 .67 .640a .16 .27 .12 .03 .29 .39 .38 .31 .32 .37 .06 .27 .24 
8.  I avoid eating sweets, fried 
foods and other high calorie 
foods most of the time 
.10 .19 .16 .764a .50 .46 .42 .08 .28 .28 .09 .09 .29 .35 .35 .32 
9.  I eat low fat foods like 
chicken, poultry, lean 
meats, or low-fat dairy 
products most of the time. 
.23 .30 .27 .50 .417a .31 .30 .08 .29 .25 .19 .22 .23 .30 .42 .35 
10.  I read food labels most of 
the time 
.03 .10 .12 .46 .31 .331a .28 .14 .27 .27 .11 .08 .31 .26 .29 .29 
11.  I exercise at least 5 times 
per week 
-.02 -.01 .03 .42 .30 .28 .314a .05 .18 .12 .21 .16 .17 .29 .32 .31 
12.  I limit alcoholic drinks to 
no more than one drink per 
day 
.12 .21 .29 .08 .08 .14 .05 .317a .28 .29 .26 .14 .41 .03 .09 .17 
16.  I call my transplant team if 
I gain more than 3 pounds 
in one day 
.24 .35 .39 .28 .29 .27 .18 .28 .448a .45 .21 .19 .46 .22 .40 .39 
17.  I call my transplant doctor 
if I urinate (pee) less than 
usual 
.22 .38 .38 .28 .25 .27 .12 .29 .45 .517a .01 .03 .49 .14 .29 .28 
Table continues 
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18.  I keep every appointment 
with my transplant doctor 
.19 .15 .31 .09 .19 .11 .21 .26 .21 .01 .863a .62 .26 .22 .33 .40 
19.  I keep my blood (lab) test 
appointments 
.28 .25 .32 .09 .22 .08 .16 .14 .19 .03 .62 .514a .14 .20 .36 .36 
20.  I call my transplant doctor 
when I have signs of an 
infection like fever, flu-like 
symptoms 
.14 .28 .37 .29 .23 .31 .17 .41 .46 .49 .26 .14 .607a .16 .26 .32 
26.  I use sunscreen when 
outdoors. 
.03 .03 .06 .35 .30 .26 .29 .03 .22 .14 .22 .20 .16 .325a .43 .38 
28.  I examine (look at 
carefully) my skin and lips 
at least once a month 
.22 .25 .27 .35 .42 .29 .32 .09 .40 .29 .33 .36 .26 .43 .704a .60 
29.  I call my transplant doctor 
if there is a change or 
suspicious lesion on my lips 
or skin 
.15 .18 .24 .32 .35 .29 .31 .17 .39 .28 .40 .36 .32 .38 .60 .552a 
Note. aReproduced communalities. 
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Table R-4 
Residual Correlation Matrix for the Reduced 16-item KT-SM Scale (5-Factor Solution) 
 Item 1 2 5 8 9 10 11 12 16 17 18 19 20 26 28 29 
1.  I take my antirejection pills as instructed by my 
transplant doctor 
 -.02 .03 .01 -.01 .01 -.01 .04 -.02 .00 -.01 -.01 -.04 .00 -.01 .04 
2.  I call my transplant team if my antirejection pills 
make me sick 
-.02  .01 .00 .02 .01 -.02 -.01 .01 -.03 -.01 .01 .02 -.02 .01 .01 
5.  I tell my transplant doctor about problems and 
concerns with my antirejection pills 
.03 .01  -.01 -.05 -.01 .05 -.02 .01 .00 .03 -.05 .02 .03 .02 -.04 
8.  I avoid eating sweets, fried foods and other high 
calorie foods most of the time 
.01 .00 -.01  .00 .00 .01 -.04 -.02 .02 .01 .00 .02 -.04 -.01 .03 
9.  I eat low fat foods like chicken, poultry, lean meats, 
or low-fat dairy products most of the time. 
-.01 .02 -.05 .00  .00 -.02 .04 -.04 .02 -.04 .07 .02 .02 .02 -.05 
10.  I read food labels most of the time .01 .01 -.01 .00 .00  -.01 .07 .06 -.04 .02 -.06 -.06 .05 .00 -.02 
11.  I exercise at least 5 times per week -.01 -.02 .05 .01 -.02 -.01  -.01 .04 -.05 -.02 .00 .00 .00 .01 .00 
12.  I limit alcoholic drinks to no more than one drink 
per day 
.04 -.01 -.02 -.04 .04 .07 -.01  -.05 -.04 -.02 .01 .05 -.07 .03 .02 
16.  I call my transplant team if I gain more than 3 
pounds in one day 
-.02 .01 .01 -.02 -.04 .06 .04 -.05  .09 .03 .02 -.05 -.01 -.01 -.03 
17.  I call my transplant doctor if I urinate (pee) less 
than usual 
.00 -.03 .00 .02 .02 -.04 -.05 -.04 .09  .00 .02 -.01 .03 -.05 .00 
18.  I keep every appointment with my transplant doctor -.01 -.01 .03 .01 -.04 .02 -.02 -.02 .03 .00  .01 -.02 .04 -.02 -.01 
19.  I keep my blood (lab) test appointments -.01 .01 -.05 .00 .07 -.06 .00 .01 .02 .02 .01  .00 -.04 -.01 .01 
20.  I call my transplant doctor when I have signs of an 
infection like fever, flu-like symptoms 
-.04 .02 .02 .02 .02 -.06 .00 .05 -.05 -.01 -.02 .00  .01 .01 .03 
26.  I use sunscreen when outdoors. .00 -.02 .03 -.04 .02 .05 .00 -.07 -.01 .03 .04 -.04 .01  -.01 .00 
28.  I examine (look at carefully) my skin and lips at 
least once a month 
-.01 .01 .02 -.01 .02 .00 .01 .03 -.01 -.05 -.02 -.01 .01 -.01  .03 
29.  I call my transplant doctor if there is a change or 
suspicious lesion on my lips or skin 
.04 .01 -.04 .03 -.05 -.02 .00 .02 -.03 .00 -.01 .01 .03 .00 .03  
Note. There are 9 (7.0%) nonredundant residuals with absolute values greater than 0.05. 
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APPENDIX S 
FACEBOOK ADVERTISEMENT MESSAGE 
 
Figure S-1. Paid Facebook Recruiting Ad. 
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APPENDIX T 
TARGETED KT FACEBOOK RECRUITING MESSAGE 
 
Figure T-1. Targeted KT Facebook Recruiting Message. 
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